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                                   Abstract 
The poor survival and migration of  transplanted Schwann cells (SCs) are major 
drawbacks for their clinical application in cell therapy for neurotrauma. To overcome such 
drawbacks we genetically modified SCs to over-express polysialic acid (PSA) by lentiviral 
vectors-mediated expression of  polysialyltransferase ST8SiaIV (PST), to study whether 
over-expression of  PSA could enhance their survival, migration, and integration when 
transplanted into the spinal cord. It was found that more PSA-expressing SCs (PST/SCs) 
survived than GFP-expressing SCs (GFP/SCs) after transplantation. In vitro expression of  
PSA on SCs can partially rescue SCs from cell death induced by serum and growth factor 
withdrawal. In addition, we found high concentration of  ATP (>3 mM) could induce SCs 
death via P2X7 receptor (P2X7R) activation. Blockade of P2X7Rs with an antagonist 
completely abolished ATP induced SCs death in vitro and also enhance the survival of  
grafted SCs in vivo. Interestingly, expression of  PSA on SCs was found to partially protect 
SCs from ATP induced cell death in vitro.  
PSA expression on SCs did not enhance the motility of  transplanted SCs in intact spinal 
cord. However, in a spinal cord crush injury model PST/SCs transplanted 2.5 mm caudal to 
the lesion site showed that more cells migrated toward the injury site compared with that of  
GFP/SCs. Induced expression of  PSA in spinal cord further facilitated the infiltration of  
PST/SCs into the lesion cavity. PST/SCs were also shown to intermingle with the host 
spinal cells while GFP/SCs formed boundaries with the host tissue. This was confirmed by 
an in vitro confrontation assay. Furthermore, PST/SCs induced much less expression of  
GFAP and CSPGs in the surrounding host tissues than GFP/SCs, indicating that expression 
of  PSA on SCs do not cause significant stress response of  astrocytes. These results 
demonstrate that over-expression of  PSA on SCs significantly changes their biological 
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properties and makes them more feasible for cell therapy after neurotrauma.  
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Chapter 1   
Introduction 
1.1 Pathology of spinal cord injury 
The pathophysiology of spinal cord injury is best described as consisting of a primary and 
secondary phase of injury. Primary injury occurs following blunt impact, compression, or 
penetrating trauma. The immediate mechanical damage to the spinal cord leads to 
necrosis at the point of impact. Similar to other central nervous system (CNS) trauma, 
several mechanisms are involved in secondary injury including microvascular alterations; 
formation of free radicals and lipid peroxidation; accumulation of excitatory 
neurotransmitters; loss of intracellular balance of sodium, potassium, calcium and 
magnesium and subsequent increased intracellular calcium level; increased level of 
opioids, especially dynorphins, at the site of injury (Abraham et al., 2000); depletion of 
energy metabolites leading to anaerobic metabolism; provocation of an inflammatory 
response and recruitment and activation of inflammatory cells associated with secretion 
of cytokines. The secondary injury can cause further tissue damage and activation of 
calpains and caspases and apoptosis (Knoblach et al., 2005). 
 
1.1.1 Inflammation 
The inflammatory process following spinal cord injury is highly complex and involves 
numerous cellular populations, including astrocytes, microglia, T cells, neutrophils, and 
invading monocytes. At acute stage, the injury site is rapidly infiltrated by neutrophils 
from blood which secrete lytic enzymes and cytokines that may further damage local 
tissue and recruit other inflammatory cells (Popovich et al., 1997). Blood 
monocytes/macrophages are recruited, as are locally activated resident microglia, both of 
which subsequently invade to phagocytose the injured tissue (Dusart and Schwab, 1994). 
These and other reactive cells produce cytokines, such as tumour necrosis factor–α 
(TNFα), interleukins and interferons, that mediate the inflammatory response and can 
contribute to further tissue damage (Bartholdi and Schwab, 1997; Klusman and Schwab, 
1997; Popovich et al., 1997; Donnelly and Popovich, 2008).  
Inflammation following spinal cord injury has been revealed as a process of 
tremendous complexity, with some aspects of the response contributing deleteriously to 
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further secondary injury, and others contributing beneficially to the removal of cellular 
debris and enhancement of the environment for regenerative growth (Fleming et al., 
2006). Strategies aimed at blocking neutrophil or macrophage influx and at inhibiting of 
phagocytic and secretory activity of macrophages in the injured spinal cord have resulted 
in neuroprotection and improved locomotory function (Giulian and Robertson, 1990). 
However, macrophages and microglia were also shown to promote regeneration of axons 
by scavenging myelin and neuronal debris (David et al., 1990; Perry and Brown, 1992; 
Neumann et al., 2009) and producing the proregenerative cytokine, transforming TNFα 
(Streit et al., 1998). It has been suggested that the better regenerative response after 
peripheral nerve injury is partially related to the more pronounced macrophage invasion 
compared that of CNS after spinal cord injury (Lazarov-Spiegler et al., 1996; Rapalino et 
al., 1998; Kim et al., 2001). TNFα, for example, clearly has beneficial and deleterious 
effects. The inhibition of TNFα signalling using neutralizing antibodies has been shown 
to improve functional neurological recovery following spinal cord injury (Bethea et al., 
1999). However, TNFα signalling has also been demonstrated to have a neuroprotective 
role both in vitro (Cheng et al., 1994) and in vivo in TNFα knockout mice which display 
higher numbers of apoptotic cells, increased lesion size, and worsened functional 
recovery when compared with the wild-type mice (Kim et al., 2001). Although many 
cytokines propagate anti-inflammatory response, other cytokines such as interleukin 
(IL)-10 are considered to have potent anti-inflammatory properties (Knoblach and Faden, 
1998). Similar to TNFα, IL-10 is produced by leukocytes, macrophages, astrocytes and 
microglia, and its administration has been shown to be neuroprotective after experimental 
spinal cord injury, possibly by inducing anti-apoptotic genes (Bethea et al., 1999; Brewer 
et al., 1999).  
 
1.1.2 Electrolyte imbalances, excitotoxicity and energy metabolism disturbance 
Local ischaemia induced by direct injury or vasculature damage around the lesion site 
causes insufficient oxygen supply. This induces a shift of metabolism from aerobic 
respiration towards anaerobic glycolysis and leads to an exhaustion of further ATP 
production and the failure of maintenance of electrolyte balances. The loss of appropriate 
ionic homeostasis is a central feature of both necrotic and apoptotic cell death following 
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injury. Regarded to be the most critical among the cations, Ca2+ is the trigger for a series 
of pathological events leading to the failure in neuronal function and spinal shock. 
Increases in intracellular Ca2+ levels can be driven by different pathways. Firstly, Ca2+ 
enters into the cells unspecifically after the initial mechanical insult. Secondly, Ca2+ 
enters due to opening of voltage-gated Ca2+ channels after the destruction of cell 
membrane potential. Thirdly, Na+–Ca2+ exchangers are reported to work in a reverse 
fashion to maintain the usually low intracellular Na+ level. More importantly, glutamate 
activation of N-methyl- D-aspartate (NMDA) receptors allows extracellular Ca2+ (and 
Na+) to move down a massive concentration gradient into the cells. Na+ dysregulation has 
also been implicated in the pathophysiology of spinal cord injury, in particular with 
regard to damage of the axonal and glial components of the white matter. An intracellular 
influx of Na+ can result from glutamate activation of NMDA, alpha-amino-3-hydroxy- 
5-methylisoxazolepropionate (AMPA) and kainite receptors, as well as from activation of 
voltage-gated Na+ channels and activity of a Na+-Ca2+ exchanger that shuttles Ca2+ out of 
the cell in exchange for Na+. Whereas action potential propagation normally involves the 
transient influx of Na+ through the activation of voltage-gated Na+ channels, the massive 
depolarization and loss of ATP-dependent ability to move the Na+ back into the 
extracellular compartment lead to a toxic accumulation of Na+ and thus water followed 
into the axon. Animal studies in which ion channel blockers were applied to the spinal 
cord shortly after injury have highlighted the relevance of dysregulated ionic homeostasis 
in the pathophysiology of spinal cord injury. Focal microinjections of tetrodotoxin (TTX), 
a potent blocker of voltage-gated Na+ channels, into the injured spinal cord was shown to 
protect against axonal loss and improve locomotor function (Rosenberg et al., 1999b). In 
another experiment, treatment with riluzole which blocks TTX sensitive Na+ channels or 
focal injection of TTX, after contusion spinal cord injury in rats helped to reduce loss of 
primarily white matter and attenuated neurological deficits (Schwartz and Fehlings, 2001). 
Similarly, glial cell susceptibility to Na+ influx through the glutamate activation of 
AMPA/kainate receptors was alleviated by focal intraspinal injections of 2,3-dihydro-6- 
nitro-7-sulfamoyl-benzo (f) quinoxaline (NBQX), an AMPA receptor antagonist 
(Rosenberg et al., 1999a). The acute, time-dependent nature of these processes is 
highlighted by the demonstration that TTX injections, although effective when performed 
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within 5 min of injury, lose their effect when applied 4 h after spinal cord injury, which 
presents a crucial time window for the treatment (Rosenberg and Wrathall, 2001).  
Glutamate, acting on both ionotropic and metabotropic receptors, is the most 
prevalent excitatory neurotransmitter in the CNS. Ionotropic glutamate receptors include 
the NMDA and AMPA/kainate receptors. Metabotropic glutamate receptors are coupled 
to G proteins that act as secondary intracellular messengers to mediate a wide spectrum 
of cellular functions. Glutamate release and accumulation occur rapidly after spinal cord 
injury in response to ischaemia and membrane depolarization, reaching toxic levels as 
early as 15 min after experimental injury (Wrathall et al., 1996). The consequence of the 
activation of NMDA receptors leads to a sharp increase of cytosolic Ca2+ concentrations 
which are normally extremely low and tightly controlled. Elevated Ca2+ concentrations 
within the cytosol and mitochondria can trigger a multitude of Ca2+-dependent processes 
that can lethally alter cellular metabolism afterwards (Choi, 1987). These processes 
which include the activation of lytic enzymes, such as calpains, phospholipase A2 and 
lipoxygenase; the generation of free radicals and the dysregulation of mitochondrial 
oxidative phosphorylation lead to the apoptotic death of the cells. Since increased 
cytosolic and mitochondrial Ca2+ may represent a common final death pathway for 
numerous insults, NMDA receptor blockade has been extensively evaluated as a potential 
treatment of spinal cord and other CNS injuries and neurodegenerative disorders. 
Adenosine-5'-triphosphate (ATP) is most commonly considered as an energy 
reservoir, which releases energy during the hydrolysis of its high energy covalent bonds. 
The roles of ATP had been first suggested as a chemical energy supply for membrane 
permeability maintenance (Caldwell and Keynes, 1957) and binding to noradrenaline in 
sympathetic nerves (Schumann, 1958). ATP can be released with noradrenaline, 
acetylcholine, and other neurotransmitters and the extracellular ATP was found to play 
important roles in neurotransmission or neuroregulation as a transmitter or a 
neuromodulator in both the CNS and PNS (Burnstock, 1972; Unsworth and Johnson, 
1990; Salgado et al., 2000; Burnstock, 2006, 2007).  
     The cytoplasmic ATP concentration is in the range 1-10 mM (Beis and Newsholme, 
1975). Abundant evidence suggests that ATP is synthesized and stored in vesicles by 
neurons in CNS and PNS and released in response to depolarisation. ATP can also be 
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released by glia cells such as astrocytes by mechanical stimulation, although the precise 
mechanism for the release is still unknown. Following a traumatic injury to CNS, high 
concentration of ATP can be released at the injury site, from both broken cells and 
mechanically stimulated cells. Released ATP binds to P2X7 purine receptors (P2X7Rs), a 
ligand-gated ion channels expressed on spinal neurons and glia cells, and activates 
several signal pathways and/or induces formation of non-selective membrane pores 
which lead to cell death. It has been shown that acute transient antagonistic blockade of 
the P2X7R in a rat model of spinal cord injury decreased cell death in the peritraumatic 
area of the lesion and led to a significant functional improvement (Wang et al., 2004).  
 
1.1.3 Free radicals and lipid peroxidation 
Loss of the Ca2+ homeostasis after injury causes defects in mitochondrial respiratory 
electron transport. Free radical intermediate products are continuously produced and 
released. These reactive oxygen species rapidly react with unsaturated and 
polyunsaturated fatty acid side chains of membrane lipids or with other components of 
the cells, thus harming the cells and generating more free radicals. Free radical-mediated 
injury is an important contributor to secondary damage following spinal cord injury with 
free radical-mediated lipid peroxidation contributing to axonal disruption and the death of 
both neurons and glial cells. Lipid peroxidation is a self-perpetuating free radical reaction 
causing membrane damage, leading to cell lysis, dysfunction of organelles, and 
contributing to Ca2+ dyshomeostasis through the oxidation of membrane lipids. The 
detection of reactive oxygen species (ROS) peaks at roughly 12 h following injury and 
remains elevated for 1 week, returning to basal, pre-injury levels 4–5 weeks after injury 
(Xiong et al., 2007; Donnelly and Popovich, 2008). The production of ROS is associated 
with both ischaemia immediately following injury and subsequent reperfusion (Sakamoto 
et al., 1991). Inhibition of free radical generation, particularly relevant to lipid 
peroxidation, is thought to be one of the principle mechanisms of action for 
pharmacological agents that have been evaluated for treatment for spinal cord injury. The 
modest neuroprotective effects of the standard methylprednisolone treatment following 
spinal cord injury are also believed to be due, at least in part, to the inhibition of lipid 
peroxidation (Fehlings, 2001; Kwon et al., 2004a). 
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1.1.4 Cell death and axonal demyelination 
Cell death after spinal cord injury may occur by necrosis and/or apoptosis. Traditionally, 
the death of neurons and glial cells after spinal cord injury was believed to be a passive 
process resulting from the initial tissue destruction and subsequent inflammatory 
reactions. In 1995, programmed cell death or apoptosis was first reported after spinal cord 
injury in rodents (Katoh et al., 1996; Li et al., 1996). Later on, the occurrence of 
programmed cell death in monkeys and humans was confirmed after spinal cord injury 
(Crowe et al., 1997; Emery et al., 1998). Typical necrotic cell death involves the swelling 
of the cells, disruption of organelles, then membrane lysis and release of the intracellular 
contents that can incite a local inflammatory reaction. Alternatively, apoptotic cell death, 
or programmed cell death, involves cellular shrinkage with intact organelles and nucleus 
fragmentation into apoptotic bodies that are subsequently cleared by phagocytosis 
without a significant inflammatory response. Both necrosis and apoptosis are initiated by 
similar insults, such as ischaemia, oxidative stress and excitotoxicity, although the more 
severe the injury, the more likely the cells will undergo necrosis. A cell subjected to 
massive injury at the site of impact can rapidly succumb to a necrotic type of death. 
However, cells around the epicenter of injuries that are spared the severe initial trauma 
may experience a sufficient secondary biochemical insult to initiate an apoptotic 
programme of self-destruction effected by the subsequent activation of caspases. It is 
likely that cell death occurs along a spectrum between the two.  
Within hours to days after initial injury some neurons and glial cells at the site of 
the lesion undergo apoptosis. Oligodendrocytes, like neurons, are highly sensitive to 
ischaemic and traumatic injury (Crowe et al., 1997). The loss of oligodendrocytes results 
in axonal demyelination, which peaks within 24 h following injury in the rat (Totoiu and 
Keirstead, 2005). Numerous neurons die in previously unaffected remote areas and axons 
undergo degeneration afterwards (Crowe et al., 1997; Emery et al., 1998; Li et al., 1999). 
This process is at least partly dependent on the activation of oligodendrocyte Fas receptor 
(FasR) or p75 neurotrophin receptor (p75NTR) which in turn activates caspase cascade 
leading to oligodendroglial cell death (Casha et al., 2001; Beattie et al., 2002; Casha et al., 
2005; Chu et al., 2007).  
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1.2 Current clinical treatments 
The priority after spinal cord injury is to stabilize the spine and release the compression 
of the spinal cord to avoid long-lasting ischaemia. Treatment begins with the emergency 
medical personnels who make an initial evaluation and immobilize the patient for 
transport. Immediate medical care within the first 8 h following injury is critical to the 
patient's recovery. Currently, no gold standard therapy for spinal cord injury has been 
established. Due to the delayed nature of these events, the secondary phase of spinal cord 
injury is the most appropriate target stage for therapeutic intervention. Steroids are the 
main approved neuroprotective drugs which have demonstrated modest, potentially 
important therapeutic benefits. Corticosteroids have been used in neurotrauma for 
decades. Their neuroprotective effects include antioxidant properties which are associated 
with a reduction in TNFα synthesis and nuclear factor κB (NF-κB) activity, enhancement 
of spinal cord blood flow, reduced calcium influx, reduced posttraumatic axonal dieback, 
and attenuated lipid peroxidation (Hall, 1992; Oudega et al., 1999). Following the 
accumulation of preclinical data that are generally supportives of a neuroprotective role 
for steroids in animal models of acute spinal cord injury (Hall, 1992), methylprednisolone 
was studied in several prospective acute spinal cord injury trials in humans, making it the 
most extensively studied drug in acute spinal cord injury (Hurlbert, 2001). 
Long-term therapy after spinal cord injury focuses on rehabilitation such as using 
lower-limb paraplegic cycling, assisted arm-cranking and active treadmill therapy with 
robotic assistance, pain relief, spasticity treatment, and the prevention of complications. It 
is well accepted that no single treatment can achieve ideal functional recovery; a 
combination of various treatments should be considered for individual patients.  
 
1.3 Strategies to promote neural repair 
1.3.1 Protecting injury induced neural cell death  
Pharmacological intervention 
Apart from the administration of corticosteroids described above, a number of promising 
pharmacological therapies are currently under investigation for their neuroprotective 
abilities in animal models of spinal cord injury. (1) The Na+ channel blocker riluzole was 
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shown to reduce glutamatergic neurotoxicity, promote the production and release of 
neurotrophic factors from astrocytes (Peluffo et al., 1997) and markedly enhance the 
survival of injured motoneurons even when the treatment was delayed (Fumagalli et al., 
2006). (2) Minocycline, a synthetic tetracycline derivative commonly used in the 
treatment of dermatological conditions such as acne and rosacea, has also been 
demonstrated to have neuroprotective effects in animal models of stroke, Parkinson 
disease, Huntington disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis 
(MS) (Yong et al., 2004). Several laboratories have reported that minocycline attenuated 
secondary injury and enhanced functional recovery in various animal models of spinal 
cord injury (Lee et al., 2003; Wells et al., 2003; Stirling et al., 2004; Teng et al., 2004). Its 
mechanism of action in spinal cord injury appears to be mediated in part by the inhibition 
of microglial activation, in addition to anti-apoptotic properties (He et al., 2001; Tikka 
and Koistinaho, 2001; Festoff et al., 2006; Yune et al., 2007). These promising preclinical 
results have led to two clinical trials, which are now ongoing. (3) The tissue-protective 
hormone erythropoietin (EPO). It has been shown that EPO can reduce brain injury 
following a variety of insults (Brines et al., 2000; Digicaylioglu and Lipton, 2001).  
Evidence shows widespread neuroprotective efficacy of recombinant human EPO in 
injury models of spinal cord (Celik et al., 2002; Gorio et al., 2002; Grasso et al., 2006).  
The mechanisms by which EPO exerts its beneficial effects are only partially understood. 
Available evidence suggests that EPO acts in a coordinated fashion at multiple levels to 
limit the production of tissue-injuring molecules such as glutamate (Kawakami et al., 
2001), reverse vasospasm (Grasso, 2001), attenuate apoptosis (Digicaylioglu and Lipton, 
2001; Celik et al., 2002), modulate inflammation (Brines et al., 2000), and recruit stem 
cells (Shingo et al., 2001). Furthermore, in recent clinical trials of EPO in stroke, it is 
both timely and prudent to consider the use of this pharmaceutical avenue in traumatic 
brain injury in humans (Mammis et al., 2009). (4) Cethrin (BioAxone Therapeutic, Inc.), 
the Rho pathway antagonist, is now under clinical trials investigating the putative 
neuroprotective and neuroregenerative properties. 
 
Molecular therapy targeted apoptosis pathway 
Apoptotic death is an active process, both energy dependent and requiring protein 
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synthesis. It represents a feasible target for therapeutic intervention by selective inhibition 
(Park et al., 2004). Following spinal cord injury, Fas ligand is expressed by microglia and 
invading lymphocytes while the FasR is predominantly found on oligodendrocytes 
(Nagata and Golstein, 1995; Casha et al., 2001, 2005). The interaction of Fas and FasR 
initiates apoptosis through the activation of the caspase cascade (Nagata and Golstein, 
1995). The potential for blocking Fas-mediated cell death following spinal cord injury 
using a soluble form of the FasR has been demonstrated in vitro and it was found through 
the intrathecal administration of this soluble form of the FasR, endogenous Fas signalling 
following spinal cord injury in rats was competitively inhibited in vivo (Ackery et al., 
2006; Austin and Fehlings, 2008).  
Caspase inhibitors have been tested in several studies. However, the efficacy of 
caspase inhibitors in counteracting injury induced damage is highly controversial (Li et 
al., 2000; Ozawa et al., 2002), since these proteases are not the only targets propagating 
detrimental apoptotic processes. Moreover, caspases also play vital roles in execution of 
chemotropic responses of growth cones (Campbell and Holt, 2003). Thus, blocking 
caspases may also directly interfere with regeneration. Other similar approach includes 
using inhibitors of calpains that are Ca2+-dependent cysteine proteases that play an 
important role in the degradation of cytoskeletal components of damaged cells (Ray et al., 
2003). The problems for clinical application, like caspase inhibitors, include the poor 
penetration to the blood-brain barrier and low cell permeability as well as lack of 
specificity because many inhibitors also act on other proteases and the proteasome. 
The ratio between Bcl-2 and Bax is regarded as a key factor deciding between life 
and death (Yuan and Yankner, 2000). Over-expression of the anti-apoptotic Bcl-2 in 
transgenetic mice led to less tissue damage after spinal cod injury but failed to bring 
about any functional improvement (Saavedra et al., 2000; Seki et al., 2003). Similarly, 
inhibition of the pro-apoptotic Bax, which resulted in strongly decreased oligodendrocyte 
death after spinal cord injury. However, it could not rescue oligodendrocyte excitotoxic 
necrosis induced by kainite (Dong et al., 2003). It indicates that targeting cell apoptosis 
alone may not be enough to rescue cell death after spinal cord injury. 
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1.3.2 Enhancing the intrinsic regenerative capacity of injured neurons 
Delivering neurotrophic factors 
Neurotrophins have long been investigated as therapeutics for neurodegenerative diseases. 
In addition to their involvement in the cell survival, axonal growth and guidance during 
development, neurotrophins have been shown to regulate neurogenesis and synaptic 
plasticity in the adult. Neurotrophic factors are released by neurons and glial cells and 
many of them are up-regulated after injury such as neurotrophin-3 (NT-3), brain-derived 
neurotrophic factor (BDNF) (Hayashi et al., 2000), ciliary neurotrophic factor (CNTF) 
(Lee et al., 1998) and glial cell line-derived neurotrophic factor (GDNF) (Satake et al., 
2000). It has been shown that the successful axonal regeneration in the PNS is partly 
dependent on the ability of SCs secreting growth factors, supporting axon elongation after 
nerve injury. Some of the trophic factors that are capable of promoting axon growth after 
injury include nerve growth factor (NGF), BDNF, NT-3, NT-4, NT-5 and GDNF, with 
different factors favouring the outgrowth of different populations of neuronal axons 
(Schnell et al., 1994; Kobayashi et al., 1997; Ramer et al., 2000; Blesch and Tuszynski, 
2003; Blesch et al., 2004). For example, the exogenous delivery of NGF in rats can 
induce extensive sprouting of nociceptive axons (Tang et al., 2004), whereas NT-3 elicits 
growth of corticospinal axons (Grill et al., 1997). BDNF induces recovery of forelimb 
function after cervical lateral hemisection and induces axonal growth of rubrospinal, 
reticulospinal, vestibulospinal, raphespinal, and local sensory and motor axons (Liu et al., 
1999; Jin et al., 2000; Jin et al., 2002), and BDNF promotes connections of corticospinal 
neurons onto spared descending interneurons in spinal cord injured rat at T8 level 
(Vavrek et al., 2006). GDNF induces growth of motor and dorsal column sensory axons 
after partial and complete spinal cord transections and induces remyelination (Blesch and 
Tuszynski, 2003). Extracellular signal regulated kinase (ERK) and Akt are two kinases 
that are activated in response to various neurotrophic factors. Akt also mediates the 
formation of collateral branches in response to local exposure to neurotrophins (Gallo and 
Letourneau, 1998; Markus et al., 2002).  
The use of trophic factors is considered to be one of the essential components of 
any combinatorial therapeutic strategy that is used to promote axon regeneration at the 
site of injury. Several studies have shown the effectiveness of genetically engineered cells 
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that secrete growth factors, or biomaterials containing trophic factors, in promoting the 
regeneration and sprouting of injured axons (Lu and Tuszynski, 2008). In addition, 
delayed delivery of growth factors like BDNF might be less effective than acute delivery 
because axons of chronically injured neurons may lack appropriate growth factor 
receptors, such as TrkB receptor which was detected on the neuronal cell bodies, but not 
on anterogradely labelled rubrospinal axons at the injury site (Kwon et al., 2004b). 
 
Targeting regeneration associated pathways 
cyclic AMP  
Raising the cAMP level in neurons has been shown to allow them to overcome the 
inhibitory effects of myelin and myelin-associated glycoprotein (MAG) and promote 
axon growth (Cai et al., 1999). It has been reported that a stronger regenerative response 
can be obtained by elevating levels of cAMP in retinal ganglion cells and in the damaged 
spinal cord (Qiu et al., 2002b; Qiu et al., 2002a; Li et al., 2003b; Rodger et al., 2005). 
Furthermore, the growth promoting action of conditioning lesions has been mostly 
attributed to the changes within the cell body of the dorsal root ganglion (DRG) neurons, 
involving an increase in cAMP concentration in the perikarya in the first days after injury 
(Qiu et al., 2002b). Elevated cAMP level enhances the regenerative ability of central 
axons by increasing growth factor receptor like TrkB translocation from the cytoplasm to 
the cell membrane (Meyer-Franke et al., 1998). cAMP also induces activation of protein 
kinase A and the subsequent activation of transcription factor cAMP response element 
binding protein (CREB). This pathway has been shown to be responsible for mediating 
the neuritogenic effects of neurotrophic factors (Gao et al., 2003).  
Regeneration associated genes 
In addition to cAMP, conditioning lesions in the peripheral branch of DRG neurons also 
induce the up-regulation of other regeneration-associated genes, such as 
growth-associated protein-43 (GAP43) (Schreyer and Skene, 1993) and activating 
transcription factor-3 (ATF3) (Seijffers et al., 2006). GAP43 protein is expressed mostly 
during development, and is down-regulated in the adult (Skene, 1989); however, it can be 
up-regulated following injury, especially in the PNS, leading to a successful regenerative 
response. In contrast to PNS, CNS axons show a reduced ability to upregulate GAP43 in 
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response to injury (Skene, 1989; Anderson et al., 1998; Rossi et al., 2001). Exogenous 
expression of ATF3 in DRG neurons promotes neurite outgrowth on permissive substrates 
(Seijffers et al., 2006), but it remains unclear whether ATF3 over-expression is sufficient 
to overcome the inhibitory effects of myelin. 
There is also another set of genes known to be upregulated after injury. These 
include those involved in the Janus kinase (JAK)/signal transducers and activators of 
transcription 3 (STAT3) pathway, through which the neuritogenic effect of cytokines such 
as leukaemia inhibitory factor (LIF) and IL-6 is mediated. IL-6 administration has been 
shown to be sufficient for axons to overcome the inhibitory effects of MAG and myelin 
in vitro and in vivo, and inhibition of the JAK–STAT3 pathway blocks the IL-6 mediated 
axon regeneration (Cao et al., 2006). However, as a potentially harmful proinflammatory 
cytokine, IL-6 is upregulated after CNS injury which contributes to increased cell death 
(Gadient and Otten, 1997). 
 
1.3.3 Neutralizing or blocking axon growth inhibitors 
Blocking the effects of myelin related molecules 
It has been shown that CNS axons can regenerate when a permissive environment was 
provided (David and Aguayo, 1981). Products of myelin breakdown and several 
myelin-associated inhibitory molecules, Nogo, MAG and oligodendrocyte myelin 
glycoprotein (OMgp) in the adult CNS were thought to be one of the key factors 
responsible for the failure of axon regrowth (Berry, 1982; Caroni and Schwab, 1988a; 
Chen et al., 2000; GrandPre et al., 2000). The myelin debris resulting from the injury may 
pose an important obstacle to the regenerating axons (Filbin, 2003). Nogo, MAG and 
OMgp are the three major inhibitors associated with myelin.   
To date, multiple distinct and quite different molecules have been identified as 
receptors for MAG, Nogo-66, OMgp, including Nogo-66 receptor 1 (NgR1) and its 
functional partners p75NTR or TROY, and Lingo-1 (the leucine-rich repeat and Ig domain 
containing, Nogo receptor-interacting protein-1) (Mi et al., 2004) , ganglioside GT1b 
(Vyas et al., 2002) and most recently paired immunoglobulin-like receptor-B (PirB) 
(Atwal et al., 2008). NgR1 was initially identified in a screen for Nogo-66 interacting 
proteins (Fournier et al., 2001). There are two sequence homologues of NgR1 in the 
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mammalian genome, NgR2 and NgR3, which are expressed in both embryonic and adult 
PNS and CNS neurons (Xie and Zheng, 2008). Upon ligand binding, the NgR1, p75NTR 
and Lingo-1 as a single receptor complex triggers intracellular signalling cascades that 
alter the balance of Rac1 and RhoA signalling. The activity of RhoA is elevated and that 
of Rac1 decreased, leading to the growth cone collapse and paralysis of growing axons. 
The activation of RhoA is regarded as a crucial step for myelin inhibitors to exert their 
inhibitory effect on axon extension. Upon stimulation, RhoA activates its immediate 
downstream effector Rho kinase (ROCK) to modify actin cytoskeleton dynamics. This 
intracellular event is a common pathway shared by multiple molecules, including MAG, 
Nogo, OMgp, Netrin-1, ephrins and chondroitin sulfate proteoglycan (CSPGs) (Yiu and 
He, 2006); therefore, it can be viewed as perhaps the key convergence point at which 
various myelin-associated inhibitors exert similar functional outcomes (Lehmann et al., 
1999; Dergham et al., 2002; Schweigreiter et al., 2004).  
Many attempts were made to block or neutralize the myelin inhibitors. In this 
regard, strategies for therapeutic intervention include delivering antibodies and peptides 
to block the binding of inhibitors to the receptor. Significant progress has been made 
since the first monoclonal antibody IN-1, which acts against Nogo-A protein has been 
found (Caroni and Schwab, 1988b). Agents presumably work either by binding to all 
three myelin inhibitors and competing out their function or disrupting the formation of 
the NgR1/p75NTR/Lingo-1/GT1b signalling complex. More recently, it was found that the 
soluble extracellular domains of both PirB and NgR1 appear to be much more efficacious 
at blocking myelin inhibition than antibodies that bind directly to the receptors (Atwal et 
al., 2008). Another approach is to interfere with the downstream signalling events of the 
myelin inhibitors. Binding of myelin inhibitors to NgR1 induces protein kinase C (PKC) 
activation. Blocking PKC activity using inhibitor Go6976 promoted regeneration of the 
dorsal column fibers (Sivasankaran et al., 2004). RhoA activation is a convergent point in 
the inhibitory signalling cascade. As the inhibitory interactions between axons and 
CSPGs may also be in part mediated by the Rho-ROCK pathway (Monnier et al., 2003), 
it may create potential that targeting Rho-ROCK and its downstream mediators could 
also have beneficial effects in helping regenerating axons overcome the glial scar. C3 
transferase has been used in several studies to inactivate RhoA to promote axonal 
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outgrowth (Lehmann et al., 1999; Dergham et al., 2002). ROCK can be inhibited with 
several agents such as Y27632 and it was shown that application of Y27632 both in vitro 
and in vivo can promote axonal growth (Dergham et al., 2002; Duffy et al., 2009). Our 
group has investigated whether lentiviral vector (LV)-mediated neuron-specific 
expression of a dominant negative mutant of ROCK (DNROCK) could promote axon 
growth. LV/DNROCK was injected into the adult rat red nucleus followed by unilateral 
rubrospinal tract transection at the C4 level. Rats in the DNROCK group showed better 
functional recovery in the affected hindlimbs and forelimbs than those in the GFP group. 
Examination of the spinal cord sections revealed more rubrospinal axonal profiles 
growing to the spinal cord caudal to the lesion in the DNROCK group than that in the 
GFP group. These results indicate that blocking the RhoA-ROCK signal pathway by 
expressing DNROCK can enhance regenerative axonal sprouting and lead to partial 
recovery of limb function (Wu et al., 2009). 
     Nogo knockout mice have been generated by several groups independently using 
different methods to assess the contribution of Nogo to regeneration failure. No 
consistent and robust regeneration has been reported in mice lacking Nogo (Kim et al., 
2003; Simonen et al., 2003; Zheng et al., 2003; Kim et al., 2004; Zheng et al., 2005). 
Enhanced axon growth in an OMgp null mutant has been reported, but it was not clear 
whether the injury models specifically assessed regeneration or sprouting, and the 
corticospinal tract did not regenerate in this mutant (Ji et al., 2008). For MAG, genetic 
studies on MAG-/- mice have not implicated any significant role in injury-induced axonal 
growth (Bartsch et al., 1995). More recently, Lee et al.,(Lee et al., 2010) generated the 
Nogo/MAG/OMgp triple null mutants. It was found deleting any one of these three 
inhibitors in mice enhanced sprouting of corticospinal or raphespinal serotonergic axons, 
there was neither associated behavioural improvement nor a synergistic effect of deleting 
all three inhibitors. Furthermore, triple-mutant mice failed to exhibit enhanced 
regeneration of either axonal tract after spinal cord injury. Thus, they suggested that 
myelin and myelin related molecules might modulate axon sprouting, but did not play a 
central role in CNS axon regeneration failure. In addition, two groups independently 
generated and characterized NgR1 null mice. Both groups failed to observe enhanced 
axon regeneration in the corticospinal tract of NgR1 mutants (Kim et al., 2004; Zheng et 
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al., 2005). Interestingly, one group found enhanced regeneration of the raphespinal and 
rubrospinal tracts and improved motor function after complete transection (Kim et al., 
2004). The selective enhancement of regeneration in certain axonal tracts in this NgR1 
mutant may reflect differences in the intrinsic regenerative capacity of various axonal 
populations or a differential response of axonal tracts to NgR1 deletion. Regardless what 
mutation they achieved, the strain genetic background and the induced compensation for 
other genes need to be considered.  
 
Modification of glial scar 
It has been known for more than two decades that CSPGs inhibit axonal growth and 
regeneration. In the adult nervous system, CSPGs are enriched in perineuronal nets, and 
their abundance is increased in reactive astrocytes following injury to brain or spinal cord. 
Following spinal cord injury, astrocytes around lesion site display cytotoxic oedema and 
undergo necrotic cell death from hours to days following injury. A delayed astrocytic 
response begins in the subacute phase, in which astrocytes become hypertrophic and 
proliferative, correlating with a dramatic increase in the expression of the glial fibrillary 
acidic protein (GFAP) (Silver and Miller, 2004). These reactive astrocytes grow multiple, 
large cytoplasmic processes that interweave to form the glial scar. This scar represents 
both a physical and chemical barrier to axonal regeneration.  
Proteoglycans are a major inhibitory component of the glial scar (Gallo et al., 
1987). Astrocytes, as the main cell type of the glial scar, are capable of producing four 
classes of proteoglycans, including heparan sulphate proteoglycan (HSPG), dermatan 
sulphate proteoglycan, keratin sulphate protoglycan and CSPG (Johnson-Green et al., 
1991). The CSPGs form a relatively large family, which includes aggrecan, brevican, 
neurocan, NG2, phosphacan and versican. Structurally CSPGs consist of a core protein to 
which sulfated glycosaminoglycan (GAG) side chains are covalently linked. GAG side 
chains are traditionally considered the main source of inhibition by CSPGs. More recently, 
it has been postulated that the protein core also contributes to the inhibition of axonal 
regeneration by acting as a physical barrier to axon elongation, due to high affinity 
interactions with other extracellular matrix components such as laminin, fibronectin, and 
neural cell adhesion molecules (NCAMs) (Yiu and He, 2006). Accumulating data suggest 
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that CSPGs mediate their inhibitory effect via disruption of integrin function on axons 
(McKeon et al., 1995; Zhou et al., 2006), and also be in part mediated by the Rho-ROCK 
pathway (Monnier et al., 2003). 
One widely used strategy to overcome the inhibitory effects of CSPGs is to 
enzymatically digest them in vivo after injury. Chondroitinase ABC (ChABC) is a 
bacterial enzyme that degrades much, but not all, of the sugar chain from CSPGs, leaving 
the protein core and stub carbohydrate behind. ChABC is effective at removing the 
inhibitory properties of CSPGs. Numerous studies have shown that ChABC treatment 
increased sprouting and improved behavioural recovery after spinal cord injury 
(Bradbury et al., 2002; Yick et al., 2003; Caggiano et al., 2005; Barritt et al., 2006; 
Garcia-Alias et al., 2008). To potentially maximize the capacity for axon regeneration and 
plasticity, ChABC has also been used in combination with transplantation of foetal tissue, 
Schwann cells (SCs) and/or olfactory ensheathing cells (OECs) or neural stem/progenitor 
cells (NSCs/NPCs) (Kwok et al., 2008). 
Last year, protein tyrosine phosphatase sigma (PTP ) was identified as the receptor 
for CSPGs (Shen et al., 2009). Similarly to ChABC treatment, functional ablation of gene 
encoding PTP  promoted neurite outgrowth in the presence of CSPGs in vitro and 
enhanced axonal growth into CSPG-rich scar tissue following spinal cord injury in vivo 
(Fry et al., 2010). The discovery of neuronal RPTP  as a receptor for inhibitory CSPGs 
not only provides important mechanistic clues about CSPG function, but also identifies a 
potential new target for enhancing axonal growth and plasticity after nervous system 
injury. 
 
Targeting other inhibitory molecules in the glial scar 
In addition to the inhibitory effects of CSPGs, several other molecules are now known to 
be up-regulated after spinal cord injury and to contribute to the growth repulsive effects 
of the glial scar, such as semaphorin and ephrins.   
Meningeal fibroblasts invading the lesion core express the secreted semaphorins 
Sema3A, Sema3B, Sema3C, Sema3E and Sema3F (Pasterkamp and Verhaagen, 2006). 
Sema3A which is a major meningeal fibroblast-derived neurite growth-inhibitory factor 
acts as a chemorepellent through its high-affinity receptor neuropilin 1. Several studies 
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have shown that after spinal cord injury, expression of Sema3A is increased in fibroblasts 
that penetrate the lesion deeply, and expression of neuropilin 1 is increased in neurons 
that project to the site of injury (Pasterkamp et al., 1999; Pasterkamp et al., 2001; De 
Winter et al., 2002). Sema3A appears to be presented not in a soluble form but as a 
substrate-bound molecule associated with the cell membrane or extracellular matrix 
(Niclou et al., 2003). Regenerating axons were excluded from the areas containing 
Sema3A, essentially creating an exclusion zone at the heart of the lesion. These 
correlative results indicate that semaphorins help to prevent the penetration of 
regenerating axons past the centre of CNS lesions. By using a strong and selective 
inhibitor SM-216289 to Sema3A, it was found that rats with transected injured spinal 
cord treated with SM-216289 showed substantially enhanced regeneration and/or 
preservation of injured axons, robust SC–mediated myelination and axonal regeneration 
in the lesion site, resulting in considerably better functional recovery (Kaneko et al., 
2006). Sema4D, a transmembrane semaphorin also known as CD100, is expressed in a 
subpopulation of oligodendrocytes and is upregulated transiently after spinal cord injury 
in oligodendrocytes in white matter areas close to the lesion site (Moreau-Fauvarque et 
al., 2003). Plexin-B1, a Sema4D receptor, displays very limited expression in the adult 
brain. However, CD72, a Sema4D receptor originally identified in the immune system, is 
broadly expressed in the mature CNS and could thus mediate the inhibitory effect of 
Sema4D on adult neurons (Moreau-Fauvarque et al., 2003). 
The Eph receptors tyrosine kinases and their ligands, the ephrins, have been 
implicated in cell migration, neurite outgrowth and axonal pathfinding, topographic 
mapping, axon fasciculation and vascular formation in the developing nervous system 
(Klein, 2004; Goldshmit et al., 2006). Several studies have indicated the importance of 
Ephs and ephrins in the prevention of axon regeneration after spinal cord injury. After 
spinal cord injury in adult rats, EphA3, A4, A6 and A8 receptors are upregulated on 
motor neurons as well as astrocytes and oligodendrocytes at the injury site (Willson et al., 
2002). It has been shown that the neurite length of wild-type embryonic cortical neurons 
was significantly longer when these neurons were plated on EphA4-/- astrocytes 
compared with those plated on wild-type astrocytes. Furthermore, compared to 
wilde-type neurons, neurite outgrowth of EphA4-/- neurons on EphA4-/- astrocytes was 
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further increased, indicating that EphA4 expressed on astrocytes and neurons both 
inhibited neurite outgrowth in response to ephrins (Goldshmit et al., 2004). Expression of 
EphB3 has also been found on astrocytes at the injury site in the adult rat spinal cord after 
a complete transection (Willson et al., 2003) or contusion (Miranda et al., 1999). It was 
proposed that the expression of EphB3 on astrocytes may inhibit regrowth of axons 
(Miranda et al., 1999). In addition, the inhibitory role of EphrinB2 and its receptor EphB2 
in astrocytes and fibroblasts at the site of injury has also been reported (Bundesen et al., 
2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-1 Glial inhibitors and their intracellular signalling mechanisms.  
The molecular inhibitors of the adult CNS glial environment include myelin-associated 
inhibitors and CSPGs associated with reactive astrocytes in the glial scar. The neuronal 
receptors and downstream signalling pathways known to be involved in transducing these 
inhibitory signals are illustrated. (The image is modified from Yiu and He, 2006). 
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1.3.4 Biomaterials   
Lack of extracellular matrix support at the lesion site is considered as one of the factors 
that hinder the regenerative process after spinal cord injury. Many studies have been 
conducted to investigate the potential of biomaterials in promoting axonal regeneration in 
the injured spinal cord, by providing a bridge through which the regenerating axons can 
be properly guided from one end of the injury to the other end.  
Native materials such as collagen, alginate, fibrin and fibronectin, synthetic 
non-degradable  polymers (silicone), synthetic biodegradable polymers such as poly 
(D,L-lactic-co-glycolic acid), poly (ε-caprolactone), poly L-lactic acid, polyethylene 
glycol and conducting polymers (polypyrrole, polyaniline) have been used in various 
nerve regeneration research. An ideal nerve conduit should be thin, flexible, porous, 
biocompatible, biodegradable, compliant, neuroinductive, neuroconductive and with 
appropriate surface and mechanical properties (Verreck et al., 2005). Although these 
biomaterials promise to fulfill some of the above stated criteria, they have some 
drawbacks which have to be overcome to meet the specific tissue engineering 
applications. For example, a scaffold made from non-degradable materials should be 
avoided to prevent the chronic inflammation and compression of the nerve over time. 
Therefore, it is preferable to use biodegradable materials. However, the advantage of 
these non-degradable materials over the biodegradable materials is that they do not 
expose the tissues to the intermediary breakdown products, which may adversely affect 
the regeneration process (Bakshi et al., 2004). Also, even for biodegradable materials, a 
surface eroding polymeric scaffold is expected to provide better contact guidance cues 
continuously for nerve regeneration. Another important property needed for successful 
graft uptake by host tissues is mechanical stability and compatibility of the scaffolds. For 
nerve tissue engineering, the scaffold should be pliable, harmless to the surrounding 
tissues, resist structural collapse during implantation (Bini et al., 2005) which may lead to 
necrosis and inflammation. Many approaches have been attempted to improve the 
properties of common biomaterials to make them suitable for neural tissue engineering 
(Subramanian et al., 2009). Intense investigation has been carried out to improve the 
neural scaffold properties by several novel fabricating techniques such as polymer 
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blending and electrospinning, incorporating nerve growth factors or cell graft in the 
scaffold, and improving the wettability of the scaffold surface by surface modifications. 
In general, biomaterial implanted into injured spinal cord showed weak or no axon 
regeneration (Joosten et al., 1995; Nomura et al., 2006). Thus, combination therapy of 
biomaterial with neurotrophic factors and/or cell graft is needed. 
 
1.3.5 Cell therapy 
Cell replacement strategies have shown much promise for the treatment of 
neurodegenerative diseases and CNS injuries. The inherent regenerative plasticity of the 
injured adult spinal cord makes acute spinal cord injury an attractive target for cell 
replacement strategies. The main goals for the cell based therapy in spinal cord injury 
mainly are to replace the dead cells, bridge the gap and provide a favorable environment 
for axon regeneration. The ultimate goal is to achieve reconstruction of appropriate spinal 
circuits. An important challenge for cell-based therapies is the determination of the 
optimal cell type, method of delivery, and timing of cellular intervention. Many types of 
cells have been investigated for their potential for cell therapy for spinal cord injury, 
including various sources of stem cells, macrophage, fibroblasts, SCs, and OECs. 
 
1.3.5.1 Stem cells 
From foetal tissue grafts and bone marrow stromal cells to neural stem cells and 
embryonic stem cell derivatives, the benefits of stem cell-based transplantation therapies 
have been well documented in the preclinical studies. Currently, there are several types of 
stem cells used as cell therapy in spinal cord injury.  
 
Embryonic stem cell  
Embryonic stem cells (ESCs) are pluripotent cells that have the capability to differentiate 
into nearly all cell types, including neuronal and glial fate cells (Erceg et al., 2009).   
Because of their plasticity and potentially unlimited capacity for self-renewal, ESC 
therapies have been proposed for regenerative medicine and tissue replacement after 
injury or disease including spinal cord injury. It has been shown that transplantation of 
human ESC-derived oligodendrocyte progenitors into into T9 spinal cord of 
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dysmyelinated shiverer mice resulted in integration, differentiation into oligodendrocytes, 
and compact myelin formation (Nistor et al., 2005). In another experiment, human 
ESC-derived NPCs transplantion into lateral ventricle of the MS mice model significantly 
reduced the clinical symptoms. Histological examination showed migration of the 
transplanted cells to the host white matter. However, the differentiation of the 
transplanted human ESC-derived NPCs into mature oligodendrocytes was extremely rare 
while the neuroprotective effect benefited from the transplanted cells was observed. This 
was demonstrated by the suppression effect on the infiltration and activation of T cells 
(Aharonowiz et al., 2008). Transplantation of ESC-derived NPCs has also been shown to 
promote regenerative axon growth and neuronal survival by activating BDNF and IL- 6 
singalling pathways (Glazova et al., 2009). Furthermore, it has been reported that human 
ESC-derived motoneurons can survive and integrate into the spinal cord (Lee et al., 
2007). 
However, there are several concerns regarding the efficacy of transplantation of 
human ESCs in humans. Apart from the ethical concerns, there are some technical issues 
associated with how to manipulate these cells to differentiate toward defined neural cell 
types and maintain the same characteristics of the cells in vivo. Moreover, the possible 
formation of teratomas following the engraftment of human ESC-derived neural cell 
should not be ignored (Li et al., 2008). Currently, a FDA approved human ESC Phase 1 
clinical trial is in progress (Geron Corporation, USA) 
 
Neural stem cell (NSC) and neural progenitor cell (NPC) 
NSCs are multipotent cells with the potential to differentiate into neurons, 
oligodendrocytes, and astrocytes. They can be efficiently propagated in vitro (Hsu et al., 
2007) depending on the developmental stage and neurogenic zones where the cells were 
derived, as well as the pathological niche into which they are transplanted (Rossi and 
Keirstead, 2009). Reynolds and Weiss were the first to isolate NPCs and NSCs from the  
subventricular zone (SVZ) of adult mouse brain (Reynolds and Weiss, 1992). Since then, 
NPCs and NSCs have been isolated from various areas of the adult brain, including the 
spinal cord, and from various species including human (Taupin and Gage, 2002). In the 
adult CNS, the tissue adjacent to ventricles and the ependymal cells directly lining the 
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lateral ventricles are known to be rich sources of multipotent NSCs (Johansson et al., 
1999). The central ependymal canal of the spinal cord where produces many new 
progenitor cells that are capable of differentiating toward cells with neural and neuronal 
characteristics (Thuret et al., 2006). 
When cultured in vitro, the NSCs maintain their capacity for self-renewal after 
several passages and are capable of secreting neurotrophic factors (Coutts and Keirstead, 
2008). Functional recovery following NSCs transplantation into spinal cord injury sites 
has generally been attributed to the remyelination or the release of growth factors from 
the transplanted cells. However, the generation of astrocytes from NSCs has been 
reported to be associated with the increased pain (Hofstetter et al., 2005) 
It is speculated that NSCs are more favorable than human ESCs for clinical 
applications because they are considered safer for cell therapy, since NSCs have less 
potential to form tumours compared with ESCs (Kim et al., 2007). However, many 
critical challenges remain, including the need for pure populations of differentiated cells, 
inefficient tracking systems, and moderate cell survival after transplantation (Zhu et al., 
2005).  
 
Mesenchymal stem cell (MSC) and bone marrow stromal cells (BMSC) 
MSCs are multipotent cells that can be derived from many different organs and tissues. 
They have been demonstrated to play a role in tissue repair and regeneration in both 
preclinical and clinical studies. Potential advantages of MSCs include the possibility of 
these cells to be harvested from autologous donors, and relatively rapid expansion in vitro. 
Thus, they have been identified as promising candidates in the treatment of spinal cord 
injury.  
BMSCs express several types of neurotrophic factors such as NGF, BDNF, GDNF, 
NT-3, vascular endothelial growth factor (VEGF), and hepatocyte growth factors (HGF) 
(Chen et al., 2005; Yaghoobi and Mowla, 2006). Moreover, when exposed to an 
inflammatory environment in vitro, BMSCs alter their growth factor expression profile, 
indicating that they are responsive to environmental cues (Zhou et al., 2009a). It has been 
shown that BMSCs transplantation increase axonal growth and plasticity (Cizkova et al., 
2006), preserve host tissue and myelinated axons and attenuate cavity formation (Wu et 
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al., 2003; Ankeny et al., 2004). The mechanisms by which BMSCs exert their effects on 
the injured spinal cord are likely as a result of expression of neurotrophins.  
Both MSCs and BMSCs have potent immunomodulatory properties. Human MSCs 
inhibit the activation of co-cultured microglia, decrease their production of TNFα and 
nitric oxide (Zhou et al., 2009a). In a couple of studies, it was found that injection of 
MSCs inhibited T-cell proliferation and attenuated the release of interferon gamma 
(IFN-γ) and TNFα, resulting in decreased demyelination, axonal loss and enhanced 
functional recovery (Zappia et al., 2005; Matysiak et al., 2008; Rafei et al., 2009). Human 
MSCs have also been shown to reduce astrogliosis and microglial activation while 
increasing motor neuron survival and motor performance following transplantation into 
the superoxide dismutase 1 mutant model of ALS (Vercelli et al., 2008). 
However, there are several limitations to the current data set that require further 
investigation. For example, transplantation of different passages of MSCs may results in 
different outcomes. Another issue that remains to be addressed is the importance of cell 
dose and whether there is a safe upper limit, especially for long-term effects, including 
tumor formation, ectopic activity and unwanted fibrosis. 
 
Induced pluripotent stem cell (iPSC) 
In 2006, Takahashi and Yamanaka showed that mouse embryonic and adult fibroblasts 
acquired properties similar to those of ESCs after retrovirally introducing genes encoding 
four transcription factors, namely Oct3/4, Sox2, Klf4, and c-Myc (Takahashi and 
Yamanaka, 2006). They called these cells induced pluripotent stem cells (iPSCs). The 
first generation iPSCs were similar to ESCs in morphology, proliferation, the expression 
of some ESC marker genes, and the formation of teratomas. From then on, impressive 
progress has been made in this field.  
These cells have been generated from mouse and human somatic cells by 
overexpression of several defined factors (Ronaghi et al.; Takahashi and Yamanaka, 2006; 
Takahashi et al., 2007; Yu et al., 2007; Lowry et al., 2008; Ronaghi et al., 2010). More 
recently, generation of iPSCs from human NSCs with a single transcription factor, OCT4, 
or using direct delivery of recombinant proteins has been discovered (Kim et al., 2009a; 
Kim et al., 2009b). iPSCs have identical patterns in gene expression, chromatin 
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methylation, and embryoid body and viable chimera formation (Amabile and Meissner, 
2009) as ESCs, thus the potential of iPSCs is considered to be at least equivalent to that 
of human ESCs. They are capable of differentiation toward all cell types, including glia, 
NPCs, and motoneurons (Dimos et al., 2008). Furthermore, the derivation of iPSCs using 
nonviral methods or by chemicals and small molecules makes it very attractive (Huangfu 
et al., 2008; Kaji et al., 2009; Zhou et al., 2009b). Potential benefits to use iPSC include 
avoiding immunological rejection after transplantation since these reprogrammed adult 
cells will be derived from the patients themselves. Also there is no ethical concern for 
using iPSC which is unlike human embryos.  
However, this type of cells shares a similar disadvantage as other stem cell sources, 
i.e., teratoma formation. There is also unique potential problem to overcome before 
iPSCs can be used in the clinic, primarily related to the forced reprogramming of somatic 
cells. It still remains unclear whether nuclear reprogramming is complete for each iPSC 
clone. Incomplete or aberrant reprogramming of somatic cells to iPSCs could result in 
impaired differentiation of iPSCs into the required cell type and may increase the risk of 
immature teratoma formation after directed differentiation (Yamanaka et al., 2000).  
Another key issue is the presence of transgenes in iPSCs. Transgenes are largely silenced 
in iPSCs, but the reactivation of such transgenes such as c-Myc could lead to 
tumorigenesis (Okita et al., 2007). Furthermore, leaky expression of these transgenes may 
also inhibit complete iPSC differentiation and maturation, leading to a greater risk of 
immature teratoma formation. 
 
1.3.5.2 Macrophage 
Macrophages, which have both beneficial and harmful components, play a critical role in 
the secondary inflammatory reaction after CNS lesion. Based on transcriptional profiling, 
proteomics and functional assays, macrophages are typically classified as 
classically-activated form (M1) or alteratively-activated forms (M2) (Mantovani et al., 
2002). M1 macrophages, activated via toll-like receptors and IFN-γ, produce 
pro-inflammatory cytokines and oxidative metabolites that facilitate their role as 
indiscriminate killers of microbes and tumor cells. Conversely, M2 macrophages form in 
the presence of IL-4 and can regulate the inflammatory reaction, clear away dead cells, 
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promote blood vessels regeneration and tissue re-establishment, and thus provide an 
environment conducive to regeneration (Gordon, 2003; Mantovani et al., 2004). 
Several studies have shown that acute depletion or functional inhibition of 
macrophages is neuroprotective and promotes recovery of function after spinal cord 
injury (Popovich et al., 1999; Gris et al., 2004). This is likely due to that microglia and 
newly recruited monocytes differentiate into proinflammatory M1 macrophages at injured 
sites (Kigerl et al., 2009). However, early recruitment of blood-borne monocytes at the 
margins of the lesion site is needed for CNS repair. The blood-borne monocytes acquire a 
beneficial phenotype only when they encounter the extracellular matrix proteins that 
delineate the lesion site (Rossignol et al., 2007). It has been demonstrated that timely 
injection to the margins of the lesion site of specifically activated autologous 
macrophages at the subacute phase can promote recovery (Schwartz and Yoles, 2006). 
The use of autologous macrophages was the first approach developed for clinical 
trial. Since the preparation of these autologous cells requires only minimal modification, 
this approach has the advantage of a relatively short development time. In addition, it 
allows the experimenter to control the number, activity, and site of administration of the 
injected cells. In a Phase I study, it is shown that autologous macrophage cell therapy is 
safe and well tolerated in patients with acute spinal cord injury (Knoller et al., 2005). The 
promising results encouraged the investigators to carry on to Phase II. However, while it 
was in progress, it was suspended due to a couple of drawbacks in the design of the 
clinical trial such as the intervention time on patients; the way of cell administration and 
the high expense involved in the recruitment of each patient. 
 
1.3.5.3 Olfactory ensheathing cell (OEC) 
A unique type of cells within the olfactory system is a specialized glial cell called the 
OEC. OECs have recently attracted much attention and been tested in a few clinical trials 
in patients with spinal cord injury.  
OECs develop from the olfactory placode and subsequently migrate into the 
olfactory nerve and olfactory bulb. This developmental origin contrasts to that of SCs, 
which arise from the neural crest. From their origin in the olfactory mucosa to their 
termination in the glomeruli of the olfactory bulb, the nonmyelinated olfactory nerves are 
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associated with OECs, which surround large numbers of contiguous axons (Raisman, 
1985; Schwob et al., 1992). The olfactory nerve and the outer nerve layer of the olfactory 
bulb are enriched in OECs, which express p75NTR. The majority of OECs used in axonal 
regeneration studies on spinal cord injury were from primary cultures obtained from the 
rat olfactory bulb or olfactory mucosa (Ramon-Cueto et al., 2000; Lu et al., 2001).  
Functional recovery and/or CNS axon regeneration has been reported when OECs 
were transplanted immediately or up to 2 months after spinal cord injury in adult rats (Li 
et al., 1997, 1998; Lu et al., 2001; Li et al., 2003a). The mechanisms by which OECs 
promote recovery after spinal cord injury are not clearly known. The growth factors 
secreted by OECs are also being investigated. In vitro OECs provide both soluble and 
contact signals to promote sprouting of neurites (Wang et al., 2003; Chung et al., 2004). 
In vivo, these transplants might also prevent loss of neural tissue (Sasaki et al., 2006) and 
may enhance myelination after spinal cord injury (Sasaki et al., 2004).  
Whether OECs directly myelinate axons after spinal cord injury remains 
controversial (Boyd et al., 2005). Remyelination by OEC transplants from a variety of 
species including humans has been reported (Imaizumi et al., 1998; Barnett et al., 2000; 
Kato et al., 2000). However, some investigators have argued that OECs are not the 
myelinating cells in those studies but that contaminating SCs are responsible for the 
remyelination (Rizek and Kawaja, 2006). In has been suggested calponin may be a 
potential marker expressed by foetal OECs but not adult SCs. They found that OECs, but 
not SCs, express calponin, a muscle fibre actin-binding protein (Boyd et al., 2006), and 
that many cells in OEC culture preparations are p75NTR positive and calponin-negative, 
thus suggesting that OEC cultures were contaminated by SCs. However, in a recent study, 
it was found that, calponin was strongly expressed by fibronectin-expressing fibroblasts 
from adult olfactory mucosa, sciatic nerve and skin as well as by meningeal cells from 
the olfactory bulb, but not by p75NTR and S100 expressing OECs in tissue culture (Ibanez 
et al., 2007). This data indicates that calponin cannot be used to distinguish adult OECs 
and SCs. Regardless of the source of transplanted OEC, or whether the myelination 
observed is primary, secondary or a combination of both, considerable evidence now 
suggests that CNS remyelination can occur as a consequence of OEC transplantation. 
OECs are also a promising candidate for combinatorial cell-based strategies (OECs in 
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combination with NPCs or SCs) (Ao et al., 2007; Bunge, 2008). 
 
 
1.3.5.4 Schwann cell  
SC is one of the most widely studied cell types for repair of the injured spinal cord. These 
cells play a crucial role in endogenous repair of peripheral nerves due to their ability to 
dedifferentiate, migrate, proliferate, express growth promoting factors, and myelinate 
regenerating axons. Following trauma to the spinal cord, SCs migrate from the periphery 
into the injury site, where they participate in endogenous repair processes. When SCs are 
transplanted into the lesioned spinal cord they fill cystic cavities and promote axonal 
regeneration and myelination. More details will be discussed in Section 1.4 
 
1.3.6 Combination strategy  
Spinal cord injury incurs damage to axons and successful repair ultimately requires 
reconnection of the disconnected axons to their appropriate functional effectors. In view 
of the repair strategy after spinal cord injury, it seems more promising to achieve 
functional regeneration by manipulating the balance of positive and negative effects of 
growth-influential molecules in the lesioned spinal cord.  
Several studies have shown that combination of autologous BMSCs grafting into 
the lesioned spinal cord with injection of LV/NT-3 into the host spinal cord rostral to the 
lesion to establish a NT-3 gradient promoted significantly more ascending sensory axons 
extended into the host spinal cord rostral to the lesion site (Taylor et al., 2006; Alto et al., 
2009). Delivery of ChABC digests restrictive chondroitin sulfate components of the glial 
scar, resolves scarring with reduction in secondary tissue loss, and increases regrowth of 
myelinated axons across the lesion gap. Massey et al. (Massey et al., 2008) found that 
application of ChABC or LV/NT-3 in the rat dorsal column nuclei (DCN) promoted 
ingrowth of some axons of transplanted DRG neurons. When the two treatments were 
combined, entrance by regenerating axons into the DCN was significantly augmented. 
Administration of cAMP or rolipram, the phosphodiesterase 4 inhibitor that prevents the 
breakdown of cAMP, induces injured axons/neurons to overcome myelin-associated 
inhibitory signals (Hannila and Filbin, 2008). In the Miami Project to Cure Paralysis, it 
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was found the most efficacious strategy for the acute complete transection/SC bridge 
model, including improvement in locomotion was the combination of SCs, OECs, and 
chondroitinase administration; the most successful combination strategy for a subacute 
spinal cord contusion injury to be SCs and elevation of cAMP via subcutaneous infusion 
of rolipram combined with direct injection of an analogue of cAMP, dibutyryl cAMP 
above and below the SC implant (Bunge, 2008). These results demonstrate that 
development of the right combination strategies that have significant synergistic effect 
may hold the key to achieve successful axon regeneration.      
An optimal recovery of specific skills was observed recently when a treatment with 
ChABC was combined with a task specific training. It seems that promotion of plasticity 
with chondroitinase opens a time window during which rehabilitation becomes more 
effective. However, it is noteworthy that only trained skills were improved whereas 
others could be negatively affected compared to the effects of chondroitinase treatment 
alone (Garcia-Alias et al., 2009). Combined with Nogo neutralization in partially lesioned 
rats, intensive training seems to interfere with functional recovery, suggesting 
competition between the underlying mechanisms when both strategies are applied 
together (Maier et al., 2009), but training starting one month after OEC transplantation in 
transected rats improves recovery (Kubasak et al., 2008). This shows that the timing for 
the application of the different strategies is crucial.  
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Fig. 1-2 Diagram shows the strategies to promote axonal regeneration.  
(The image is modified from L. McKerracher and S. David, 2004). 
 
1.4 Schwann cell for neural repair  
1.4.1 Characterization of Schwann cells 
SC is named in honor of the German physiologist Theodor Schwann (1810-1882) who is 
now acknowledged as the founder of modern histology. Two intermediate cell types are 
known to be involved in the generation of SCs from neural crest cells. The first, the SC 
precursor, is found in rat peripheral nerves at E14 and 15 (mouse E12 and 13). The 
second, the immature SC, is present from E17 (mouse E15) to around birth. At this time, 
the immature cells start to differentiate. Myelinating SCs mature first, and the 
non-myelinating cells appearing later (Mirsky et al., 2002). Even though all SCs are of 
neural crest lineage, SCs in the mature PNS can be further classified by their morphology, 
antigenic phenotype, biochemistry and anatomical location. These categories are (1) 
myelinating SCs, (2) non-myelinating SCs, (3) perisynaptic SCs at the neuromuscular 
junction where they not only enwrap the axonal length but also extend processes to 
encompass the synapse (Corfas et al., 2004) and (4) satellite cells that are found in the 
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DRG and ensheathe the cell bodies of sensory neurons (Hanani, 2005). 
In a mixed peripheral nerve unmyelinated fibres vs. myelinated fibres by a ratio of 
three or four to one (Jacobs and Love, 1985). In rodents, the postnatal formation of 
myelinating and non-myelinating cells is a slow process, taking several weeks to 
complete. During the early postnatal period, immature SCs diverge, generating 
myelinating cells that wrap the large diameter axons and non-myelinating cells that 
accommodate small diameter axons in shallow troughs along their surface. Although the 
physiological roles of non-myelinating SCs are poorly defined, it is becoming apparent 
that they are vital for the function and maintenance of unmyelinated axons and also 
necessary for pain sensation (Chen et al., 2003).  
Following nerve transection, mature SCs promptly undergo radical changes in 
morphology and gene expression leading to developmental regression of individual SCs 
and myelin breakdown. In nerves, these processes are accompanied by SC proliferation 
(Fawcett and Keynes, 1990). The eventual outcome is the generation of a single 
population of cells that are comparable, although not identical, to immature SCs in 
neonatal nerves (Jessen and Mirsky, 1992). Such cells provide an environment 
particularly conducive to axonal re-growth, which is probably related to their relatively 
high level expression of neurotrophic factors and cell adhesion molecules (Mirsky et al., 
2002).  
 
1.4.2 Advantages of using Schwann cell in neural repair 
SCs have several unique features making them one of the best cell types for therapy. 
Firstly, they express a variety of factors that support the growth of central axons. Among 
them are members of the neurotrophin family including NGF, BDNF, and NT-3, as well 
as CNTF, GDNF, and fibroblast growth factor (FGF). Secondly, SCs express surface 
molecules such as L1/Ng-cell adhesion molecules and NCAM (Martini and Schachner, 
1988), both of which have been demonstrated to support axon growth through contact 
guidance (Lemmon et al., 1989; Cremer et al., 1997). Finally, SCs produce axon 
growth-promoting substrates such as laminin, fibronectin, and collagen (Oudega and Xu, 
2006). One principal advantage of SCs over other cell types for transplantation into the 
injured CNS is that SCs are able to myelinate both regenerating and intact central axons 
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(Oudega and Xu, 2006; Lavdas et al., 2008). Many other cell types promote axonal 
regeneration, but do not form myelin sheaths around the new axon sprouts. SCs do so and 
thus facilitate signal conduction in the regenerated axons. 
To employ SCs for transplantation into the injured CNS, obtaining large numbers is 
necessary to fill up large and numerous cystic cavities developed following the initial 
injury. The development of in vitro systems to harvest and expand human SCs presents a 
unique opportunity for autologous transplantation (Casella et al., 1996; Levi, 1996). 
Importantly, the cultured SCs were shown to retain their ability to myelinate and promote 
axonal regeneration. A new approach of isolating skin-derived precursors and 
differentiating the cells into SC progeny may provide another source of SCs for 
transplantation (Toma et al., 2005; Biernaskie et al., 2006; McKenzie et al., 2006). 
Recently human MSC-derived SC-like cells were also transplanted into spinal cord and 
were shown to promote axonal growth (Park et al., 2010). 
The efficacy of SCs in promoting axonal regeneration and myelination in the 
injured adult mammalian PNS and CNS has been extensively studied in a variety of 
experimental models (Oudega and Xu, 2006; Fortun et al., 2009). SCs transplantation in 
injured peripheral nerve, optic nerve and spinal cord promoted axonal regeneration, and 
ensheathed or myelinated the regenerated axons (Oudega and Xu, 2006; Fortun et al., 
2009). In cases where axons in the spinal cord were demyelinated but not severed, 
remyelination by grafted SCs re-established normal conduction velocity across the lesion 
and thus achieved functional repair. Moreover, SCs mixed with Matrigel, when seeded 
into semipermeable polyacrylonitrile/polyvinylchoride polymer tubes then grafted 
between stumps of the completely transected (Xu et al., 1997) or hemisected (Xu et al., 
1999) adult rat thoracic spinal cord have been shown to promote propriospinal and 
supraspinal axonal growth across the gap and myelination. The cord stumps were bridged 
by a tissue cable that contained SCs and axons were at different stages of myelination or 
ensheathment by SCs (Xu et al., 1995b; Xu et al., 1995a; Xu et al., 1997). The absence of 
SCs in control grafts resulted in scarce axonal growth. Moreover, SC can be genetically 
modified to over-express neurotrophic factors such as BDNF and NT-3. Behavioural 
assays (Rotarod assay and Grid walk assay) showed that NT-3- and BDNF-transduced 
SCs promoted faster and stronger functional recovery than GFP-transduced SCs when 
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they were transplanted into demyelinated spinal cords of adult mice induced by 
lysophosphatidylcholine injection. Moreover, NT-3-transduced SCs provided 
neuroprotection and reduced astrogliosis (Girard et al., 2005). 
 
1.4.3 Limitations of using Schwann cell in neural repair 
Although SCs transplanted into the CNS can promote axon regeneration, remyelination 
and improve functional recovery in animal models of spinal cord injury, poor survival of 
transplanted SCs in the CNS is a common problem and limits their therapeutic potential. 
Lack of matrix support, serum and trophic factor withdrawal and inflammation have been 
shown to induce cell death (Li et al., 2003c; Hill et al., 2006). Though it still remains 
unclear whether this is the key factor that can cause much difference for the final 
functional recovery, the predominant idea is that enhanced survival of transplanted grafts 
will benefit the ultimate outcome. 
To address their nature as PNS neuroglia which is distinct from CNS neuroglia, it 
needs to be aware of the limited integration of transplanted SCs. It was reported that SCs, 
when in contact with astrocytes in vitro, could induce stress response of astrocytes 
(Lakatos et al., 2000; Fairless et al., 2005), i.e.: boundary formation and astrocyte 
activation (increases in cytoplasmic area and expression of both GFAP and CSPGs (Wu 
et al., 1998; Lakatos et al., 2000). This is further confirmed by in vivo SCs transplantation 
experiment (Lakatos et al., 2003b). 
Taken together, the poor survival and lack of integration ability with host tissue are 
two key issues need to be solved. Overcoming these obvious disadvantages is critical 
before SCs can be used for efficacious therapeutic intervention. One of the solutions is to 
genetically modify SCs in vitro by long-term and stable expression of growth-promoting 
or inhibitor-blocking molecules or agents. 
 
1.5 Potential factors responsible for the death of transplanted Schwann 
cells 
1.5.1 Serum and growth factor withdrawal 
SCs underwent apoptosis in vitro upon serum withdrawal for 48 h (Syroid et al., 1996). 
Evidence suggested that lysophosphatidic acid (1-acyl-2-sn-glycerol-3-phosphate) (LPA) 
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could be a potential candidate for mediating this survival effect of serum. LPA is present 
in serum at micromolar concentrations. Furthermore, LPA receptor, LPA1, is highly 
expressed in SCs throughout sciatic nerve development and in cultured SCs (Eichholtz et 
al., 1993; Weiner and Chun, 1999; Weiner et al., 2001). It was found 60–75% of SCs 
underwent apoptosis by 48 h of serum withdrawal, and up to 80–90% by 72 h. Under 
serum deprivation, LPA at concentrations as low as 10 nM significantly rescued SCs from 
apoptosis and the effect was concentration-dependent. The reduced cell death following 
LPA treatment was the result of cell survival rather than cell proliferation, as BrdU 
incorporation was not increased by LPA treatment (Weiner and Chun, 1999). Furthermore, 
it was found LPA had comparable efficacy in promoting SC survival as neuregulin (NRG), 
another potent SC survival factor. Treatment with either molecule was observed to inhibit 
around 50% of the apoptosis induced by serum deprivation, suggesting that they may 
activate convergent singalling pathways (Ye et al., 2002).  
     A number of growth factors influence SCs development and death, including NRGs, 
transforming growth factor-β, FGF, PDGF, and insulin-like growth factor-1 (IGF-1) 
(Eccleston et al., 1993; Dong et al., 1995; Gavrilovic et al., 1995; Syroid et al., 1996). 
SCs express receptors for these trophic factors, including the PDGF and NRG receptors, 
and the type-1 IGF receptor (IGF-1R) (Eccleston et al., 1993; Leventhal et al., 1995; 
Grinspan et al., 1996; Carroll et al., 1997).  
     Basic fibroblast growth factor, also known as bFGF, FGF2 or FGF-β, is a member 
of the fibroblast growth factor family. bFGF is available during peripheral nervous 
system development and regeneration as neurons synthesize bFGF (Eckenstein et al., 
1994) and increase bFGF expression after axotomy (Ji et al., 1995). SCs express bFGF 
receptor (Neuberger and De Vries, 1993a, b), a receptor with endogenous tyrosine kinase 
activity (Ullrich and Schlessinger, 1990) and respond to exogenous bFGF by activation of 
cellular division (Raff et al., 1978). In addition to its mitogenic effect on SCs (Chen et al., 
1991), bFGF prevents cAMP-induced apoptosis in cultured SCs (Shaw et al., 1997). 
     IGFs, including IGF-1 and IGF-2 are trophic factors whose growth-promoting 
actions are mediated via IGF-1R and modulated by six IGF binding proteins. IGF-1 and 
IGF-1R are present in SC and axons in developing nerves, reaching peak levels during 
periods of myelination (Cheng et al., 1999). It was found when SCs were switched to 
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serum-free defined media for 12–72 h, they underwent apoptosis. Addition of insulin or 
IGF-1 prevented apoptosis. The phosphatidylinositol 3-kinase (PI3-K) inhibitor 
LY294002 blocked IGF-1–mediated protection and Akt, a downstream kinase of PI-3K, 
mediate this effect. It was found in dominant negative K179M Akt (K179M) transfected 
SC, Akt is not activated in response to IGF-1. In addition, IGF-1 is unable to promote SC 
motility and survival in K179M-SC which suggest a critical role for Akt in IGF-1 
mediated motility and survival in SC (Syroid et al., 1999). In animal studies, there is a 
significant increase in IGF-1 expression in injured peripheral nerves (Glazner and Ishii, 
1995). In the CNS, IGF-1 is the only growth factor that promotes oligodendrocytes to 
proliferate, differentiate, and myelinate (McMorris et al., 1993). In mice that were 
genetically altered to over express IGF-1, brain mass was increased because of enhanced 
myelin production by oligodendrocytes (Carson et al., 1993). 
     β-Neuregulin (βNRG) is a potent SC survival factor that binds to and activates a 
heterodimeric ErbB2/ErbB3 receptor complex. It was found that NRG receptor singalling 
rapidly activated PI3K in serum-starved SCs, while PI3K inhibitors markedly 
exacerbated apoptosis and completely blocked NRG-mediated rescue. NRG also rapidly 
signaled the phosphorylation of mitogen-activated protein kinase (MAPK) and the 
serine/threonine kinase Akt. The activation of Akt and MAPK in parallel pathways 
downstream from PI3K resulted in the phosphorylation of Bad at different serine residues. 
As mentioned above, several factors that rescue SCs from apoptosis have been identified, 
including bFGF, IGF, and the βNRG. The survival of early SC precursors was shown to 
be dependent on FGF-2 and IGF, but NRG becomes a predominant survival factor as the 
SCs mature (Jessen et al., 1994; Dong et al., 1995; Gavrilovic et al., 1995). An autocrine 
mechanism emerges during the postnatal period when SCs begin secreting their own 
survival factors, including NRG and IGF-1 (Cheng et al., 1998; Syroid et al., 1999). In 
addition to survival, NRGs mediate SC differentiation, proliferation, and migration 
through binding and activation of a heterodimeric ErbB2/ErbB3 coreceptor (Grinspan et 
al., 1996; Vartanian et al., 1997). 
     Forskolin increases intracellular cAMP levels and is implicated in SC proliferation 
(Jessen and Mirsky, 1992). It was shown forskolin promoted survival after transfer of SCs 
from serum to serum-free medium (Cheng and Mudge, 1996). However, in another study, 
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it was found forskolin itself had no effect on survival of SCs in serum-free medium, but it 
enhanced the effect induced by the other growth factors (Cheng et al., 1998). 
 
1.5.2 Glutamate  
Glutamate is the principal excitatory neurotransmitter. The two main types of glutamate 
receptors are ionotropic and metabotropic. Ionotropic receptors are directly coupled to 
membrane ion channels. The metabotropic receptors are coupled to intermediary 
compounds, such as G protein, and modulate intracellular second messengers, such as 
inositol-1,4,5-trisphosphate, calcium, and cyclic nucleotides. The directly coupled 
ionotropic receptor can be further subdivided into three subtypes: NMDA, AMPA and 
kainate. The NMDA receptors activation allows the influx of extracellular calcium (and 
sodium followed). Excessive accumulation of intracellular calcium is the key observed 
process leading to neuronal death or injury. 
Normal extracellular glutamate concentration is about 0.6 µM (Bouvier et al., 
1992). Substantial neuronal excitotoxic injury occurs with glutamate concentrations of 2 
to 5 µM (Meldrum and Garthwaite, 1990; Rosenberg et al., 1992). Traumatic injury to 
neurons can release the intracellular glutamate to the extracellular space, with 
concentrations reaching to about 10 µM. One recent therapeutic strategy is to 
immediately treat patients with injuries to the head or spinal column with glutamate 
receptor blockers to minimize the spread of neuronal death beyond the immediate 
physically disrupted neurons (Muir, 2006). Pharmacological study has shown NMDA 
receptors localized on SCs from guinea pig (Fink et al., 1999) 
 
1.5.3 ATP 
1.5.3.1. Biological functions of extracellular ATP and purinoceptors 
The concentrations of ATP in cells are in the range of 1-10 mM (Beis and Newsholme, 
1975). Upon cell breakage after injury, intracellular ATP will be released and the local 
concentration of ATP could be in mM range. Extracellular ATP can be degraded to ADP 
by ectoATPase. Druing cell transplantation procedure, although it is done very carefully 
to minimize the damage to the host tissue, certain injury is unavoidable due to penetration 
of injection needle. Also the space occupied by transplanted cells will put pressure on the 
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surrounding host tissues which may trigger the release of ATP from astrocytes, which has 
been shown to release large amount of ATP even by mechanical stimulation (Newman, 
2001). 
The extracellular effects of purines (and some pyrimidines as well) are mediated by 
purinoceptors, which has been classified into P1 and P2 families (Burnstock and 
Kennedy, 1985). P1 (also called adenosine receptors) consists of A1, A2a, A2b, and A3 
subtypes, is sensitive to adenosine and AMP. P2 purinoceptors are subdivided into P2X 
(ligand-gated ion channels) and P2Y (G-protein-coupled metabotropic receptors) 
subfamilies, which are activated by ATP, UTP, or ADP. Seven subtypes of P2X and eight 
subtypes of P2Y receptors have been cloned (Abbracchio et al., 2009). Each subtype of 
purinoceptors showed different affinities to different agonists and antagonists. Many of 
the P2X subtypes can form heteromultimers and gain new biophysical properties. 
 
1.5.3.2. Expression and biological functions of P2X7R 
Special attention has been paid to P2X7R subtype due to its involvement in inflammation 
and immune response. The P2X7R is highly expressed in macrophages, monocytes and 
lymphocytes (Surprenant et al., 1996). Within the CNS, functional P2X7R is localized on 
microglia and astrocytes (Ferrari et al., 1996; Collo et al., 1997; Sim et al., 2004). In rat 
DRG, P2X7R appears to be selectively localized on glial cells, but not neurons (Zhang et 
al., 2005). However, the existence of functional P2X7R on peripheral or central neurons 
remains controversial due to the poor specificity of both antibodies and ligands targeting 
the rat P2X7R (Sim et al., 2004; Anderson and Nedergaard, 2006). Unlike other members 
of the P2 receptor superfamily, homomeric P2X7R is activated by high concentrations of 
ATP (> 100 µM) and 2′,3′-O-(4-benzoylbenzoyl)-ATP (BzATP). BzATP is the most 
potent agonist for P2X7R, though it is not a selective agonist for this receptor (Jacobson 
et al., 2002). Brief activation of P2X7R by ATP results in Na+ and Ca2+ influx, K+ efflux, 
membrane depolarization. During continued or prolonged application of agonist, the 
P2X7R channels can aggregate to form large pores that allowed large molecules such as 
YO-PRO to pass through them (Surprenant et al., 1996). Membrane blebbing, cell 
apoptosis, inflammatory cytokine and chemokine expression are also involved in the 
P2X7R activation (Donnelly-Roberts and Jarvis, 2007).  
 57 
It has been reported that the activation of P2X7R was related to the process of 
cytokines singalling (Solle et al., 2001). The leukocytes from P2X7R knockout mice were 
found having abolished responses to ATP, such as the expressions of L-selectin and IL-1β. 
Additionally, the P2X7R knockout mice had markedly less incidence and severity of 
monoclonal anti-collagen-antibody induced arthritis compared to that of the wild-type 
mice. These data indicated the P2X7R can be seen as a crucial component of an in vivo 
inflammatory response (Labasi et al., 2002).   
The finding that disruption of P2X7R not only altered inflammatory pain but also 
reduces pain associated with frank nerve injury (Chessell et al., 2005) provided new 
insights into the potential physiological role of P2X7R in sensory functions. Previous 
data have shown that endogenous IL-1 levels were increased in the nervous system in 
response to trauma associated with mechanical damage, ischaemia, and hyperexcitability 
(Touzani et al., 2002). Increased IL-1 levels are also associated with enhanced 
nociceptive singalling in a concentration related fashion (Bianchi et al., 1998). Blockade 
of IL-1 receptors with the IL-1 receptor antagonist in spinal cord resulted in reduced 
nociception in animal models of inflammation and nerve injury induced pain 
(Safieh-Garabedian et al., 1995; Sommer et al., 1999). 
It is well established that ATP acting at P2X7R serves as an efficient secondary 
stimulus for the maturation and release of IL-1β from microglia and macrophages 
(Perregaux and Gabel, 1994; Ferrari et al., 2006). Thus, P2X7R activation may act as a 
danger signal in the context of tissue injury (Ferrari et al., 2006). However, due to the 
previous lack of appropriate pharmacological tools, the progress in disease models was 
quite slow. 
 
1.5.3.3 P2X7R activation and cell death 
Prolonged (>15 min) ligation of the P2X7R is reported to cause cell death and dramatic 
morphology changes in microglia/thymocytes/macrophages (Hogquist et al., 1991; 
Perregaux and Gabel, 1994; Falzoni et al., 1995; Ferrari et al., 1999; Tsukimoto et al., 
2005). More recently, it was found P2X7R was expressed in hematopoietic stem 
cells/progenitor cells, and P2X7R activation was involved in the cell apoptosis induced 
by ATP (Yoon et al., 2007; Delarasse et al., 2009).  
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Severe retardation of cell proliferation and cell apoptosis were observed following 
high-dosage ATP stimulation. The activation of intracellular caspases by the P2X7R is 
required for apoptotic alteration of ATP-induced cell death (Ferrari et al., 1999; Yoon et 
al., 2007; Delarasse et al., 2009). In another study investigating the detail mechanism of 
ATP induced cell death, it was found the BzATP-induced cell shrinkage was blocked 
when media Cl- was replaced with gluconate. Removal of extracellular Cl- blocked the 
BzATP-induced lactate dehydrogenase release, but not the pore formation and the 
membrane depolarization, which indicats that removal of extracellular Cl- did not prevent 
BzATP from binding to P2X7R but affected the process of apoptotic cell death. Taking 
the involvement of pore formation in cell shrinkage into consideration, they supposed that 
the involvement of extracellular Cl- influx via the pore formed in the P2X7R-mediated 
apoptotic cell death (Tsukimoto et al., 2005).  
P2X7R has been shown to be localized on mouse SCs by electrophysiology and 
immunocytochemistry (Colomar and Amedee, 2001). However, no direct study shows 
whether P2X7R activation induce SC death. If P2X7R is involved in the SC death 
during/after transplantation when high concentration of ATP is released, targeting P2X7R 
may enhance the survival of transplanted cells. 
 
1.6 Polysialic acid (PSA) 
1.6.1 Structure and biophysical properties of polysialic acid 
PSA is a linear polymer of N-acetylneuraminic acid in α2,8-linkage (Finne et al., 1983). It 
is mainly attached to the two asparagines in the Ig5 domain of the extracellular part of 
NCAM via a typical N-linked glycan (Hildebrandt et al., 2008). A single PSA chain may 
consist of more than 50 monomers, but the chain length may vary substantially (from 8 to 
100 monomers) (Inoue and Inoue, 2001; Galuska et al., 2006). These variations occur 
during developmental stage, between different regions of a tissue, and even on an 
individual neuron. Polysialylation can add 30% of relative molecular mass to NCAM 
molecules. PSA is mainly detected on NCAM, but is also found on the α subunit of 
sodium channels in adult rat brain (Zuber et al., 1992) and on neuropilin-2 of human 
dendritic cells (Curreli et al., 2007).  
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Fig. 1-3 Schematic representation of the structures of cell adhesion molecule NCAM. 
The three main isoforms of NCAM have five Ig-like domains and two fibronectin III 
repeats. NCAM-120 lacks a cytoplasmic domain and is attached to the membrane via a 
glycosylphosphatidylinositol link. Two polysialic acid chains can be attached to the fifth 
Ig domain of the NCAM molecule. (The image is modified from H. Hildebrandt et al., 
2008).  
 
     PSA is negatively charged and can occupy large space when hydrated (Yang et al., 
1992; Yang et al., 1994; Rutishauser, 2008). Electron microscopy images show that PSA 
expression increases intercellular spacing by 10–15 nm (Rutishauser et al., 1988). By 
directly measuring the repulsive and adhesive forces between two lipid membranes with 
membrane-bound NCAM, PSA-NCAM, or cadherin, it has been shown that NCAM 
polysialylation increases the range and magnitude of inter membrane repulsion (Johnson 
et al., 2005). The repulsion can attenuate not only homophilic NCAM–NCAM binding 
but also affects heterophilic binding with other cell surface molecules such as L1, laminin, 
cadherin, and integrin (Rutishauser et al., 1988; Acheson et al., 1991; Rutishauser and 
Landmesser, 1996; Johnson et al., 2005). Those interactions do not appear to depend 
directly on NCAM’s intrinsic binding function, because they are unaffected by NCAM 
cytoplasmic domain splicing variations and deletion of NCAM Ig 1–4 domains (Fujimoto 
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et al., 2001). Instead, the interactions are linked to PSA steric repulsion effect on 
membrane–membrane apposition. The steric repulsion effect allows dynamic changes in 
cell interactions and thereby facilitates axon growth, branching and plasticity. Due to the 
nature of PSA biophysical properties, it is unlikely that PSA can act as a ligand or 
receptor for signalling molecules. However, it may be able to influence the signal 
transduction of other molecules indirectly by increasing intercellular space, by affecting 
the clustering of signal molecules, or by assisting the accumulation of growth factors. 
One such example is demonstrated by the influence of PSA on the interaction of NCAM 
and FGF receptor (FGFR). The firm adhesion mediated by unpolysialylated NCAM may 
prevent the interactions between NCAM and FGFR. The disruption of tight binding 
between NCAMs by PSA may assist the dimerizatioin and clustering of FGFR and turn 
NCAM from an adhesion molecule to a singalling molecule (Kiselyov et al., 2005). PSA 
has also been shown to enhance or facilitate BDNF activation of its receptor TrkB and 
sensitize hippocampal pyramidal cells to the action of the growth factor (Muller et al., 
2000). Administration of exogenous BDNF rescues newborn (P0) rat cortical neurons 
death. In addition, it also reversed the adverse effects on on the P0 cortical neurons 
differentiation, induced by removal of PSA from cell surface in vitro (Vutskits et al., 
2001). Several models have been proposed for the observed cross-talk between 
PSA-NCAM and BDNF (Vutskits et al., 2001). In a recent study, it was shown that 
NCAM and TrkB directly interacted via sequences in their intracellular domains and 
binding of TrkB to the NCAM regulates phosphorylation of NCAM and 
NCAM-dependent neurite outgrowth (Cassens et al., 2010). 
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Fig. 1-4 The steric role of PSA at the cell surface. 
Schematic representation of molecular interactions during membrane-membrane contact. 
Note that while PSA is only attached to NCAM, its global effect on membrane-membrane 
apposition affects other contact-dependent receptors, such as cadherins. (The image is 
from Rutishauser, 2008). 
 
1.6.2 ST8SiaIV (PST) and ST8SiaII (STX) 
Polysialylation of NCAM was shown to be achieved by two α2,8-polysialyltransferases, 
ST8Sia IV (PST) and ST8Sia II (STX) (Cho and Troy, 1994; Nakayama et al., 1998; 
Franceschini et al., 2001). During development both enzymes are often expressed in the 
same region of the brain and work cooperatively on polysialylation. Both PST and STX 
transcripts are barely detectable at E8 and increased after E9 in mouse. STX is the 
dominating enzyme in the embryonic and early postnatal mouse, whereas PST prevails in 
the adult (Hildebrandt et al., 1998a; Ong et al., 1998). After birth the level of STX 
transcripts declines dramatically, whereas the level of PST transcripts gradually declines 
and maintains at a stable expression level. In adult nervous system, PST is more abundant 
than STX, and both transcripts are detectable only in restricted areas such as 
hippocampus, hypothalamus, and olfactory bulb where PSA expression persists (Seki and 
Arai, 1993; Angata et al., 1997; Phillips et al., 1997; Hildebrandt et al., 1998b; 
Hildebrandt et al., 1998a; Ong et al., 1998). The genetic ablation of PST generated mice 
in which the PSA synthesis was not significantly altered during development but almost 
completely absent in the adult (Eckhardt et al., 2000). In contrast, depletion of STX 
generated animals with ongoing PSA synthesis in the adult brain (Angata et al., 2004). 
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Both strains did not show gross anatomical abnormalities. Although distinct deficits have 
been identified in histological, electrophysiological, behavioural analyses (Eckhardt et al., 
2000; Angata et al., 2004), the data suggest that each gene partially compensates for the 
absence of the other. However, STX and PST double knockout mice exhibit postnatal 
lethality and morphological brain anomalies, such as hydrocephalus, reduction in size of 
the internal capsule, and malformation of the anterior commissure and corticospinal tract 
(Weinhold et al., 2005). Furthermore, these phenotypes were not observed in mice 
deficient in NCAM, STX, or PST alone while many of these phenotypes were rescued in 
mice lacking NCAM, STX, and PST (Weinhold et al., 2005), indicating that NCAM 
protein in PSA deficient mice is responsible for the severe phenotypes seen in STX and 
PST double knockout mice. 
It has been reported that, the degree of polysialylation by STX is lower than that by 
PST (about 20 residues less) (Angata et al., 2002). Both PST and STX are moderately 
related to another α2,8-sialyltransferase, ST8Sia III. However, PST and STX catalyze 
polysialylation of NCAM much more efficiently than ST8Sia III (Angata et al., 2000). 
It remains unclear whether the biofunction of polysialylation formed by STX or PST 
is different. In one experiment, it has been shown both STX and PST can polysialylate 
NCAM-140 and polysialyated NCAM-140 facilitates neurite outgrowth better than 
nonpolysialylated NCAM-140. However, NCAM-140 polysialylated by PST served as a 
better substrate for neurite outgrowth than NCAM- 140 polysialylated by STX (Angata et 
al., 1997).  
 
1.6.3 Expression of PSA in the central nervous system 
PSA is a developmentally regulated carbohydrate and is found to be most prevalent in the 
late development stage.The broadest expression of PSA within any tissue, including the 
nervous system, occurs in the early phases of its development, when it has been 
demonstrated to create permissive conditions for post-mitotic migration of neural and 
non-neural precursor cells. The classic example of the role of PSA in the neonatal 
nervous system has been in the rostral migration of large numbers of progenitors cells 
from the their birth place in the SVZ along a pathway to the olfactory bulb, where they 
become interneurons. Impaired migration of precursor cells has been reported in the 
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NCAM knockout mouse (Tomasiewicz et al., 1993) and PST/STX knockout mouse 
(Angata et al., 2007), or after removing or blocking PSA in diverse models (Ono et al., 
1994; Hu et al., 1996; Kiss, 1998; Yoshida et al., 1999; Decker et al., 2000), indicating 
that polysialylated NCAM plays an important role in the mobility of precursor cells. In 
most cases, PSA is permanently lost after the migration process is completed. However, a 
subset of those cells, in particular neurons that produce long axonal tracts, retain PSA 
which allows their growing processes to bundle and branch appropriately during axon 
path finding (Tang et al., 1992). As with cell migration, the arrival of axons at their final 
destination is often accompanied by a loss of PSA, possibly to facilitate the establishment 
of stable synapses (Bruses et al., 1995; Bruses et al., 2002). In addition to the role of PSA 
in migration of neuronal precursor cells, it has now been recognized that the presence of 
PSA on newly generated cells in the SVZ can also influence the timing of their 
differentiation (Seki et al., 2007). Previous studies have demonstrated that PSA-NCAM 
acts as a negative regulator of myelination and that axonal expression of PSA is 
down-regulated to allow myelin deposition on PSA-free axons (Charles et al., 2000; 
Jakovcevski et al., 2007). In line with this, the time window identified for the major loss 
of PSA coincides with the onset of myelination (Uzman and Rumley, 1958; Matthieu et 
al., 1973). Inverse to PSA down-regulation, massive up-regulation of NCAM-120, the 
characteristic isoform of oligodendrocytes and myelin sheaths (Bhat and Silberberg, 1986, 
1988), was observed. The majority of brain NCAM-120 was found in the PSA-free form, 
which is in agreement with the finding that migrating oligodendrocyte precursor cells but 
not mature myelinating oligodendrocytes express PSA (Trotter et al., 1989; Ben-Hur et al., 
1998). 
While overall PSA levels are greatly reduced in the adult brain, high levels of PSA 
persist in distinct regions that exhibit physiological plasticity, including regions of the 
hypothalamus, hippocampal, thalamus, habenular nuclei, mesencephalic central gray, 
lateral geniculate nucleus, and dorsal spinal laminae (Seki and Arai, 1991a, b; Bonfanti et 
al., 1992). Several studies (Theodosis et al., 1991; Nothias et al., 1997; Theodosis et al., 
1999; Monlezun et al., 2005) have revealed that perturbation of PSA levels influences a 
wide range of CNS functions, and/or that PSA is associated with cellular elements known 
to be directly involved in behavioural plasticity, such as learning and memory, regulation 
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of circadian rhythms, secretion of hypophyseal hormones, chronic pain and emotional 
reactions such as anxiety and aggression (Schauer, 2009). Because of the anatomical and 
functional complexity of these regions, it has not been possible to define the role of PSA 
to the same degree described for developing systems.  
Moreover, PSA is involved in the survival of neurons at development stage. Severe 
defects in anatomical organization of the forebrain associated with apoptotic cell death 
were reported in STX and PST double mutants (Angata et al., 2007). In vitro loss or 
inactivation of the PSA from NCAM on rat cortical neurons led to reduced differentiation 
and survival (Vutskits et al., 2001). An in vitro study showed that PSA is required for the 
survival of newly generated neurons (Vutskits et al., 2006; Gascon et al., 2007). By 
comparing cell death in NCAM knockout mice and wild-type animals and testing the 
effect of removing or blocking PSA-NCAM in a culture model, the results demonstrate 
that PSA-NCAM promotes neuronal survival by regulating p75NTR expression. It has ben 
speculated that by limiting p75NTR expression, PSA-NCAM may protect newborn 
neurons from being dependent on trophic support before integration into olfactory circuits. 
This may ensure that enough cells arrive and compete in the olfactory bulb. Neurons 
having reached their appropriate place in the granule/glomerular layer, and having 
established synaptic connections, would be coupled to network activity that is crucial for 
their long-term survival (Miwa and Storm, 2005). The progressive down-regulation of 
PSA-NCAM and the increase in p75NTR expression during maturation would contribute to 
the elimination of non-integrated and/or misplaced cells.  
 
1.6.4 Use of PSA in repair of central nervous system  
Expression of PSA leads to reduction in cell–cell adhesion that can create permissive 
conditions for structural remodeling, an essential step towards CNS repair. One of the 
environmental factors that are consistently found to be negative for axon regrowth is the 
astrocytes that form a scar at the lesion site. It has been found that, the few axon sprouts 
that display a more persistent growth in vivo tend to be found in close apposition with a 
subpopulation of astrocytes that transiently upregulate PSA following lesion, and 
enzymatic removal of this PSA blocks the sprouting (Aubert et al., 1998; Dusart et al., 
1999; Camand et al., 2004). These studies suggested that a more sustained elevation of 
 65 
PSA might allow further regeneration to occur. Transduction of scar astrocytes with a 
construct that expresses PST has been used to obtain sustained high levels of PSA. With 
this treatment, a substantial portion of severed corticospinal tract axons as well as sensory 
ascending axons were able to grow through the spinal injury site (Zhang et al., 2007c).  
Similarly, it was found that induced PSA expression in a path extending from the SVZ to 
a lesion near the cortical surface increased recruitment of BrdU+/nestin+ cells along the 
path and into the injury site (El Maarouf et al., 2006). These displaced precursors were 
able to differentiate in a regionally appropriate manner. These findings suggest that 
induced PSA expression can be used as a strategy for promoting tissue repair involving 
both replacement of cells and rebuilding of neural connections. In the past few years, our 
group has generated LV carrying a PST cDNA (LV/PST) or a fused PST-GFP cDNA 
(LV/PST-GFP). When SCs transduced by LV/PST were transplanted into the cerebellum 
of L1/GAP-43 transgenic mice, it was shown that much more Purkinje cell axons 
regenerating into the transplant than the control group (GFP/SCs) (Zhang et al., 2007a). 
When LV/PST was injected into the dorsal root entry zone (DREZ), it transduced the 
cells in spinal cord and promoted a significant number of injured sensory axons to cross 
DREZ into spinal cord (Zhang et al., 2007b). It was also observed that a large number of 
SCs migrated into the PSA-expressing region of the spinal cord and many regenerating 
axons were closely associated with the SCs. Similarly, engineered expression of PSA in 
combination with a conditioning lesion in spinal cord has been shown to promote the 
regeneration of sensory axons through the injury site (Zhang et al., 2007c). The results 
indicate that over-expression of PSA on grafted SCs or on cells in spinal cord can 
promote axon regeneration. More recently, it was found subdural infusion of PSA 
mimetic over 2 weeks immediately after spinal cord compression injury in mice, animals 
showed improved functional recovery assessed by locomotor rating and video-based 
motion analysis over a 6-week observation period. Moreover, compared with control 
mice, higher numbers of cholinergic and glutamatergic terminals and monaminergic 
axons in the lumbar spinal cord, and better axonal myelination were found in PSA 
mimetic-treated mice (Mehanna et al., 2010).  
In addition of directly inducing the expression of PSA in the host tissues or 
delivery PSA mimetic, over-expression of PSA on grafted SCs also showed promising 
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effects on promoting axonal growth and neural repair. When SCs transduced by LV/PST 
were transplanted into the cerebellum of L1/GAP-43 transgenic mice, it was shown that 
much more Purkinje cell axons regenerating into the transplant than the control group 
(GFP/SCs) (Zhang et al., 2007a). Moreover, when SCs transduced by LV or retroviral 
vector encoding STX were transplanted into compression injury iste of mice spinal cord 
(Papastefanaki et al., 2007) or lysophosphatidylcholine induced demyelinated mice spinal 
cord (Bachelin et al., 2010), they showed enhanced migration ability towards lesion site 
(Bachelin et al., 2010) and remyelination potential (Papastefanaki et al., 2007; Bachelin 
et al., 2010). Improved locomotor recovery was also observed (Papastefanaki et al., 2007) 
It has been suggested that PSA facilitate cell migration, neurite outgrowth and 
synaptic plasticity because its hydration volume could enhance flexibility of cell 
interactions. Evidence for receptors of PSA has so far been elusive. In a recent study, 
histone H1 was dentified as binding partner of PSA. Administration of histone H1 to 
lesioned femoral nerves promotes survival of motoneurons, axonal regrowth, precision of 
reinnervation, and better regeneration of the injured femoral nerve, leading to a 
remarkable complete functional recovery of locomotion after injury (Mishra et al., 2010) 
which is similar to those positive effects on recovery after femoral nerve lesion in mice 
treated with PSA-mimicking peptides (Mehanna et al., 2009). More studies need to be 
carried out to investigate the interaction between histone H1 and PSA. 
The neuroprotective effect of PSA-NCAM could also be important under 
pathological conditions. PSA is known to be reexpressed in lesion contexts, such as in 
mechanical damage, focal ischaemia, axotomy, stroke and epileptic seizures (Gascon et 
al., 2007). Remarkably, blockade or enzymatic disruption of PSA leads to an impaired 
repair process (Daniloff et al., 1986; Bonfanti et al., 1996) and the NCAM knockout mice 
exhibit deficient recovery after cortical lesions (Troncoso et al., 2004). It has been 
reported that, in a mice model of ALS, surviving motoneurons in transgenic animals 
express PSA-NCAM (Warita et al., 2001), which raises the possibility that PSA 
re-expression protects undamaged and functional neurons from cell death. Furthermore, it 
was found that enzymatic removal of PSA resulted in increased hippocampal neurons 
death via glutamate-induced excitotoxicity (Hammond et al., 2006) which indicates PSA 
could prevent excitotoxicity via inhibition of NR2B subunit-containing NMDA receptors. 
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1.7 Hypotheses and aims 
As discussed above, to make SC transplantation a more clinically applicable procedure, 
genetic modification of SCs in vitro before transplantation is an option to overcome the 
drawbacks of SCs in CNS repair. In this study, we genentically modified SCs by 
LV-mediated expression of PST to over-express PSA. 
SCs normally express little or no PSA. It is speculated that over-expression of PSA 
on SCs will reduce their adhesion and facilitate their migration. Engineered expression of 
PSA on SCs has been shown to enhance their migratory potential in vitro (Lavdas et al., 
2006). As we have shown that engineered expression of PSA on spinal cells can promote 
sensory axons growing across DREZ and facilitate the migration of endogenous SCs into 
the spinal cord (Zhang et al., 2007c), we also speculate that over-expression of PSA on 
spinal cells will provide a pathway to facilitate the migration of transplanted SCs. 
Recently, it was reported that PSA-expressing SCs showed enhanced migratory potential 
without impairment of their myelinating ability in vitro (Lavdas et al., 2006). It is 
reasonable to speculate that over-expression of PSA on grafted SCs can enhance their 
ability to provide a supportive environment for regrowth and remyelination of damaged 
axons. 
Extensive SC death after transplantation is another issue need to be solved. PSA 
has been shown to promote neuronal survival in physical and pathological conditions, 
although the underlying mechanisms for such phenomena are unclear. We propose that 
modification of SCs to over-express PSA may improve the survival rate of grafted SCs. 
In this study we studied over-expression of PSA on SCs on promoting their 
survival after transplantation, their migration in uninjured and injured spinal cord, their 
integration with the host tissue and their interactions with astrocytes in vitro.   
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Chapter 2  
Materials and methods 
2.1 Production of lentiviral vectors 
2.1.1 Preparation of lentiviral transfer vector  
The mouse PST cDNA was kindly provided by M. Eckhardt (Eckhardt et al., 1995) and 
subcloned into the lentiviral transfer vector pRRL (Naldini et al., 1996). In order to directly 
visualize the expression and localization of PST, PST cDNA was fused to the N-terminal 
of GFP cDNA to generate PST-GFP (Zhang et al., 2007c). The addition of GFP to the 
C-terminal of PST does not interfere with its enzymatic activity (Angata et al., 2001). 
mCherry (a kind gift from Roger Tsien) and GFP cDNAs were also subcloned into pRRL 
transfer vectors.  
Transfer vectors were transformed into NovaBlue competent cells (Novagen) and 
transformants were selected on LB agar plates containing ampicillin (100 µg/ml). After 
overnight incubation at 37°C, colonies were picked and grown in 3 ml Terrific Broth 
medium supplemented with 100 µg/ml ampicillin overnight until the ideal density was 
reached. Plasmid DNAs were then isolated and purified using Miniprep kit (QIAprep). To 
check whether the mini-prep plasmids have the predicted sequence, plasmid DNAs were 
digested with selected restriction enzymes in 20 μl at 37°C for 1 h. The digested plasmids 
were loaded into an 1% agarose gel to identify the sizes of the DNA bands. After 
confirmation, the midi-cultures were grown, followed by midi-prep (QIAprep kit) to 
produce larger quantity of plasmids for transfection. Plasmid DNA concentration were 
measured using an UV spectrophotometre, with sbsorption wave length at 260 nm. The 
purity of the DNA preparations was estimated by calculating the ratio of the absorbance at 
260 nm and 280 nm. It should be between 1.65 and 1.85. Plasmid DNAs were diluted to 1 
µg/µl. 0.5 µg of each plasmid was digested again with restriction enzymes to further 
confirm the DNA sequences and the concentrations of DNAs. Plasmid DNAs were stored 
at -80ºC until use. 
 
2.1.2 Production of lentiviral vectors 
The self-inactivating LV system was obtained from Prof. J.Verhaagen in Netherlands 
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Institute for Brain Research with the permission from Prof. Naldini in University of Naples 
Federico II, Italy. The production of the LV carrying the fused mouse PST-GFP 
(LV/PST-GFP) or LV carrying GFP (LV/GFP from J.Verhaagen) or LV carrying mCherry 
( LV/mCherry) was based on the protocol of Dull et al. (Dull et al., 1998).  
     HEK293T cells (2.5-5 × 106) were plated in a 10 cm dish in HEK cell complete 
medium: Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat 
inactivated foetal bovine serum (FBS, Invitrogen), 100 unit/ml penicillin, 100 µg/ml 
streptomycin (Sigma-Aldrich) and 2 mM L-Glutamine (Sigma-Aldrich). Cells were 
cultured in a humidified incubator at 37°C with 5% CO2 + 95% air. One dish of cells was 
split into 4 dishes when they reached 75% confluency. When the required number of dishes 
of HEK cells was reached and the cell density was about 90% confluency, transfection was 
carried out using calcium precipitation method. Medium in the dishes was replaced 2 h 
before transfection to ensure the pH in the medium was 7.2 as pH will affect the transfectin 
efficiency. The amount of transfection mix prepared was based on the numbers of 10 cm 
dishes of cells (see the table below). Varied amount of sterile H2O, 0.1 × Tris-EDTA (TE), 
transfer vector, package vector (PACK), and envelope vector (ENV) were mixed together 
(Table. 2-1). CaCl2 was then added and mixed again. To obtain high transfection 
efficiency, the mixture was vortexed vigorously while adding equal volume of 
HEPES-buffered saline (HBS) drop by drop. The speed was about at 2 drops per second. 
The mixture was then immediately added to the dish. The dishes were swirled gently in 
different directions to make sure the transfection mixture was distributed evenly.    
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Table. 2-1 Preparation of transfection mixture  
Components   For 1 × 10 cm dish For 2 × 10 cm dishes 
Sterile H2O 180 μl 360 μl 
0.1 x TE 250 μl 500 μl 
ENV* 3.5 μl 7 μl 
PACK* 6.5 μl 13 μl 
Transfer vector* 10 μl 20 μl 
2.5 M CaCl2 50 μl 100 μl 
2 x HBS 500 μl 1,000 μl 
Total 1,000 μl 2,000 μl 
                       *All plasmids were diluted to 1 µg/µl. 
The medium was replaced 14 to 16 h after transfection with 9 ml medium containing 2% 
FBS. Over 90% cells should be green at this time if the transfection was good. Medium was 
collected 48 h after transfection and centrifuged at 1000 rpm for 5 min to remove the cell 
debris. The medium was then filtered through 0.22-µm pore-sized cellulose acetate filters. 
For concentration of the viral vectors, the medium from three dishes was loaded into a 28 
ml Ultracone tube and concentrated by centrifugation at 20,000 rpm (~74,000 ×g) for 2.5 h 
in a Sorvall Surespin 630 swing-bucket rotor. The supernatant was discarded carefully by 
suction. To remove the medium as much as possible, the tubes were then put upside down 
for 5-10 min. The medium around the neck of the tubes was removed by suction. The viral 
vector pellet was resuspended in 50 µl of filtration sterilized PBS and incubated at room 
temperature (RT) for 30 min to allow it disperse in PBS thoroughly. The resuspended viral 
particles were then aliquoted in screw-capped tubes (5 µl each) and stored at -80°C.   
 
2.1.3 Titration of lentiviral stocks 
The day before titration, HEK cells were plated at 2.5-5 × 105 cells/well in 6-well-plates in 
HEK cell complete medium. Serial dilutions of viral stock from 10-3 to 10-8 were prepared 
in HEK cell complete medium (Fig.2-1). Culture medium was replaced with 1 ml fresh 
medium plus 1 ml diluted viral stock. Twenty four h after infection, medium was replaced 
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with fresh one and the cells were incubated for another 24 h. Cells were then fixed and the 
transduced cells expressing GFP or mCherry were counted for calculating the transduction 
unit (TU) according to the formula below: 
Number of green (or red for mCherry) cells (in one field of 10× objective lens) × viral 
stock dilution × 700 = TU/ml 
The titre for LV/PST-GFP was in the range of 0.5 - 1 × 1010 TU/ml, and 1 - 7 × 1010 TU/ml 
for LV/GFP and LV/mCherry.  
 
 
Fig. 2-1 Preparation of viral serial dilutions for titre evaluation 
Serial viral stock dilutions (from 10-3 to 10-8) were made in HEK cell complete medium. 
Comp. Medium = HEK cell complete medium.   
 
2.2 Cell culture and transduction 
2.2.1 HeLa-NCAM140 cell lines  
2.2.1.1 Thawing frozen cell stocks 
HeLa-NCAM140 stable cell lines were kindly provided by Minoru Fukuda (Angata et al., 
1997). A vial of frozen cells was taken out from liquid nitrogen and kept on dry ice. The 
cells were incubated in water bath at 37ºC under gently shaking until completely thawed. 
The cells were transferred into a 15 ml centrifuge tube containing 10 ml pre-warmed 
complete medium (same as HEK cell complete medium). Cells were then centrifuged at 
1,000 rpm for 5 min and the supernatant was carefully removed. Cells were resuspended in 
 72 
1 ml complete medium by pipetting up and down and transferred into a 10 cm Petri dish. 
The medium was replaced with fresh one after 12-24 h.  
 
2.2.1.2 Subculturing  
Cells were normally confluent and ready for passaging by the second or the third day after 
thawing and then every 3-4 days afterwards, at a dilution of 1 to 4 or 1 to 6 depending on 
the density of the cells. The medium was removed and cells were washed with Hanks’ 
balanced salt solution (Sigma-Aldrich). Two ml of 0.25% trypsin/EDTA solution 
(Sigma-Aldrich) was added and cells were incubated at 37ºC for several min until they 
began to detach. Eight ml complete medium was added to neutralize trypsin. Cells were 
triturated several times and transferred into a 15 ml centrifuge tube, then centrifuged at 800 
rpm for 5 min. After removing the supernatant, the cell pellet was resuspended in 1 ml 
fresh complete medium. The density of cells was determined by haemocytometry. The 
number of cells seeded into a new Petri dish depended on the size of the Petri dish. Fresh 
medium was added to reach the desired volume.  
 
2.2.1.3 Transfection of PST into HeLa-NCAM140 cells 
HeLa-NCAM140 cells were transfected with pRRL/PST-GFP using Lipofectamine 2000 
according to the manufacturer’s instructions (Invitrogen) with slight modification. Cells 
were grown on poly-L-lysine (PLL, Sigma, 10 μg/ml) coated coverslips placed in a 35 mm 
dish. To obtain high transfection efficiency, transfection was carried out when the cells 
reached 90-95% confluency. To prevent cell death, growth medium was replaced with the 
medium without antibiotics before transfection. The amounts of Lipofectamine 2000, 
DNA and medium used for transfection were adjusted according to the size of Petri dish 
and cell types (Table. 2-2). 
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Table. 2-2 Preparations of transfection of Lipofectamine 2000 
Culture  
Vessel 
Volume of Plating  
Medium 
DNA (µg) and  
Dilution Volume (µl) 
Lipofectamine 2000 (µl)  
and Dilution Volume (µl) 
24 well 500 µl 1 µg in 50 µl 3 µl in 50 µl 
35 mm 2 ml 2 µg in 100 µl 6 µl in 100 µl 
60 mm 5 ml 4 µg in 250 µl 12 µl in 250 µl 
10 cm 10 ml 10 µg in 1 ml 30 µl in 1 ml 
 
Two 1.5 ml tubes were prepared for each transfection. The required amounts of Opti-MEM 
I medium (Invitrogen) were dispensed into each tube. Lipofectamine 2000 reagent was 
diluted into one of the Eppendorf tubes and incubated for 5 min at RT. The required 
quantity of plasmids was added into the second Eppendorf tube. The diluted Lipofectamine 
2000 was then combined with the diluted plasmid by mixing them gently and incubated for 
20 min at RT. This stage allows the DNA-Lipofectamine 2000 complexes to form. The 
complexes were added directly to each dish and mixed gently by rocking the dish. The cells 
were incubated at 37ºC in a humidified incubator with 5% CO2. Medium was replaced with 
complete medium after 12 h to minimize the toxicity caused by Lipofectamine 2000.  
 
2.2.1.4 Detection of PSA expression on HeLa-NCAM140 cells 
Forty-eight h after transfection, some PST transfected cells on coverslips were fixed with 
cold 4% paraformaldehyde (PFA) for 10 min, washed in PBS 3 × 5 min and then processed 
by immunocytochemistry to identify PSA expression. It was found GFP fluorescence 
mainly distributed in the Golgi apparatus in pRRL/PST-GFP transfected cells where PST 
located.   
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Fig. 2-2 Expression of PSA on Hela-NCAM140 cells 
HeLa-NACM transfected with pRRL/PST-GFP immunostained with anti-PSA antibody 
mAb735 (red in B, C). Arrows point to PST-GFP fusion protein. Scale bar = 50 µm.  
 
 
2.2.2 HEK cells 
HEK 293T cells were cultured with the similar procedures as for HeLa-NCAM140 cells.   
2.2.3 Schwann cell culture and transduction 
2.2.3.1 Purification and culture of Schwann cells 
SCs were purified from 2-3 days old (P2-3) neonatal Wistar rats according to the method 
of Brockes et al. (Brockes et al., 1979). The dissecting area and equipment were sterilized 
with 70% ethanol. A corkboard was covered with tin foil and then sterilized with 70% 
ethanol. P2-3 neonatal rats were killed by decapitation. The bodies were pinned onto the 
corkboard and sterilized with 70% ethanol. Sciatic nerves and nerves from brachial 
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plexus were dissected out under a dissection microscope, and placed in a 35 mm dish 
containing L15 medium (Sigma-Aldrich), which was kept on ice. After being stripped of 
epineural sheath and connective tissue, the desheathed nerves were placed in a fresh dish 
containing L15. Nerves were incubated with 2.5% trypsin (Sigma-Aldrich) (100 µl per 
pup) and equal volume of 0.4% collagenase (Type II, Worthington Biochemical 
Corporation) at 37oC for 35 min. Nerves were dissociated by mechanical trituration using 
a 1 ml tip and incubated for a further 10 min. They were then triturated again with a 200 
μl tip until they were fully dissociated. Equal volume of fresh complete medium was 
added to stop the enzymatic digestion. The digested nerves were then passed through a 
filtre (70 µm in pore-size, BD), transferred to a 15 ml tube and centrifuged for 10 min at 
1,000 rpm. The supernatant was carefully removed. Cells were resuspended in fresh SC 
culture medium (DMEM medium containing 10% FBS, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 25 ng/ml ß-heregulin (R&D Systems), 2 µM forskolin (Sigma), 25 ng/ml 
FGF (PeproTech) and 5 µg/ml insulin (Sigma) and plated in a PLL (Sigma, 10 μg/ml) 
coated 10 cm dish. Culture medium was replaced every 3 days afterwards. SCs were 
identified with immunostaining using anti-p75NTR or anti-S100 antibodies.  
 
2.2.3.2 Transduction of Schwann cells 
Cultured SCs were transduced with either LV/GFP (referred as GFP/SCs) or LV/PST-GFP 
(referred as PST/SCs). Due to weak GFP fluorescence from PST-GFP fusion protein 
expressed in SCs in vivo, LV/PST-GFP transduced SCs were co-transduced with LV/GFP 
for easy identification. To further confirm the polysialylation of NCAM, PST/SCs or 
naïve SCs were washed in pre-chilled Hanks’ balanced salt solution and harvested by a 
cell culture scraper without TE treatment to avoid membrane protein degradation. The 
detached cells were transferred into a 15 ml centrifuge tube, spun at 800 rpm for 5 min, 
followed with PBS washing, and pelleted by centrifugation again. Cells were either used 
immediately or stored at -80°C for Western blotting analysis. Some samples were treated 
with 0.7 units endoneuraminidase (Endo-N, AbCys S.A, France) for 1 h at 37°C to 
remove PSA from NCAM. 
 
2.2.3.3 Preparing LV-transduced Schwann cells for transplantation 
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PST/SCs or GFP/SCs were washed with 1 ml of DMEM before adding 600 µl of 0.25% 
trypsin/EDTA to dissociate the cells. The cells were checked under a microscope to make 
sure most of the cells were detached from the dishes before 2 ml of complete medium was 
added to neutralize trypsin. Dissociated cells were then transferred into a 15 ml centrifuge 
tube. One ml complete medium was added to the dish to collect the cells remained in the 
dishes. Cells were then centrifuged at 900 rpm for 10 min. After removing the medium the 
cell pellet was resuspended in 1 ml of DMEM and transferred to a 1.5 ml tube. The 
resuspended cells were centrifuged at 2,500 rpm for 5 min. The wash step was repeated 
once more. Cell pellet was resuspended in 5-10 µl DMEM. Cells were counted and the 
density of cells was adjusted to 100,000 cells/µl. Cells were kept on ice and ready for 
transplantation. 
 
2.2.4 Astrocyte culture and transduction 
Astrocytes were purified from the cerebral cortex of neonatal (P2-3) rat according to 
McCarthy and de Vellis (Braunewell et al., 1995). Two P3 neonatal pups of Wistar rat were 
sacrificed by decapitation. Using micro-dissection scissors, the skin was opened at the 
midline of the head, cutting from the base of the skull to the mid-eye area. After folding 
back the skin flaps with the scissors, the skull was cut at the midline fissure, without cutting 
into the brain tissue. The raised skullcap was removed with the curved forceps, applying 
slight pressure. The brain was then released from the skull cavity by running a 
micro-spatula underneath and along the length of the brain from the olfactory lobes to the 
beginning of the spinal cord. 
     Dissected brains were gently transferred to a 35 mm Petri dish containing 2.5 ml 
DMEM/F12 serum free medium (SFM). One brain was removed from the 35 mm Petri dish 
to the inverted lid of a 35 mm Petri dish. Cerebral hemispheres were removed using 
microdissecting forceps and the olfactory lobes were no longer attached. The cerebral 
hemispheres were immediately immersed in SFM in another sterile 35 mm Petri dish. 
Hemispheres were then placed onto the inverted lid of a second Petri dish. Meninges and 
blood vessels were removed using microdissecting forceps. The hemisphere piece was 
placed into a fresh Petri dish containing DMEM/F12 SFM. The brain was chopped and 
incubated with 0.1% trypsin in DMEM for 30 min at 37°C in a humidified incubator with 
 77 
5% CO2. The mixture was then triturated in triturating solution (10% FBS in DMEM 
containing 100 µg/ml soybean trypsin inhibitor, 0.5 µg/ml DNase I) and the cells were 
centrifuged and resuspended in DMEM + 10% FBS. Cells were plated in PLL-coated (10 
μg/ml) 75 cm2 tissue culture flasks at a concentration of 1.5 × 107 cells in 10 ml of medium 
or in 25 cm2 tissue culture flasks at a concentration of 5 × 106 cells in 5 ml of medium. 
Incubating the flasks with lid loosened at 37°C in a moisturized incubator with 5% CO2 and 
95% air, allowing the cells sufficient time to adhere and begin multiplying. The medium 
was changed every 48-72 h afterwards. After 6-7 days' culture, the medium was changed to 
remove microglia which were floating in the medium. At the end of 7-9 days phase-dark, 
process-bearing cells were observed to approximate a confluent phase-gray bed layer of 
cells. The culture medium was then changed again. Flasks were closed tight with lids, 
placed on a shaking platform in a horizontal position, and were shaken at 200 rpm for 6 h at 
37ºC to separate the oligodendrocytes from the astrocytes. Medium was changed and the 
flasks were shaken for 18 h (the discarded medium usually contains oligodendrocytes, 
dividing astrocytes and macrophages). The medium was changed again and the shaking 
process was repeated for further 24-48 h to remove additional oligodendrocytes. The flasks 
were then replenished with fresh culture medium and shaken at 100 rpm, until fewer than 
10 phases–dark cells per microscope field of view (10× objective lens) were observed. 
Fresh medium was replenished every 2 days afterwards. According to the experimental 
design, some cultured astrocytes were transduced with LV/PST-GFP or LV/GFP.  Five 
days later cells were subsequently subcultured. All medium was removed from the flasks, 
and the cells were firstly washed with 5 ml of Hanks’ balanced salt solution and then 
incubated with 2 ml of 0.25% trypsin/EDTA solution at 37°C for 5-10 min until the cells 
were completely disaggregated. The cells were resuspended in 8 ml DMEM plus 10% FBS 
and transferred to a 15 ml centrifuge tube. After being centrifuged for 5 min at 800 rpm, the 
medium was discarded and cells were resuspended in 2 ml fresh culture medium. The cell 
density was determined by haemocytometre and 4 × 105 cells were plated in each 35 mm 
Petri dish or on coverslips in Petri dishes depending on the purpose of each individual 
experiment.  
 
2.2.5 Neural stem/progenitor cell culture 
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NSCs/NPCs were obtained from a colleague in our Centre. The procedure for isolation 
and proliferation of neural stem/progenitor cells was performed according to the 
protocols of Pacey et al. (Pacey, 2006) and Hutton and Pevny (Hutton, 2008). P7 neonatal 
C57BL/6J mice were sacrificed and sprayed with 70% ethanol. Under sterile conditions, 
the brain tissue of the mice was isolated and washed with PBS for three times, then cut 
into small pieces. Brain tissue clumps were treated with 0.05% trypsin (Gibco) at 37ºC 
for 5 min, and filtered with a 70 µm cell strainer (BD). The cells were collected and 
centrifuged at 1000 rpm for 7 min. The precipitated cells were resuspended and seeded 
into a 60 mm dish in the serum-free medium containing DMEM/F12 (Invitrogen), B27 
(2%, Invitrogen), bFGF (20 ng/ml, Invitrogen) and epidermal growth factor (EGF, 20 
ng/mL, R&D). The cells were cultured at 37ºC with 5% CO2. Medium was replaced 
every day. After 6–7 days of suspension culture, the neurospheres were re-plated onto 
matrigel-coated 60 mm tissue culture dishes for adherent culture in the same medium for 
another 2–3 days. The adherent neurospheres were dissociated with 0.25% trypsin/EDTA 
into single cells and passaged for monolayer culture. The NPCs in mono-layer culture for 
2–3 passages were characterized by immunostaining with anti-nestin antibody. 
 
2.3 Surgeries 
2.3.1 Cell transplantation and spinal cord crush injury 
All the surgery procedures were performed strictly in accordance with UK government 
legislation on animal care and genetic manipulation. Adult female Wistar rats (200-250 g) 
were used for SC transplantation experiments. 
 
Transplantation of Schwann cells to intact spinal cord  
Animals were deeply anaesthetized with isoflurane. A laminectomy was performed to 
expose spinal cord at T8 level. One μl containing 100,000 PST/SCs or GFP/SCs was 
injected into the dorsal column (1.2 mm depth from dura) using a Hamilton syringe 
connected to a 33 gauge fine metal needle. The injecting speed was 200 nl/min controlled 
by UltraMicroPump II (World Precision Instruments, Sarasota, FL, USA). The needle 
was left at the injection site for a further 5 min to prevent leakage from the needle track. 
Animals were treated with or without ciclosporin (10 mg/kg intraperitoneally, daily) to 
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assess the effect of immune response on the survival of transplanted SCs. The rats were 
sacrificed by perfusion with 4% PFA at 1, 7, 19, and 30 days after transplantation. The 
segments of spinal cords containing the transplanted SCs were removed.  
 
Transplantation of Schwann cells to the spinal cord caudal to the lesion site  
Spinal cord at T8 level was crushed with a pair of fine forceps at a depth of 1.5 mm for 5 
s. One μl (100,000 cells) of PST/SCs or GFP/SCs were injected into the dorsal column 
2.5 mm caudal to the lesion site as described above. To study whether engineered 
expression of PSA in the spinal cord can further enhance the migration of transplanted 
SCs towards the lesion sites, LV/mCherry (as control) or LV/PST-GFP were injected 
adjacent to the lesion sites immediately after transplantation of PST/SCs or GFP/SCs. 
The muscle and skin incisions were closed with sutures. Animals were treated with 
ciclosporin daily. Three weeks after transplantation animals were killed by perfusion with 
4% PFA and the segments of spinal cord containing the injury site and transplanted SCs 
were removed. Animals were monitored daily after surgery. Weight of animals was 
recorded daily. Saline was administered for animals with severe weight loss, up to 20 
ml/day. Bladder expression was performed one or two times per day, until the animal 
recovered its bladder function. 
 
2.3.2 Tissue preparation  
Animals at different time points after surgery were briefly anaesthetised by CO2 and then 
overdosed with Euthanal (60 mg/kg) by intraperitoneal injection. When reflexes were no 
longer present but before respiration failed, the ventral abdominal wall was opened along 
the midline and the diaphragm was cut around part of its periphery. The rib cage was 
opened with scissors along both sides and pulled back and secured with clamps to expose 
the heart widely. The right atrium was opened with a pair of scissors to release venous 
blood. A blunt cannula was immediately inserted into the left ventricle and up into the 
aorta. The animals were first exsanguinated with 200 ml of 0.9% saline and then perfused 
with 300 ml of pre-chilled 4% PFA in 0.1 M phosphate buffer (PB), pH 7.4. Spinal cords 
containing the transplanted SCs and the lesion site were removed and postfixed in the 
same fixative overnight and then cryoprotected with 30% sucrose in 0.1 M PB at 4°C 
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until they had sunk. Samples were then embedded with OCT on dry ice. Segments of 
T8-9 spinal cords were cut longitudinally at a thickness of 15 µm in a cryostat. The 
sections were collected on polysine-coated slides (BDH). 
 
2.4 Immunoblotting 
2.4.1 Sample preparation 
2.4.1.1 Protein dissociation from cultured cells  
The collected cell pellets were resuspended in cell solubilization buffer (20 mM Tris-HCl, 
150 mM NaCl, 2 mM EDTA, 0.8% NP-40, pH 7.4) containing Complete Mini protease 
inhibitors (Roche, 1 tablet added into 7 ml solubilization buffer) at a 1:5 weight/volume 
ratio and kept on ice for 1 h with occasional tapping of the tubes. They were then 
centrifuged at 13,000 rpm for 15 min at 4°C. Supernatants were collected, aliquoted, and 
used for sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) 
immediately or stored at -80°C. 
 
2.4.1.2 Measurement of protein concentration  
Concentrations of solubilized proteins were measured using the DC Protein Assay kit from 
Bio-Rad. A standard curve was constructed using bovine serum albumin (BSA, New 
England Biolab) diluted with the same solubilization buffer for the sample preparation in 
the following concentrations (mg/ml): 0.2, 0.4, 0.7, 1.0 and 1.5. Five µl of standards and 
samples were added into Eppendorf tubes. For the blank, 5 µl of solubilization buffer was 
used. Twenty-five µl of Reagent A and 200 µl of Reagent B were added into each tube. The 
components in each tube were mixed gently by inverting the tube for several times. After 
incubation for 15 min, the absorbance was then read at the wavelength of 750 nm. 
 
2.4.1.3 Endo-N treatment 
Solubilized proteins (10 µg) from LV/PST-GFP transduced SCs were treated with 0.7 unit 
of Endo-N (AbCys S.A, Paris, France) at 37°C for 1 h to remove PSA from NCAM.  
 
2.4.2 SDS-PAGE 
2.4.2.1 Gel casting  
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Separating and stacking gel solutions were prepared separately (Table. 2-3). Usually, 10 ml 
separating and 3 ml stacking gel solutions are enough for 2 mini gels (10 cm × 10 cm). 
                       
                    Table. 2-3 SDS-PAGE preparation 
 
Components Separating Gel  
 
Stacking Gel 
10% 8% 6% 
H2O 4.0 ml 4.63 ml 5.3 ml 2 ml 
30% acrylamide 3.3 ml 2.67 ml 2 ml 0.5 ml 
1.5 M Tris pH 8.8 2.5 ml 2.5 ml 2.5 ml ------- 
1.0 M Tris pH 6.8 ------- ------- ------- 0.38 ml 
10% SDS 100 µl 100 µl 100 µl 23 µl 
*10%Ammonium Persulphate   100 µl 100 µl 100 µl 23 µl 
TEMED 4 µl 4 µl 4 µl 2.3µl 
Total 10 µl 10 µl 10 µl 3 µl 
*Ammonium persulphate (APS) was prepared freshly in water. 
 
The ingredients of separating gel were mixed gently and the solution was poured quickly 
into gel cast until its height reached 1 cm below the bottom line of the comb. The gel was 
overlaid with distilled water very carefully to ensure a flat surface and to exclude air. After 
the gel polymerized completely (about 20-30 min), the distilled water was removed. The 
stacking gel solution was mixed well before being poured on top of separating gel and a 
comb was inserted. After the gel set (about 10-15 min), the comb was removed and the gel 
tank was filled with electrophoresis running buffer (25 mM Tris-base, 25 mM glycine, 
0.1% SDS). Gel wells were washed with running buffer using a syringe and the air bubbles 
between the two glass-plates were removed before the samples were loaded. 
 
2.4.2.2 Sample loading and electrophoresis 
Samples were mixed with 5 × sample buffer (62.5 mM Tris-HCl, PH 6.8, 20% glycerol, 2% 
SDS, 0.025% Bromophenol blue, 5% β-mercaptoethanol) in the ratio of 4:1 and heated at 
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95ºC in a heat block for 5 min to denaturize the proteins. Samples were then chilled on ice 
and ready for loading. Samples (10 µg proteins) and Precision Plus Protein Dual Color 
Standards from Bio-Rad were loaded into the wells of the polyacrylamide gel. The gels 
were run using a mini gel system (Bio-Rad) at 100-150 V constantly for 1-2 h until the 
markers appeared in the expected places.  
 
2.4.2.3 Membrane transfer 
Polyvinyldifluoride (PVDF) membrane (Bio-Rad) and filter paper were cut to size slightly 
bigger than the gel. PVDF membrane was soaked in methanol for 5 min. Gel was removed 
from electrophoresis apparatus, trimmed (the stacking gel was discarded) and rinsed in 
distalled water remove SDS. Pads, filter papers, gel and wet PVDF membrane were then 
pre-soaked in transfer buffer (120 mM glycine, 15.6 mM Tris-base, and 20% methanol) for 
10 min. The “transfer sandwich” was assembled in the following order from cathode (-) to 
anode (+): pad, filter paper, gel, PVDF membrane, filter paper, pad. Caution was taken to 
avoid air bubbles during the sandwich preparation. The “transfer sandwich” was then 
placed in a mini gel transfer tank (Bio-Rad). An ice pack was placed in to cool down the 
buffer during transfer. The transfer tank was filled with 1 × pre-chilled transfer buffer 
(about 800 ml for one transfer) and the separated proteins were transferred at 200 mA 
constant at 4°C for 1 h.  
 
2.4.2.4 Immunoprobing 
The membrane was removed from the transfer apparatus and washed in Tris buffered 
saline (TBS, 20 mM Tris-HCl, 150 mM NaCl, pH 7.5) for 5 min twice on  a platform 
shaker. The wash is important to reduce spotted or blotched background. The membrane 
was marked with pencil for the orientation at this stage. After blocking in 10% skimmed 
milk freshly made in Tris buffered saline (TBS) on a shaker for 1-2 h at room temperature 
or overnight at 4°C the membrane was rinsed in TBS with Tween 20 (TTBS, TBS + 0.1% 
Tween 20, Sigma-Aldrich) for 5-10 min. To minimize the usage of antibodies the 
membrane was trimmed to an appropriate size and probed with different primary 
antibodies in TTBS/10% skimmed milk overnight at 4°C or for 2 h at RT on a shaker. A 
mouse monoclonal antibody mAb735 (gift from Hildebrandt and Gerardy-Schahn in 
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University of Hanover, Germany, 1:1000) was used to immunoblot PSA. The membrane 
was washed 3 × 20 min in TTBS, followed by incubation with anti-mouse IgG-horseradish 
peroxidase (Amersham, 1:10,000) for 90 min at RT on a shaker. The excess secondary 
antibody was rinsed off with TTBS 3 × 10 min. The membrane was then ready for 
detection with ECL Plus Western Blotting Detection Reagents (Amersham).  
 
2.4.2.5 Detection 
Amersham ECL western blotting detection kit (GE healthcare) was used in this step. The 
detection reagents were equilibrated to RT before opening. The detection solutions A and 
B were mixed in a ratio of 40:1. The final volume of detection regent required was 0.1 
ml/cm2 of membrane. The excess wash buffer was drained from the membrane and the 
membrane was placed on a sheet of cling film with protein side facing up. The mixed 
detection reagent was pipetted on to the membrane evenly. The reagents should have 
covered the entire surface of the membrane. Membrane was incubated for 5 min at RT.  
The excess detection reagent was drained off. Membrane was placed protein side down to 
a piece of Saran Wrap and wrapped gently to remove any air bubble. The wrapped 
membrane was then placed protein side up in an X-ray film cassette. The following stages 
were carried out in a dark room. A sheet of Hyperfilm ECL (Amersham) was cut to an 
appropriate size and placed on top of the membrane. The cassette was closed and the film 
was exposed for different times in order to achieve the best signals and minimum of 
background. The exposure time varied from 5 s to 30 min.  
 
2.5 Immunocytochemistry and Immunohistochemistry 
2.5.1 Immunocytochemistry  
Cells were fixed in 4% PFA washed in PBS containing 0.2% Triton X-100, then blocked 
with 10% normal donkey serum (NDS) or 10% normal goat serum (NGS) in PBS 
according to the species of the secondary antibodies. The following primary antibodies 
were used: polyclonal anti-GFAP antibody or monoclonal anti-GFAP antibody, 
polyclonal anti-p75NTR antibody, monoclonal anti-PSA antibody, monoclonal anti-BrdU 
antibody, pan anti-CSPGs, CS-56. Primary antibodies were diluted with 10% NDS (or 
10% NGS) and 1% BSA containing 0.2% Triton X-100 in PBS and applied for 60 min at 
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RT, followed by incubation with appropriate secondary antibodies for 60 min. To detect 
cell membrane proteins, no detergent was used in blocking solution and washing buffer. 
To detect other proteins, Triton X-100 or Tween 20 was used in blocking solution and 
washing buffer to permerbilize the cell membrane.  
For nucleus staining, 4’,6’diaminidino-2-phenylindole (DAPI, 0.0002%, 
Sigma-Aldrich) was applied for 5 min. After final wash, coverslips were mounted in 1:9 
PBS-glycerol.  
For BrdU staining, cells were fixed in 4% PFA, followed by treatment with 2 M HCl 
for 1 h. After thorough wash, cells were immunolabeled with anti-BrdU antibody 
overnight at 4°C, followed by incubation with TRITC conjugated anti-mouse IgG (1:600) 
for 60 min.  
 
2.5.2 Immunohistochemistry 
Routine immunohistochemistry was carried out on parasagittal cryosections (15 µm thick) 
of spinal cords. For GFAP/PSA or CSPGs/PSA double staining, sections were first 
incubated with blocking solution (10% NDS or NGS) for 2 h, and then in a mixture of 
antibodies against GFAP or CSPG and PSA diluted in blocking solution overnight at 4°C. 
After thorough wash with PBS (3 × 10 min), the sections were subsequently incubated 
with a mixture of appropriate secondary antibodies for 2 h. The sections were washed in 
PBS, mounted in 1:9 PBS-glycerol. 
To detect myelination of implanted SCs, mouse monoclonal anti-P0 antibody was 
used, slides were rinsed with PBS (3 × 5 min), pre-treated with ice-cold methanol for 5 
min at -20ºC followed by washing with PBS (3 × 10 min). Then an appropriate secondary 
antibody was applied. 
 
The details of the antibodies used in this thesis for immunostaining are shown in Table. 2-4 
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Table. 2-4 Details of antibodies used  
Name  Concentrati
on 
Source  
Primary antibodies 
Mouse monoclonal IgG anti-PSA (mAb735) 1:1,000 Gift from 
Prof.Hildebrandt and 
Gerardy-Schahn in 
Hannover Medical 
School, Germany 
Mouse monoclonal IgM anti-PSA (5A5) 1:50 BD Pharmingen 
Mouse monoclonal IgG anti-GFAP  1:1,000 Sigma-Aldrich 
Mouse monoclonal IgG anti-Neurocan  1:1,000 Millipore 
Rabbit polyclonal IgG anti-GFAP 1:1,000 Dako 
Rabbit polyclonal anti-CD68 antibody 1:1,000 Serotec  
Mouse monoclonal IgG anti- neutrophils 1:1,000 Gift from Prof.Hugh 
Perry 
Mouse monoclonal IgM pan anti-CSPG 
(CS56) 
1:700 Sigma-Aldrich 
Mouse monoclonal IgG anti-BrdU 1:200 Chemicon 
Mouse monoclonal IgG anti-P0  1:3,000 Astexx Ltd 
Mouse monoclonal IgG anti- Nestin 1:200 Chemicon 
Rabbit polyclonal IgG anti-p75NTR  1:3,000 Chemicon 
Rabbit polyclonal IgG anti-P2X7R 1:70 Alomone, Jerusalem 
Mouse monoclonal anti S-100 
 
1:2,000 Sigma-Aldrich 
 
Secondary antibodies 
Donkey anti-mouse IgM TRITC  1:600 Jackson Immunoresearch 
Donkey anti-rabbit IgG Cy-5 1:600 Jackson Immunoresearch 
Donkey anti-mouse IgG TRITC 1:600 Jackson Immunoresearch 
Donkey anti-mouse IgG FITC 1:600 Jackson Immunoresearch 
Donkey anti-rabbit IgG FITC  1:600 Jackson Immunoresearch 
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Donkey anti-mouse IgG AMCA 1:600 Jackson Immunoresearch 
Donkey anti-rabbit IgG AMCA 1:600 Jackson Immunoresearch 
Goat anti-mouse IgG Alexa 647 1:600 Invitrogen 
 
2.5.3 Terminal transferase dUTP nick-end-labeling (TUNEL) assay 
For TUNEL assay, slides were washed 3 times for 15 min each in PBS in 0.2% Triton 
X-100 in PBS then treated with 20 μg/ml Proteinase K in 10 mM Tris, PH 7.5 and 5 mM 
EDTA at RT for 15 min to strip off nuclear proteins. After washing twice with PBS for 2 
min each, slides were treated with equilibration buffer for 15 min. Then slides were then 
incubated with a reaction buffer containing terminal deoxynucleotidyl transferase (TdT, 
0.3 unit/μl, Promega) for 60 min at 37 ºC. Slides were put in a coplin jar filled with 
wash/stop buffer (wash/stop buffer was diluted with distilled water at a ratio 1:34, 
Promega), agitated for 15 s and then incubated at RT for 10 min. After triple wash with 
PBS for 5 min each, slides were incubated with anti-digoxigenin conjugate solution 
(blocking solution:anti-digoxigenin rhodamine conjugate = 68:62) for 30 min at RT. 
DAPI was applied for 5 min incubation followed by thorough wash. The sections were 
coverslipped with 1:9 PBS-glycerol.  
 
Positive controls: After Proteinase K treatment and quick wash, slides were incubated 
with DN buffer (30 mM Trizma base, PH 7.2, 4 mM MgCl2, 0.1 mM DTT) at RT for 5 
min. Slides were treated with DNase I (1000 U/ml) for 30 min at 15-25ºC to induce DNA 
strand breaks, and then followed by labelling procedure above. 
 
Negative control: After Proteinase K treatment and quick wash, slides were incubated 
with reaction buffer without TdT, and then followed by labelling procedure above. 
.  
2.5.4 Flow cytometry Annexin V staining  
Trypsinized SCs were centrifuged at 960 rpm for 8 min, the cells were washed in PBS once. 
SCs were then resuspended in 400 µl of Becton Dickinson (BD) Annexin V Binding Buffer 
(Cat. No.556454). Cells suspension were incubated with 2 µl Annexin V-FITC (BD, Cat. 
No. 556420), at RT for 15 min, then 5 µg/ml (final concentration) viability dye propidium 
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iodide was added. The samples were then subjected to flow cytometry.  
 
2.6 Imaging  
Sections were viewed under a Leica fluorescence microscope. Photographs were taken 
using a Hamamatsu (C-4742-95) digital camera (Herrsching, Germany) and Hipic 
software. Tetramethyl rhodamine isothyocyanate (TRITC), fluorescein isothiocyanate 
(FITC), amino methyl coumarin acetic acid (AMCA) and Alexa 647 or Cy-5 stained 
sections were viewed under the Leica Y3, L5, A4  and Y5 filter blocks, respectively. 
Some sections were viewed in a Zeiss confocal microscope (LSM 510). 
 
2.7 Quantification and statistical analysis  
Quantification of SC culture purity: Purity of all primary SC cultures was evaluated by 
the ratio of p75NTR+ or S100+ cell number/DAPI+ nuclei. Twenty fields were randomly 
captured under a 20× objective lens. Highly purified cultures (> 95%) and up to three 
passages were used in all SC experiments.  
 
Quantification of transduction efficiency of LV to SCs: the transduction efficiency of 
LV/GFP was assessed by the ratio of GFP+ cell number/DAPI+ nuclei. Twenty fields were 
randomly captured under a 20× objective lens. The efficiency of transduction was 95 ± 2%. 
The co-transduction efficiency of LV/GFP and LV/PST-GFP was assessed by the ratio of 
GFP+ cell number/PSA-ir+ cell number. Twenty fields were randomly captured under a 
20× objective lens. The efficiency of co-transduction was 90 ± 2%. 
 
Quantification of PSA-immunoreactivity on SCs in vivo: images of GFP and PSA 
double-labelled transplanted cells at 7 or 30 days in 9 fields on 9 sections (3 sections 
from each of the 3 animals) were randomly captured on the basis of GFP fluorescence 
using a 63× oil immersion objective of a confocal microscope (Zeiss 510). All the 
parameters were kept constant for each session of measurements. Expression levels of 
PSA were estimated as the ratio of the area of PSA-ir over the area of GFP+ cells using 
ImageJ software.   
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Quantification of SCs survival in vivo: to estimate the survival of transplanted SCs, the 
areas occupied by transplanted SCs (defined by GFP fluorescence) were measured in 
consecutive parasagittal sections of spinal cord (45 µm apart) with ImageJ software. 
 
Quantification of SCs migration in vivo: the distances of 20 cells that spread the 
furthest from the epicenter of the transplants on three selected sections from each animal 
were measured with ImageJ software. 
 
Quantification of proliferation of SC or astrocytes in vitro: to analyze the proliferation 
of GFP/SCs or PST/SCs in culture medium, five randomly selected fields per coverslip 
under a 20× objective lens of a Leica microscope were captured for counting. Six 
coverslips were used per experiment and the experiment was repeated 3 times. GFP/SCs 
or PST/SCs were identified with GFP fluorescence. The data are expressed as the ratio of 
double GFP+/BrdU+ cells over double GFP+/DAPI+ cells for the proliferation rate of SCs.  
To analyze the proliferation of astrocytes in culture medium or in co-culture with 
GFP/SCs or PST/SCs, five randomly selected fields per coverslip under a 20× objective 
lens of a Leica microscope were captured for counting. Six coverslips were used per 
experiment and the experiment was repeated 3 times. Astrocytes were identified with a 
GFAP antibody. The data are expressed as the ratio of double GFAP+/BrdU+ cells over 
double GFAP+/DAPI+ cells for the proliferation rate of astrocytes.  
 
Quantification of expression level of p75NTR on SCs in vitro: GFP/SCs or PST/SCs 
were plated on the coverslips and double immunostained for p75NTR (rabbit polyclonal 
IgG anti-p75NTR, 1:15,000) and PSA (mouse monoclonal IgG anti-PSA, mAb735, 
1:2,500). Donkey anti-rabbit IgG TRITC (1:800) or goat anti-mouse IgG Alexa 647 
(1:800) was used as the secondary antibodies. SCs were identified with GFP fluorescence. 
Mean grey value of the p75NTR-ir was measured under 40× objective lens of a Leica 
microscope on 120 randomly selected cells from each group using ImageJ software. The 
experiments were repeated twice.  
 
Quantification of infiltration of neutrophils or macrophage to SC grafts: to assess the 
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infiltration of neutrophils or macrophages, six randomly selected fields from two sections 
of each animal (n = 3) under a 10× objective lens of a Leica microscope were captured 
for measurement. The ratio of the area occupied by infiltrated neutrophils or macrophages 
within the SC grafts over the area occupied by the transplanted SCs was calculated as an 
index for the level of inflammatory cell.  
All the data were represented as mean ± S.E. Statistical significance was 
determined using two-tailed Student’s t-test.  
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Chapter 3 
Engineered expression of PSA improves Schwann cell survival after 
transplantation into the spinal cord  
 
3.1 Abstract 
Poor survival is a common phenomenon for transplanted cells. It has been reported the 
majority of cells dies within the first week due to necrosis and apoptosis. In the current 
study SCs were transplanted both in uninjured or injured spinal cord with or without 
immunosuppression. It was found that without ciclosporin treatment, more PST/SCs 
survived at 7, 19 and 30 days after transplantation compared with GFP/SCs. Ciclosporin 
treatment significantly increased the survival of GFP/SCs but has no effect on the 
survival of transplanted PST/SCs. Similarly, in a spinal cord crush injury model, when 
GFP/SCs or PST/SCs were transplanted caudal to the lesion site with ciclosporin 
treatment daily, no marked difference was found in the overall survival of SCs between 
these two groups 3 weeks after transplantation. These data indicate PSA expression on 
SCs may have similar effect to ciclosporin treatment in protecting grafted SCs from host 
immune response. Moreover, with ciclosporin treatment, still more PST/SCs survived 
than GFP/SCs at early stage (7 days after transplantation). Proliferation and apoptosis of 
transplanted SCs were examined to see whether these two factors were accounted for the 
enhanced survival of PST/SCs. BrdU incorporation assay showed no proliferation of  
grafted SCs in both groups 19 days after transplantation, indicating that the difference in 
the survival between PST/SCs and GFP/SCs was not due to increased proliferation of 
PST/SCs. Also no difference was found in TUNEL+ SCs between grafted GFP/SCs and 
PST/SCs 1 day, 7 and 19 days after transplantation. However, we found much lower 
p75NTR-ir in PST/SCs compared with that in GFP/SCs in vitro by immunocytochemistry. 
It has been reported that p75NTR is involved in SC death both in vitro and in vivo. We 
speculate PSA induced down-regulation of p75NTR expression on SCs may partially 
contribute to the enhanced survival of PST/SCs.  
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3.2 Aims 
In this study, we investigated the effect of PSA expression on (1) the survival of SCs both 
in uninjured and injured spinal cord in vivo; (2) SC proliferation both in vivo and in vitro; 
(3) apoptosis of SCs after grafting; (4) recruitment of inflammatory cells to the SC grafts 
at early stage and (5) expression level of p75NTR in SCs. 
 
3.3 Results 
3.3.1 Purity of cultured Schwann cells and efficiency of lentiviral vector 
transduction of Schwann cells in vitro. 
SCs were isolated from the sciatic nerves and brachial plexuses of neonatal rats. In 
culture, the majority of the dissociated cells displayed bipolar or tripolar shape, which is 
typical for cultured SCs. A very small proportion of cells displayed fat or polygonal shape, 
which was recognized as fibroblasts. The purity of SCs was assessed by using p75NTR or 
S100 immunostaining. The ratio of p75NTR+ or S100+ cells over DAPI stained nuclei was 
calculated from photomicrographs using a 20× objective lens, which remained at 98 ± 
0.3% throughout the period of the study (SCs of up to three passages were used in all the 
experiments) (Fig. 3-1A-C). Transduction of SCs with LV/GFP resulted in robust GFP 
expression. Transduction efficiency was calculated as the ratio of GFP+ cells over DAPI 
stained nuclei, which stood at 95 ± 2% at MOI (multiplicity of infection) of 15 (Fig. 
3-2A-C).  
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Fig. 3-1 Purity of cultured Schwann cells. 
(A) Cultured SCs double stained with anti-p75NTR (A) and anti-S100 antibody (B). (C) 
Nuclei of cultured cells stained with DAPI. (D) Merged image of (A) (B) and (C). Scale 
bar = 50 µm. 
   
 
Fig. 3-2 Efficiency of lentiviral vector mediated transfer of GFP to Schwann cells. 
(A) SCs expressed high level of GFP protein 5 days after being transduced with LV/GFP. 
(B) Nuclei of cultured cells were stained with DAPI. (C) Merged image of (A) and (B). 
Scale bar = 100 µm. 
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3.3.2. Expression of PSA on LV/PST-GFP transduced Schwann cells in vitro. 
PSA immunoreactivity (PSA-ir) was hardly detectable in LV/GFP transduced SCs. Very 
low level of PSA-ir was found on a few LV/GFP transduced SCs (Fig. 3-3C1-C3). In 
contrast, LV/PST-GFP transduced SCs displayed strong PSA-ir on the cell surface of 
unpermeabilized cells (Fig. 3-3D1-D3). Although the PSA-ir was present all over the cell 
bodies and the processes, granules with high-density of PSA-ir were a common feature. 
Such PSA-ir profile is similar to those reported before (Arellano et al., 2002). The 
expression of PST-GFP fusion protein was demonstrated by the GFP fluorescence on the 
Golgi apparatus (Fig. 3-3A) where they exert their biological functions. The expression 
of PSA in LV/PST-GFP transduced SCs was also confirmed by immunoblotting (Fig. 
3-3B). A dense smear with molecular mass over 150 KD was identified in the lane of 
LV/PST-GFP transduced SCs. The molecular mass corresponds to that of polysialylated 
NCAM. The band was absent after the treatment with Endo-N, indicating the specificity 
of the antibody for PSA. No PSA specific band was detected in naïve SCs. For easy 
identification of transplanted SCs, SCs were co-transduced with LV/PST-GFP and 
LV/GFP. The co-transduction efficiency was over 90%.  
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Fig. 3-3 Detection of PSA expression on PST/SCs in vitro. 
(A) The expression of PST-GFP fusion protein was demonstrated by the GFP 
fluorescence. Arrows point to the location of PST-GFP fusion protein. (B) 
Immunoblotting image shows a band of polysialylated NCAM in the lane of 
LV/PST-GFP transduced SCs and the band was absent after the treatment with Endo-N. 
No PSA specific band was detected in naïve SCs. (C1-3) Low level of PSA-ir present in a 
few SCs transduced by LV/GFP. (D1-3) Extensive and high-level expression of PSA was 
detected on SCs co-transduced by LV/PST-GFP and LV/GFP. Scale bar for A = 10 µm; 
scale bar for C and D = 50 µm. 
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3.3.3 Down-regulation of PSA expression on LV/PST-GFP transduced Schwann cells 
in vivo. 
In order to define the time window of PSA expression on the grafted PST/SCs, we 
analyzed animals receiving PST/SCs at 7 and 30 days after transplantation. Images of 
GFP and PSA double-labeled transplanted cells at 7 or 30 days in 9 fields of view on 9 
sections (3 sections from each of the 3 animals) were randomly captured using a 63× oil 
immersion objective of a confocal microscope (Zeiss 510). All the parameters were kept 
constant for each session of measurements. Expression levels of PSA were estimated as 
the percentage of the area of PSA-ir over the area of GFP+ cells using the image 
analysing software ImageJ. Most of the grafted PST/SCs expressed PSA at 7 days after 
transplantation (77.6 ± 6.9%, PSA-ir vs. GFP fluorescence) (Fig. 3-4A-C). The 
expression dropped to a lower level at 30 days (44.8 ± 3.7%) (Fig. 3-4D-F). 
 
Fig. 3-4 Detection of PSA expression on Schwann cell grafts in vivo. 
PSA-ir was remained detectable on PST/SCs at 7 days (A-C) and 30 days (D-F) post 
transplantation by using the antibody mAb735 antibody. Arrows pointed to the 
PSA-expressing SCs. Scale bar = 10 µm. 
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3.3.4 Survival of grafted Schwann cells after transplantation into the uninjured 
spinal cord. 
3.3.4.1 Survival of Schwann cells after transplantation into uninjured spinal cord 
without ciclosporin treatment. 
GFP/SCs or PST/SCs were transplanted into T8 level of rat spinal cord. One day after 
SCs transplantation many bright green cells with oblong and round profiles were found in 
both GFP/SCs and PST/SCs grafts (Fig. 3-5A-B). Cells with such profiles were dead 
cells as cells shrank significantly so that GFP florescence condensed inside the cells to 
make them appear very bright. Dead cells were hardly visible in 7-days grafts. The dead 
green cells made quantification of cell survival impossible in 1-day grafts by using 
ImageJ to measure the areas occupied by GFP/SCs. Therefore, only animals from 7 days 
upwards were used for comparing the survival of transplanted SCs between PST/SCs and 
GFP/SCs groups.  
 
Fig. 3-5 Transplanted Schwann cells in host spinal cord 1 day after transplantation. 
Images show that many bright green dead cells with oblong and round profiles were 
found in the injection site in both GFP/SCs (A) and PST/SCs grafts (B) one day after SCs 
transplantation. Axes indicate the orientation of the spinal cord. Scale bar = 100 µm. 
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 The total areas occupied by transplanted SCs (identified with GFP fluorescence) 
were measured with ImageJ to assess the survival of transplanted SCs. The level of 
survival for GFP/SCs and PST/SCs were 0.50 mm2 vs. 1.88 mm2; 0.33 mm2 vs. 1.00 mm2    
and 0.08 mm2 vs. 0.31 mm2, p < 0.01 or p < 0.05, Fig. 3-8A-C) at 7, 19, and 30 days 
respectively after transplantation. Significantly more PST/SCs survived than GFP/SCs 
over these 3 time points after transplantation (compare Fig. 3-6A-C). 
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Fig. 3-6 Survival of Schwann cells after transplantation into uninjured spinal cord 
without ciclosporin treatment.  
Consecutive parasagittal sections of spinal cord illustrating the transplanted GFP/SCs (A) 
and PST/SCs (B) 7 days after transplantation. (C) Areas occupied by transplanted SCs in 
serial parasagittal sections of spinal cord measured using ImageJ. *p < 0.05; **p < 0.01. 
Axes indicate the orientation of the spinal cord. Scale bar = 100 µm. n = 8. 
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3.3.4.2 Survival of Schwann cells after transplantation in uninjured spinal cord with 
ciclosporin treatment. 
In order to exclude the effect of immune rejection of the transplanted SCs, some animals 
received ciclosprin injection daily. Similar to the untreated groups, bright green dead cells 
were found in the injection site in both GFP/SCs and PST/SCs grafts 1 day after 
transplantation (Fig. 3-7A-B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-7 Transplanted Schwann cells in host spinal cord with ciclosporin treatment 1 
day after transplantation. 
Images show that bright green dead cells with oblong and round profile were found in 
both GFP/SCs (A) and PST/SCs grafts (B) 1 day after SCs transplantation. Axes indicate 
the orientation of the spinal cord. Scale bar = 100 µm.  
 
Significantly more PST/SCs survived 7 days after transplantation comparing with 
GFP/SCs (0.88 ± 0.17 mm2 vs. 2.09 ± 0.54 mm2, p < 0.05, Fig. 3-8A-C). However, there 
is no difference between the two groups 30 days after transplantation (0.38 ± 0.05 mm2 vs. 
0.40 ± 0.06 mm2, p > 0.05, Fig. 3-8C). Ciclosporin treatment increased the survival of 
transplanted GFP/SCs both 7 days and 30 days after transplantation, but it did not have 
significant effect on the overall survival of transplanted PST/SCs (Fig. 3-8D).   
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Fig. 3-8 Survival of Schwann cells with ciclosporin treatment.  
Consecutive parasagittal sections of spinal cord illustrate the transplanted GFP/SCs (A) 
and PST/SCs (B) 7 days after transplantation. (C) Graph shows the areas occupied by 
transplanted SCs measured in serial sections of spinal cord using ImageJ. (D) Graph 
shows the survival level of transplanted SCs with/without ciclosporin treatment. *p < 
0.05; **p < 0.01. Axes indicate the orientation of the spinal cord. Scale bar = 100 µm. n = 
8. 
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3.3.4.3 Survival of Schwann cells after transplantation in injured spinal cord with 
ciclosporin treatment. 
In order to investigate whether PSA expression could enhance the survival of SCs grafts 
in injured spinal cord, GFP/SCs or PST/SCs were transplanted 2.5 mm caudal to a 
hemi-curshed injury site of spinal cord. Animals were treated with ciclosporin daily and 
sacrificed 3 weeks post transplantation. By measuring the total area occupied by 
transplanted SCs in serial parasagittal sections of spinal cord, no difference was found 
between these two groups (0.49 mm2 vs. 0.71 mm2 for GFP/SCs and PST/SCs group 
respectively. p > 0.05, Fig. 3-9) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-9 Survival of Schwann cells after transplantation in injured spinal cord.  
Total areas occupied by transplanted SCs were measured in serial sections of spinal cord 
using ImageJ. There is no difference in overall survival of the SCs between these two 
groups. n = 8. 
 
3.3.5 Assessment of the proliferation of transplanted Schwann cells in the spinal 
cord using BrdU incorporation assay.  
After we have found that more PST/SCs survived than GFP/SCs after transplantation, we 
wanted to know whether it was partially due to a higher proliferation degree of PST/SCs. 
We first tested whether PSA expression on SCs had any effect on the proliferation of SCs 
in vitro. High proportions of SCs in both groups were BrdU+, indicating the cells were 
proliferating vigorously. However, no difference was detected in the proportions of 
BrdU+ nuclei between GFP/SCs and PST/SCs (54.3% vs. 53.7%, p > 0.05, Fig. 3-10).  
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Fig. 3-10 Assessment of proliferation of PST/SCs and GFP/SCs in vitro using BrdU 
incorporation assay. 
SCs transduced with LV/GFP (A) or LV/PST-GFP (B) immunostained with anti-BrdU 
antibody. (C) Graph shows that there is no difference in BrdU incorporated nuclei 
between there two groups. Scale bar = 25 µm. n = 3. 
 
To check the proliferation of the transplanted SCs, four animals from each group 
receiving GFP/SCs or PST/SCs transplantation were given BrdU injection for 3 days 
just before they were sacrificed. Hardly any GFP/SCs (Fig. 3-11A-D) or PST/SCs (Fig. 
3-11E-H) were found to incorporate BrdU 19 days after grafting. Some BrdU+ cells were 
observed close to the transplanted SCs (Fig. 3-11B, 11F) which were probably reactive 
astrocytes as they were GFP negative. 
 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-11 BrdU incorportation for transplanted Schwann cells in spinal cord. 
GFP/SCs (A-D) or PST/SCs (E-H) immunostained with anti-BrdU antibody (red in B, F) 
and DAPI (C, G) 19 days after being grafted into rat spinal cord. (D) and (H) are merged 
images of (A, B, C) and (E, F, G) respectively. Arrowheads point to the BrdU 
incorporated cells. These cells appeared GFP negative. Scale bar = 100 µm. 
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3.3.6 d-UTP-digoxigenin nick end-labeling (TUNEL) assay. 
TUNEL staining was used to identify apoptosis of transplanted SCs. At 1 day (Fig. 
3-12C-D; 12G-H) and 7 days (Fig. 3-13C-D; 3-13G-H) after SCs transplantation a few 
PST/SCs and GFP/SCs were found to be TUNEL+. The numbers of TUNEL+ cells were 
similar between PST/SCs and GFP/SCs. At 19 days post transplantation TUNEL+ cells 
were hardly detectable (Fig. 3-14C-H; 14G-H). 
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Fig. 3-12 TUNEL assay for Schwann cells grafts 1 day post transplantation.                           
GFP/SCs (A-D) and PST/SCs (E-H) 1 day after being grafted into rat spinal cord. Nuclei 
were stained with DAPI (B, F), TUNEL+ nuclei are shown in red (C, G). (D) and (H) are 
merged images of (A, B, C) and (E, F, G) respectively. Arrows point to the TUNEL+  
SCs. Scale bar = 100 µm. n = 2. 
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Fig. 3-13 TUNEL assay for Schwann cell grafts 7 days post transplantation.                          
GFP/SCs (A-D) and PST/ SCs (E-H) 7 days after being grafted into rat spinal cord. Red 
for TUNEL+ nuclei. (C, G). Nuclei were stained with DAPI (B, F). (D) and (H) are 
merged images of (A, B, C) and (E, F, G) respectively. Scale bar = 100 µm. n = 2. 
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Fig.3-14 TUNEL assay for Schwann cells grafts 19 days post transplantation.                           
GFP/SCs (A-D) and PST/SCs (E-H) 19 days after being grafted into rat spinal cord. Red 
is for TUNEL staining (C, G). Nuclei were stained with DAPI (B, F). (D) and (H) are 
merged images of (A, B, C) and (E, G, F) respectively demonstrating the apoptosis of 
transplanted GFP/SCs in spinal cord; TUNEL+ cells are hardly detectable on GFP/SCs or 
PST/SCs at 19 days after transplantation. Scale bar = 100 µm. 
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3.3.7 Recruitment of inflammatory cells at Schwann cell transplantation sites in 
uninjured spinal cord in early stages.  
As shown previously, the majority of cell death after transplantation occurs in the first 
week. During the process of transplantation, the blood-spinal cord barrier is disrupted 
which leads to an inflammatory response that enhances cell death. Neutrophil and 
macrophage are the main type of inflammatory cells that infiltrate the spinal cord at the 
early stage after transplantation. Three animals receiving GFP/SCs or PST/SCs 
transplantation without ciclosporin treatment were used in this study. To assess the 
infiltration of neutrophils or macrophages, the proportion of the area occupied by 
infiltrated neutrophils or macrophages within the transplanted SCs grafts over the area 
occupied by the transplanted SCs was calculated to assess the level of inflammatory cell 
infiltration. It was found that the presence of neutrophil infiltration around SC transplants 
was obvious at 1 day and 7 days post transplantation (Fig. 3-15, 3-16). However, there is 
no difference between PST/SCs and GFP/SCs groups in the level of neutrophil 
infiltration (Fig. 3-15, 3-16).  
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Fig. 3-15 Assessment of neutrophil infiltration 1 day post transplantation in 
uninjured spinal cord. 
GFP/SCs (A) and PST/SCs (D) grafts immunostained with a specific antibody for 
neutrophils (B, E) 1 day post transplantation. (C) and (F) are merged images of (A) and 
(B), (D) and (E) respectively. (G) Proportion of the areas of occupied by neurophils over 
the area occupied by transplanted SCs as an index for the level of neutropil infiltration. 
No difference was found between GFP/SCs and PST/SCs groups. Axes indicate the 
orientation of the spinal cord. Scale bar = 100 µm. n = 3. 
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Fig. 3-16 Assessment of neutrophils infiltration 7 days post transplantation in 
uninjured spinal cord. 
Neutrophil infiltration at the transplantation site 7 days post transplantation of GFP/SCs 
(A) or PST/SCs (D) in intact spinal cord. SC grafts were immnostained with a neutrophil 
antibody (B, E). (C) and (F) are merged images of (A) and (B), (D) and (E) respectively. 
(G) Proportion of the areas of occupied by neurophils over the area occupied by 
transplanted SCs as an index for the level of neutropil infiltration No difference was 
found between GFP/SCs and PST/SCs groups. Axes indicate the orientation of the spinal 
cord. Scale bar = 100 µm. n = 3. 
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    Like neutrophils, many ED1+ macrophages were also present in or around the 
transplanted cells 1 day after transplantation (Fig. 3-17). However, no difference was 
found in the levels of ED1+ cells at the transplantation sites between PST/SCs and 
GFP/SCs groups 1 day after transplantation. In contrast to neutrophils, only a few 
macrophages/microglias were present at the transplantation site 7 days after 
transplantation (Fig. 3-18). No quantification was performed to compare the levels of 
ED1+ cells at the transplantation sites between the PST/SCs and GFP/SCs groups at this 
time point due to negligible level of ED1+ cells.  
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Fig. 3-17 Assessment of macrophage infiltration 1 day post transplantation in 
uninjured spinal cord. 
GFP/SCs (A) and PST/SCs (D) grafts immnostained with a specific antibody for 
macrophage ED1 (B, E) 1 day post transplantation. (C) and (F) are merged images of (A) 
and (B), (D) and (E) respectively. (G) Proportion of the areas of occupied by ED1+ cells 
over the area occupied by transplanted SCs as an index for the level of macrophage 
infiltration. No difference was found between GFP/SCs and PST/SCs groups 1 day post 
transplantation. Axes indicate the orientation of the spinal cord. Scale bar = 100 µm. n = 
3. 
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Fig. 3-18 Assessment of macrophage infiltration 7 days post transplantation in 
uninjured spinal cord. 
GFP/SCs (A) and PST/SCs (D) grafts immnostained with a specific antibody for 
macrophage, ED1 (B, E) 7 day post transplantation. Only few macrophages were detected 
in both groups. (C) and (F) are merged images of (A) and (B), (D) and (E) respectively. 
Axes indicate the orientation of the spinal cord. Scale bar = 100 µm. n = 3. 
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3.3.8 PSA expression regulates p75 NTR expression on cultured Schwann cells. 
It has been reported that immature neurons lacking PSA-NCAM expressed significantly 
higher level of p75NTR than the cells with PSA-NCAM. Removal of PSA from NCAM 
induced an enhanced activation of p75NTR singalling pathways and led to increased cell 
death. It was suggested that by limiting p75NTR expression, PSA-NCAM might protect 
newborn neurons in the developing stage (Gascon et al., 2007). Thus, it is possible that 
PSA expression in PST/SCs may induce the down-regulation of p75NTR expression on 
transplanted SCs and enhance their survival. In this study, we tested the expression level 
of p75NTR on both PST/SCs and GFP/SCs by immunocytochemistry using a series of 
diluted anti-p75NTR antibody. With the dilution of 1:12,000 or 1:15,000 the difference in 
the levels of p75NTR-ir between PST/SCs and GFP/SCs became obvious (compare Fig. 
3-19B against F). Mean grey value of p75NTR –ir was measured on 120 randomly selected 
cells using ImageJ to assess the p75NTR expression level. It was found that there was 
much lower level of p75NTR –ir present in PST/SCs compared with GFP/SCs (p < 0.001) 
(Fig. 3-19I). 
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Fig. 3-19 Assessment of the expression level of p75NTR on Schwann cell in vitro. 
Expression of p75NTR in GFP/SCs (A-D) and PST/SCs (E-H) in vitro. Weak p75NTR–ir 
(red) was presented in LV/PST-GFP transduced PSA+ (blue in G, H) SCs compared with 
LV/GFP transduced PSA- SCs (C, D). SCs were identified with GFP fluorescence. (I) 
Quantification of mean grey value of p75NTR-ir of PST/SCs and GFP/SCs. Significantly 
much lower level of p75NTR –ir was found in PST/SCs compared with that in GFP/SCs. 
***p < 0.001. Scale bars = 25 µm. Experiemnts were repeated twice.        
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3.4 Discussion 
Although SCs transplanted into the CNS can promote axonal regeneration and 
remyelination and improve functional recovery in animal models of spinal cord injury, 
poor survival of transplanted SCs in the CNS is a common problem and limits their 
therapeutic potential. It has been reported that 78% reduction in SC number within the 
first week after transplantation was mainly due to necrosis, and only around 15% of SCs 
survived 28 days after transplantation (Hill et al., 2007). Such trend of SC death was 
confirmed in our study and we also observed that TUNEL+ cells were surprisingly low at 
1 day and 7 days post transplantation given the extent of cell death, indicating that 
necrosis was the main type of cell death. The second wave of SC death occurred after 
they have integrated into the spinal cord tissue could result from transplant rejection since 
the survival of transplanted SCs can be enhanced by immunosuppression (Hill et al., 
2006). In the current study we also showed that ciclosporin treatment improved the 
survival of GFP/SCs by 4.6-fold at 30 days, indicating immune rejection plays a major 
role in cell loss at the late stage. However, without immunosuppression, we found 
PST/SCs survived better than GFP/SCs at all three time points, 7, 19 and 30 days after 
transplantation. With ciclosporin treatment, the significant difference between the PST 
group and GFP group in survival only existed at the early stage (7 days); no difference 
was seen between the two groups at 30 days after transplantation. The result indicates that 
ciclosporin can significantly improve the survival of GFP/SCs over the time, but has little 
effect on the survival of PST/SCs. The effects of PSA on the survival of transplanted SCs 
without ciclosporin treatment is similar to the effect of ciclosporin on transplanted 
GFP/SCs, especially at the late stage, indicating PSA may have certain immunoprotective 
effects for transplanted cells.  
We have examined several potential factors that might have contributed to the 
better survival of PST/SCs. First, we investigated whether PST/SCs have a higher level of 
proliferation. Cultured SCs in both groups showed high population of BrdU+ cells, 
however, there was no difference between these two groups. BrdU staining showed there 
was no obvious cell proliferation in both groups at 19 days post transplantation. Thus, the 
improved survival of PST/SCs was not due to cell expansion after grafting.  
TUNEL staining on 1, 7, 19 days after transplantation showed that there were more 
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TUNEL+ cells on 1 day, whereas, much less on 19 days, although the number of stained 
cells in tissue sections was quite small even 1 day after transplantation. No difference was 
found in the numbers of TUNEL+ cells in these two groups. However, we cannot draw the 
conclusion that PSA over-expression does not rescue SC from apoptosis based on the 
negative TUNEL staining results due to the narrow time window for the apoptosis 
detection using TUNEL assay. 
In this study, recruitment of macrophage and infiltration of neutrophils to the 
transplantation site were assessed with immunohistochemistry by using another set of 
spinal sections from animals without ciclosporin injection. However, there is no 
difference between PST/SCs and GFP/SCs groups in the levels of neutrophil or 
macrophage infiltration 1 and 7 days after transplantation which indicates PSA 
over-expression on SCs does not reduce the recruitment of inflammatory cells at SC 
transplantation sites at early stage. It has been reported that sialic acids have 
anti-recognition effect. They can shield antigenic sites and thus weaken the 
immuno-reactivity. Sialic acids render cells as “self”, not allowing recognition by the 
immune system or by, e.g., macrophage lectins (Schauer, 2004). The antirecognition 
effects of sialic acids are explained by their negative charges in combination with a bulky, 
hydrophilic molecule (Kelm and Schauer, 1997). After sialidase treatment of mammalian 
erythrocytes and re-injecting them back to the bloodstream, most of the modified cells 
disappeared from the bloodstream within a few hours, although their normal survival time 
in humans is about 120 days (Janicik et al., 1978). These cells were phagocytosed by 
liver Kupffer cells, spleen, or peritoneal macrophages. It is reasonable to propose that 
expression of PSA on SCs may shield the antigenic sites on the cells and thus diminish 
the immune response from the host. The masking effect of PSA has been explored to 
protect therapeutic peptides, enzymes, and other proteins from being removed from 
circulation after administration so as to prolong their effects and reduce the dosage 
(Gregoriadis et al., 2000).  
In addition, we also found that the survival of PST/SCs in animals without 
ciclosporin treatment was still significantly better than GFP/SCs in animals with 
ciclosporin treatment at 7 days, indicating PSA may have other potential mechanisms to 
protect transplanted SCs from death apart from the purported immunoprotective effects.  
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It has been reported that immature neurons lacking PSA-NCAM expressed significantly 
higher level of p75NTR than the cells with PSA-NCAM. Removal of PSA from NCAM 
induced an enhanced activation of p75NTR signalling pathways and led to increased cell 
death. It was suggested that by limiting p75NTR expression, PSA-NCAM might protect 
newborn neurons in the developing stage (Gascon et al., 2007). It has also been 
demonstrated that TNFα, one of the potent cytotoxic molecules activated during 
inflammation, can mediate SC death by up-regulating p75NTR expression (Boyle et al., 
2005). Indeed, we did find the expressing level of p75NTR in PST/SCs was significant 
lower than that in GFP/SCs. Thus, we proposed PSA expression in PST/SCs may 
down-regulate expression of p75NTR on transplanted SCs and enhance their survival, 
which could be one of the mechanisms to improve the survival of PST/SCs compared 
with GFP/SCs. 
There are several predominant pathways that lead to SC death during/after 
transplantation. The first stress the cells encounter during the transplantation process is 
the lack of matrix support, which begins before transplantation. Typical cell preparations 
for injection involve enzymatically dispersed cells suspended in protein-free medium, and 
stored on ice. During this period, important adhesion-related survival signals such as 
laminin could be absent and not reinitiated for many hours until the cells find themselves 
in the context of a recipient spinal cord and even then, the proper basal surface for the 
cells may not be present (Koda et al., 2008). Serum and trophic factor deprivation is 
another issue. LPA in serum has been proved to support SC survival in vitro (Li et al., 
2003c) and growth cocktail used in SC culture includes several types of factors which 
have been shown to boost SCs survival and proliferation (Dong et al., 1995; Gavrilovic et 
al., 1995; Syroid et al., 1996). Large amount of released ATP or glutamate from the 
damaged cells also may activate their own receptors to induce toxicity on transplanted 
SCs. These factors will be discussed in Chapter 4. 
     In conclusion, PSA over-expression enhances the survival of transplanted SCs to a 
certain degree which may be related to protecting cells from the attack of host immune 
system and the down-regulation of p75NTR. 
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Chapter 4 
Investigation of the molecular mechanisms underlying Schwann cells 
death after transplantation 
 
4.1 Abstract 
Poor cell survival is one of factors potentially limiting the efficacy of the cell 
transplatation therapy. The current study tested several potential factors contributed to SC 
death after grafting. It was found that high concentration of glutamate (1 mM) did not 
induce SC death. Short-term (up to 5 h) serum and growth factor withdrawal did not 
cause obvious morphological change of SCs. Prolonged serum and growth factor 
withdrawal (over 26 h) caused significant SC death. Interestingly, PSA expression can 
partially protect SCs from death induced by serum and growth factor withdrawal. In the 
current study we confirmed that SCs from rats or mice expressing P2X7Rs using 
immunocytochemistry and immunohistolgy. High-concentration of ATP has been 
reported to induce death of certain types of cells by activating P2X7R. ATP was found to 
induce SC death on a concentration-dependant manner. Cell death caused by ATP can be 
blocked by an irreversible P2X7R antagonist, oxidized ATP (oxATP), confirming that 
ATP induced SCs death is mediated by P2X7Rs. Moreover, PSA expression can also 
partially protect SCs from ATP induced cell death in vitro. In addition, SCs pretreated 
with oxATP before transplantation showed 38.2% more SCs survived than that of 
untreated SCs one week after transplation into the intact spinal cord. Taken together, 
these results indicate that targeting P2X7R on SCs could be a potential therapeutic 
strategy to prevent cell death after transplantation. 
 
4.2 Aims 
The process of cell transplantation is accompanied with injury to the transplantation site 
and vessel breakage, which causes large amount of glutamate and ATP release to the 
extracellular space at the injection site. Glutamate receptors have been reported to be 
expressed on SCs (Dememes et al., 1995; Fink et al., 1999), but it is not known whether 
glutamate can induce SC. Serum and several growth factors used in the SC culture 
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medium have shown to enhance SC survival (Dong et al., 1995; Gavrilovic et al., 1995; 
Syroid et al., 1996). It has been speculated serum and growth factors withdrawal plays an 
important role in the early necrosis and apoptosis of transplanted SCs (Hill et al., 2007). 
P2X7R activation by high concentration of extracellular ATP can induce the death of 
several types of cells (Hogquist et al., 1991; Perregaux and Gabel, 1994; Falzoni et al., 
1995; Ferrari et al., 1999; Tsukimoto et al., 2005). P2X7R expression on mouse SCs has 
been demonstrated by electrophysiological and immunohistochemical studies (Colomar 
and Amedee, 2001). In this study, we tested the effects of (1) glutamate; (2) serum and 
growth factor withdrawal; (3) ATP on the survival of SC in vitro, and (4) whether 
blockade P2X7Rs using oxATP can rescue the SC death induced by ATP both in vitro and 
in vivo. 
 
4.3 Results 
4.3.1. Glutamate does not induce significant Schwann cell death in vitro. 
We first tested the effect of glutamate on the survival of SCs. 0.1 mM or 1 mM (final 
concentration) glutamate was added into the culture dish for up to 1 h. By direct 
observation under a microscope, there was no obvious cell morphology change was found 
either when cell incubated with 0.1 or 1 mM glutamate for 1 h. Flow cytometry apoptosis 
assay results showed 94.1 ± 2.3%, 95.3 ± 2.8% and 94.6 ± 1.7% of live cells in culture 
medium (as control), 0.1 mM, and 1 mM glutamate treated group respectively. No 
significant difference in cell survival was found between these three groups, indicating 
SCs are insensitive to high concentration of glutamate (Fig. 4-1).  
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Fig. 4-1 Effect of glutamate on the survival of Schwann cells in vitro.  
Phase contrast images show no obvious morphology change when SCs exposed to 0 (A), 
0.1 mM (B) and 1 mM glutamate (C) for 30 min. (D) Flow cytometry apoptosis assay 
shows the similar portion of live cells in these three groups 1 h after glutamate treatment. 
(E) Graph shows percentage of live cells using flow cytometry apoptosis assay. Glu: 
glutamate. Experiments were repeated three times. 
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4.3.2. Serum and growth factor withdrawal induce Schwann cells death in vitro.  
Long-term (> 26 h) serum withdrawal has been shown to induce SC and OEC death in 
vitro (Weiner and Chun, 1999; Zhao et al., 2007). For all SC transplantation experiments 
in this study, SCs were resuspended in DMEM medium without both serum and growth 
factors. To mimic the in vivo environment that transplanted SCs may encounter, we tested 
the effect of both serum and growth factors withdrawal on the survival of SCs in vitro. No 
significant cell death was observed under microscope 5 h after serum and growth factor 
withdrawal, indicating SCs can withstand serum- and growth factors-free condition for a 
few hours. After prolonged (26 h) serum and growth factors withdrawal the processes of 
SCs shrank and became slimmer, but it was difficult to tell the difference between the two 
groups under micrsoscope (Fig.4-2C, F). However, flow cytometry apoptosis assay 
showed more PST/SCs were alive than GFP/SCs (51.1 ± 1.3% vs. 38.2 ± 1.8%, p < 0.01, 
Fig. 4-2). The data indicates PSA expression may protect SCs death from serum and 
growth factors withdrawal to a certain degree.  
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Fig. 4-2 Effect of serum and growth factor withdrawal on the survival of Schwann 
cells in vitro. 
Phase contrast images show no obvious morphology change of SCs 5 h after serum and 
growth factor withdrawal (B, E) compared with SCs in normal culture medium (as 
control) (A, D). Long-term (26 h) serum and growth factor withdrawal resulted in the 
morphology change of SCs. They became shranked and slimmer in the both groups (C, F). 
(G) Graph shows the percentage of live cells 26 h after serum and growth factor 
withdrawal measured using flow cytometry cell apoptosis assay. Scale bar = 100 µm. **p 
< 0.01. Experiments were repeated three times. 
 
4.3.3 ATP induces Schwann cell death in vitro. 
P2X7R is known as the receptor subtype that mediates high-concentration ATP induced 
cell death. In the previous study, P2X7R has been shown to be localized on mouse SCs 
by electrophysiology and immunocytochemistry (Colomar and Amedee, 2001). 
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(1) Schwann cells express P2X7Rs  
In this study, we first examined the expression of P2X7R on the rat SCs in culture as well 
as in sciatic nerves with immunohistochemistry. The most widely used antibody for 
P2X7R is a polyclonal anti-P2X7R from Alomone (Jerusalem, Israel, Cat. number: 
APR-004, with a dilution of 1:70). In order to further assure the specificity of the 
antibody, sciatic nerves from C57/Bl6 wild-type and P2X7R knockout mice (kindly 
provided by GSK) were stained with the same antibody. In vitro P2X7R 
immunoreactivity (P2X7R-ir) was shown to be distributed inside cytoplasm of S100+ SCs 
(Fig. 4-3A-C).  P2X7R-ir was not detected in cultured astrocytes (Fig. 4-3D-F), which 
may account for their resistance to ATP induced death (see Fig.4-8). .  
 
Fig. 4-3 Detection of P2X7Rs on Schwann cells and astrocytes.  
(A) Expression of P2X7Rs on cultured SCs (A-C). SCs were identified with a SC marker 
S100 (green in A, C). In contrast to SCs, no P2X7R-ir (red) was detected on cultured 
astrocytes (D-F). Astrocytes were identified with an antibody againt GFAP (green in D, 
F). Scale bar = 50 µm. 
  
     The specificity of the P2X7R antibody was confirmed since P2X7R-ir was not 
detected on the sciatic nerve from P2X7R knockout mice (Fig. 4-4B), while strong 
P2X7R-ir was detected on sciatic nerve from the wild-type mice (Fig. 4-4A). 
Co-localization of P2X7R and S100 immunosignals confirmed the presence of P2X7R on 
SCs (Fig. 4-4D-E).  
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Fig. 4-4 Detection of P2X7Rs on mouse sciatic nerve.  
Expression of P2X7Rs on mouse sciatic nerve from wild-type mice (A) and P2X7R 
knockout mice (B) stained with an anti-P2X7R antibody. SCs were identified with a SC 
marker S100. High magnification images show P2X7R mainly located on the nodes of 
Ravier (Arrows in C-E). Scale bar = 50 µM in A-B and 10 µM in C-E. WT: wild-type, 
KO: knockout.  
 
(2) ATP inducd cultured Schwann cell death is dose-dependent 
We found that exposure of SCs to high concentrations (over 3 mM) of ATP led to 
significant cell death in vitro (Fig. 4-5). Morphological change of SCs occurred within 15 
min after exposure to 5 mM ATP, demonstrated by withdrawal of cell processes and 
rounded-up of cells bodies. Most of SCs detached from the culture dish after 1 h exposure 
to 5 mM ATP. By using flow cytometry apoptosis assay kit to measure the cell death, it 
was shown that 73.9 ± 5.6%, 63.2 ± 4.5%, and 52.3 ± 2.9% cells were alive after being 
exposed to 3, 4, 5 mM ATP respectively. Significantly more cells were dead with ATP 
increasing concentrations (p < 0.05 or p < 0.001). 
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Fig. 4-5 ATP induces Schwann cell death in vitro.  
Phase contrast images show SCs in culture before (A) and after exposure to 0.1 mM ATP 
(B) or 5 mM ATP (C) for 30 min. (D) Flow cytometry shows the proportions of live cells 
after exposure to 3, 4, 5 mM ATP for 1 h. (E) Graph illustrates the percentage of live cells 
with the increasing concentrations of ATP. *p < 0.05, ***p < 0.001, one-way ANOVA. 
Experiments were repeated three times. 
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To further confirm whether P2X7R activation can induce SC death, BzATP, the 
most potent agonist for P2X7R was added to the culture medium and the morphology 
change of cells was observed under microscope. It was found that cells in the dish 
containing 200 µM BzATP started to shrink and round up within 15 min. By 30 min, 
nearly all the cells in the BzATP dish became rounded. After incubation for 1 h, cells 
were dissociated and subjected to flow cytometry apoptosis assay. 68.7 ± 2.3% cells were 
alive after exposure to BzATP, in comparison with 95.1 ± 2.7% live cells in the control 
dish ( Fig. 4-6, p < 0.01), indicating that P2X7R activation cause SC death. 
 
 
Fig. 4-6 Schwann cell death induced by BzATP. 
Flow cytometry apoptosis assay shows that the percentage of live cells in culture medium 
(A) or after exposure to 200 µM BzATP (B) for 1 h. (C) Graph illustrates percentage of 
live cells after BzATP treatment. **p < 0.01. Experiments were repeated three times. 
 
 
(3) ATP does not induce fibroblasts or astrocytes death in vitro 
SC cultures were normally contaminated with a few fibroblasts. When exposed to 5 mM 
ATP, the majority of SCs rounded up or detached from the culture dishes while the 
fibroblasts remained attached without obvious change in morphology, indicating that 
fibroblasts are insensitive to ATP at the concentration tested (Fig. 4-7).  
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Fig. 4-7 Fibroblasts are insensitive to ATP. 
Phase contrast image shows the majority of SCs rounded while the contaminated 
fibroblasts remained attached to the culture dish without obvious change of morphology 
after exposure to 5 mM ATP for 60 min. Arrows point to fibroblasts. Scale bar = 100 µm. 
 
     We also compared the sensitivity of SCs and astrocytes to high concentration of ATP. 
ATP (5 mM) was added to the co-culture of GFP transduced SCs and astrocytes (at 3:1 
ratio). As seen in previous experiments, SCs started to round up within 15 min, while no 
obvious morphological change was observed in astrocytes (Fig. 4-8). At the current study 
using an antibody (rabbit anti-P2X7; Alamone Labs, Jerusalem, Israel) that recognizes 
the C-terminal part of P2X7R (Sim et al., 2004), no P2X7R-ir were observed on 
astrocytes from Wistar rats, and they were insensitive to high concentration of ATP. 
However, P2X7R was reported on mouse astrocytes (Duan et al., 2003; Nagasawa et al., 
2009) and Sprague Dawley rat astrocytes (Panenka et al., 2001) in previous studies, 
which may be due to the different sources of astrocytes or the different antibody used 
(rabbit anti-P2X7, Chemicon) (Duan et al., 2003) that lack of specificity. It has been 
reported that P2X7R protein expression was much lower in rat than mouse astrocytes 
(Nagasawa et al., 2009).  
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Fig. 4-8 ATP induces Schwann cells death with no obvious effect on astrocytes in 
Schwann cell and astrocyte co-culture. 
Phase contrast images show morphological changes and detachment of SCs in co-culture 
with astrocytes before (A) and after exposure to 5 mM ATP at 30 min (B) or at 2 h 30 min 
(C). (D) and (E) are images taken from the same field showing phase contrast (D) and 
fluorescence (E, green for SCs transduced with LV/GFP). The rounding of SCs and 
formation of varicosities on the processes of SCs (arrowheads in D and E) while 
astrocytes (arrows in D) remained the same morphology after exposure to 5 mM ATP at 
100 min. Scale bar = 100 µm in A-C and 25 µm in D-E.  
  
 
(4) P2X7R is responsible for ATP induced Schwann cell death 
To test whether blocking P2X7R can rescue the SC from ATP induced death, we applied 
oxATP, an irreversible and slow P2X7R antagonist which requires 1 to 2 h incubation to 
block the functional activation of P2X7R (Di Virgilio, 2003) to the cultured SCs before 
the exposure ATP. oxATP was added to one group of culture dishes to a final 
concentration of 0.35 mM. After incubation for 2 h, oxATP treated and untreated cells (as 
control) were exposed to 3, 4, 5 mM ATP in the CO2 incubator for 1 h. By observation 
directly under a microscope, it was found that cells treated with oxATP remained the 
same while most of cells without oxATP treatment rounded or detached after exposure to 
ATP.  SCs were then dissociated from the culture dishes and processed with Annexin V 
Apoptosis Assay kit using flow cytometry. It was shown that the percentage of live cells 
without/with oxATP treatment were 73.9% vs. 97.1%, 63.2% vs. 92.3%, and 52.3% vs. 
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93.6% at 3, 4, 5 mM ATP respectively. oxATP pretreatment completely rescued SCs from 
ATP induced cells death (p < 0.01, Fig. 4-9) and the percentage of live cells was similar 
to that of untreated cells in culture medium (92.0%). 
 
 
Fig. 4-9 Blockade of ATP induced Schwann cell death with the P2X7R antagonist 
oxATP in vitro. SCs were pretreated with 0.35 mM oxATP for 2 h before exposure to 
different concentrations of ATP. Untreated SCs were used as control. Flow cytometry 
apoptosis assay was performed 1 h after exposure to ATP. *p < 0.05, **p < 0.01, ***p < 
0.001 compared with control. ++p < 0.01 compared with the corresponding untreated 
group exposed to the same concentration of ATP. Experiments were repeated three times. 
 
      
4.3.4 PSA partially rescues Schwann cell death induced by ATP in vitro. 
We also found that PSA expression on SCs could partially protect SC from ATP induced 
cell death in vitro (Fig. 4-10). PSA expression on cells has been reported to reduce the 
cell attachment (Fujimoto et al., 2001). To exclude this potential effect that might cause 
the different sensitivity of PST/SCs or GFP/SCs to ATP toxicity, PST/SCs and GFP/SCs 
were first dissociated from the culture dishes and resuspended in 4 ml medium. Cell 
suspension was aliquoted into 1 ml to four 15 ml tubes. ATP of different concentration 
(0, 3, 4, 5 mM) was added into the tubes with cell suspension repetitively. The tubes were 
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incubated in the CO2 incubator for 1 h with caps loosened. The tubes were gently shaken 
a few times to expose the cells to ATP evenly. The cell suspensions were then 
centrifuged at 800 rpm for 6 min and resuspend in 400 ul Annexin V Binding Buffer 
(BD). Cells suspension were incubated with 2 µl AnnexinV-Fluor 647 (BioLedeng) at RT 
for 15 min, then 5 µg/ml (final concentration) viability dye propidium iodide was added. 
The samples were processed immediately analysed with flow cytometry. The percentage 
of live cells in GFP/SCs and PST/SCs groups were 57.8% vs. 75.4%, 51.1% vs. 65.3% 
and 44.3% vs. 61.1% respectively after exposure to 3, 4 and 5 mM ATP for 1 h. There 
were significantly more live cells in PST/SCs group compared with GFP/SCs group at all 
three ATP concentrations (p < 0.05 or p < 0.01). As to whether such protective effect of 
PSA against ATP induced cell death reflects the improved survival of PSA-expressing 
SCs in spinal cord, further studies need to be carried out.  
 
Fig. 4-10 PSA partially protects Schwann cells from ATP induced death in vitro.  
Flow cytometry apoptosis assay was performed on PST/SCs and GFP/SCs. Graph shows 
the percentage of live cell after SCs were exposed to 3, 4 and 5 mM ATP for 1 h. 
Significantly more PST/SCs survived compared with GFP/SCs. *p < 0.05, **p < 0.01. 
Experiments were repeated three times. 
 
 
4.3.5 Prevention of the death of transplanted Schwann cells with a P2X7R 
antagonist. 
To test whether blockade of P2X7R can improve the survival of transplanted SCs, we 
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exploited the irreversible blockade property of oxATP. After the irreversible blockade of 
P2X7R in SCs, new P2X7Rs will be synthesized and transported to the cell membrane. 
First we studied the time window for SCs to become responsive again to ATP induced 
cell death after blockade of P2X7Rs with oxATP.  
 
(1) Recovery of blockade effect of oxATP 
oxATP (0.35 mM ) was added to the SC culture medium. After incubation for 2 h, 
oxATP was washed out and fresh medium was replaced. At 3, 4, and 6 h after the wash, 3 
or 4 mM ATP was added to the SC culture to test the recovery of SC response to ATP. 
By direct observation under a light microscope, it was found that between 4 and 6 h after 
oxATP washout, SCs started to be responsive to ATP again (Table. 4-1). This 4 h 
window may be enough to offer certain degree of protection against ATP induced SC 
death after transplantation as ATP release occurs instantly at the site of transplantation 
and may last for a few hours.  
Table. 4-1 Recovery from the blockade effect of oxATP 
  
Time oxATP 3 h washout  
% of rounded cells 
oxATP 4 h washout  
% of rounded cells 
oxATP 6 h washout  
% of rounded cells 
 3 mM  
ATP 
4 mM  
 ATP 
3 mM  
ATP 
4 mM  
ATP 
3 mM  
ATP 
4 mM  
ATP 
10’ - - - - 5%  15%  
20’ - - - - 5% 40%  
 
30’ - - - - 15% 50%  
 40’ 
 
- - - - 20% 60%  
 60’ 
 
- - - - 20-30% 70-80%  
90’ - - - - 20-30% 90%  
 
(2) oxATP treatment increases the survival of transplanted Schwann cells 
Next we investigated whether blockade of P2X7R in SCs with oxATP could improve 
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their survival after transplantation into spinal cords. SCs from P2 pups of Wistar rat were 
transduced with LV/GFP for easy identification. One group of cells (100,000 in 1 µl) was 
treated with 0.35 mM oxATP for 2 h while the same number of untreated cells from the 
same batch was used as control. Both groups of cells were harvested at the same time and 
transplanted into either side of the spinal cord dorsal columns of adult Wistar rat (Fig. 
4-11, n = 4). 
 
 
 
 
 
 
 
 
Fig. 4-11 Diagram illustrates transplantation of GFP labelled Schwann cells 
with/without oxATP treatment into either side of dorsal column of rat T8 spinal 
cord. 
   
One week later, animals were sacrificed and the areas occupied by GFP+ SCs in the spinal 
cord sections were measured using ImageJ. 38.2 ± 2.8% more oxATP treated SCs 
survived than the untreated SCs after transplantation (Fig. 4-12), indicating that blocking 
P2X7R in SCs can improve their survival after transplantation. 
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Fig. 4-12 oxATP pretreatment increases the survival of transplanted Schwann cells. 
(A) GFP labelled SCs transplanted into spinal cord. Right panel: pretreated with oxATP; 
left panel: without oxATP pretreatment. Dashed line indicates midline. (B) Quantification 
of the survived SCs 1 week after transplantation. n = 4, *p < 0.05.  
 
4.3.6 P2X7R activation induces neural stem cell death 
It has been shown that P2X7R expressed in hematopoietic stem cells/progenitor cells and 
ATP could induce apoptosis in these cells (Yoon et al., 2007). More recently, it has been 
reported that P2X7R activation can mediate NPC death in vitro (Delarasse et al., 2009). 
This result may have significant implication for researchers using NSCs for 
transplantation as NSCs also undergo cell death after being transplanted into CNS 
although the survived cells can proliferate in the host tissue. To confirm this result, we 
did some preliminary experiments on NSCs from P7 pups of C57BL/6J mice. 
Immunocytochemistry study showed that P2X7Rs were widely expressed on NSCs (Fig. 
4-13). Exposure of NSCs to 5 mM ATP induced significant morphological changes of 
NSCs similar to that of SCs observed under light microscope in vitro (Fig. 4-14), 
confirming that high concentration of ATP can also induce NSC death.  
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Fig. 4-13 Expression of P2X7Rs on cultured neural stem cells. 
NSCs identified with a stem cell marker nestin stained with an anti-P2X7R antibody. 
Scale bar = 25 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4-14 ATP induces neural stem cells death in vitro. Phase contrast images show 
NSCs in culture before (A) and after exposure to 5 mM ATP at 15 min (B), 40 min (C), or 
60 min (D). NSCs displayed similar response to 5 mM ATP as that of SCs, i.e., cells 
rounded, detached, shrank, or broken up over the experimental period.. 
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4.4 Discussion 
Much research has been performed to investigate the potential factors involved in cell 
death after transplantation. In the last few years we have been investigating whether 
over-expression of PSA on SCs can promote their survival and migration after 
transplantation into the spinal cord. However, compared with the enhanced migration 
ability, the survival of PSA-expressing SCs is still far from satisfactory, indicating 
additional factors may be unidentified.  
In this study, we first tested the effect of glutamate on the survival of SCs. Unlike 
the excitotoxicity of glutamate to neurons, glutamate up to 1 mM did not induce SCs 
death. Glutamate plays important roles in axon-SC singalling. It has been shown that 
glutamate or a glutamate-like substance is released from axons during excitation to 
activate a kainate receptor on the SCs (Lieberman, 1991). Moreover, AMPA receptor 
subunits: GluR2/R3 and GluR4 have been detected on SCs (Dememes et al., 1995). But, 
NMDA receptors have not been proved to be located on rat SCs, which may explain the 
insensitivity of SCs to high dose of glutamate.  
During the SCs harvesting process for transplantation, the original culture medium 
which contains serum and growth factor cocktails was replaced with DMEM only as the 
suspension medium. Serum and growth factor withdrawal may not exactly mimic the 
environment SCs encountered after being transplanted into spinal cord. However, this 
instant shock may still affect the survival of transplanted cells. Indeed, in this study, we 
found that the prolonged withdrawal of serum and growth factors induced significant cell 
death in vitro. In our study, over-expression PSA on SCs can partially protected SCs from 
serum and growth factor withdrawal induced cell death. The underlying mechanism for 
such phenomenon is still unknown and needs to be explored in future studies.  
An important discovery in the current study is that high concentration of ATP can 
induce SC death in vitro. The evidence provided in the current study indicates that 
P2X7R is the subtype of P2X receptors that mediates the SC death. One line of evidence 
is from the concentration of ATP used. No obvious cell death was detected with ATP 
concentration lower than 1 mM, as P2X7R is the only subtype of P2X receptors that is 
activated with ATP in mM range. Another line of evidence is that P2X7R agonist BzATP 
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was also potent in inducing SC death. The third line of evidence is that P2X7R antagonist 
oxATP can block the SC death induced by ATP. We also performed a preliminary 
experiment by exposing SCs from P2X7R knockout and wild-type mice to 4 mM ATP 
and subjected the cells to flow cytometry. SCs from P2X7R knockout mice showed no 
obvious cell death (95% live cells), while only 4% SCs from the wild-type mice were 
alive (no graph is presented as the experiment needs to be repeated). The functional data 
were further supported by the evidence that P2X7Rs are expressed in cultured SCs and 
NSCs, but not in fibroblasts and astrocytes which were resistant to ATP induced cell 
death. Moreover, deletion of P2X7R gene abolished the ATP induced SC death.  
The above in vitro evidences clearly demonstrate that high concentration of ATP 
can induce SC death. It is tempting to speculate that ATP may contribute to the death of 
the transplanted SCs in the spinal cord. One crucial question is that whether ATP released 
during transplantation procedure will reach concentration high enough to induce SC death. 
It has already been known that concentrations of ATP in cells are in the range of 1-10 mM 
(Beis and Newsholme, 1975). Upon cell breakage after injury, intracellular ATP will be 
released and the local concentration of ATP could be in mM range. It has been reported 
that mechanical stimulation can lead to release of ATP from astrocytes (Newman, 2001). 
Sustained high-level ATP release at spinal cord injury site was reported to last for 6 h 
(Wang et al., 2004). Cell transplantation procedure, although it has been done very 
carefully to minimize the damage to the host tissue, certain injury is unavoidable due to 
penetration of injection needle. Also the space occupied by transplanted cells will put 
pressure on the surrounding host tissues which may trigger the release of ATP from 
astrocytes. Therefore, it is highly possible that released ATP at the transplantation site 
may reach mM range and induce the death of transplanted SCs.  
By using the irreversible P2X7R antagonist oxATP to block the P2X7R on SCs 
before transplantation, we did observe significantly improved survival of SCs in 
comparison with untreated SCs. However, the application of oxATP to improve the 
survival of transplanted cells may not be an ideal approach since oxATP has many other 
targets like ATPases in the cells apart from P2X7R and is cytotoxic to cells (Craighead et 
al., 2001). We did observe that higher concentration of oxATP such as 0.5 mM could 
induce a certain degree of cell death (data not presented). At 0.35 mM, oxATP induced 
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SC death was not statistically significant although the percentage of live cells was lower 
than the control group. Another interesting phenomenon we observed but didn't have time 
to explore further is that ATP seems to have certain protective effect against the toxicity 
of oxATP on SCs, i.e., the percentage of live cells in the group treated with oxATP and 
ATP was higher than that the group treated with oxATP only. One potential explanation is 
that after the blockade of P2X7Rs, ATP may activate other subtypes of P2 receptors, 
especially the metabotrophic P2Y receptor subtypes. It is also possible that adenosine 
derived from ATP may also exert protective effect via adenosine receptors on SCs 
(Stevens et al., 2004). Another reason that oxATP is not an ideal P2X7R blocker for the in 
vivo study is that, although irreversible, newly synthesized P2X7Rs will make SCs 
sensitive to ATP again 4 h after removal of oxATP. The sensitivity returned to oxATP 
pre-treatment level after 16 h. Therefore, other approaches which are more specific at 
targeting P2X7R and have longer effects need to be developed. One potential method is 
to use small interfering RNA (siRNA) to knock down P2X7Rs in SCs and then study 
their survival after transplantation into spinal cord. Several publications have reported 
successful knockdown of P2X7R with siRNA (Chen et al., 2008; Cesaro et al., 2010). 
P2X7Rs have also been reported on several types of cells in the CNS, mostly on 
microglia (Di Virgilio et al., 1999). This receptor has been reported to participate in the 
processing and release of cytokines such as IL-1β, and in the initiation of cell death via 
both apoptotic and necrotic pathways (Schneider et al., 2006). In the CNS, P2X7R has 
been implicated in many pathological processes including neuroinflammation (Le Feuvre 
et al., 2002; Sperlagh et al., 2006; Skaper et al., 2010). P2X7R mediated release of 
inflammatory factors at the injury site may also contribute to the death of transplanted 
cells. In the normal rodent brain, P2X7R expression in astrocytes is generally quite low, 
but quickly up-regulated in response to brain injury or pro-inflammatory stimulation in 
cell culture conditions (Franke et al., 2004; Narcisse et al., 2005). In astrocytes, P2X7R 
activation can potentiate pro-inflammatory singalling, as it enhances IL-1β-induced 
activation of NF-κB and activator protein 1, leading to increased production of nitric 
oxide as well as increased production of the chemokines monocyte chemoattractant 
protein-1 and IL-8 (John et al., 2001; Panenka et al., 2001). Such processes may lead to 
more inflammatory factor release via the activation of P2X7R. It is likely that more cell 
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death will occur after cells being transplanted into the lesioned spinal cord. It was 
reported that intravenous administration of Brilliant Blue G (BBG), a commonly used 
food additive, and also a selective P2X7R antagonist, significantly reduced spinal cord 
anatomic damage, and improved motor recovery after spinal cord injury (Peng et al., 
2009). BBG treatment also directly reduced local activation of astrocytes and microglia, 
and neutrophil infiltration. We have planned to administrate BBG to rats before the 
transplantation of SCs to see such treatment would also be able to enhance the survival of 
transplanted SCs. If the treatment is effective, further enhancement of survival may be 
achieved by combining with knockdown of P2X7Rs on SC.  
The results obtained in the current study indicate that blockade P2X7Rs in SCs 
may promote their survival after transplantation and improve function recovery. 
Moreover, in our preliminary study, it confirmed that NSCs, a potential cell source for 
treating neurodegeneration diseases like Parkinson’s disease and Huntington’s disease 
(Dunnett et al., 2001; Wright and Barker, 2007), also express high-level of P2X7Rs. 
Furthermore, high concentration of ATP also induced NSC death. Targeting P2X7R may 
also be an effective approach to improve the survival of NSCs/NPCs after transplantation. 
Therefore, the current work on P2X7R induced SC death may have much bigger impact 
in the cell therapy field. 
Another interesting finding is that PSA can also partly protect SC from ATP 
induced cell death. It may also contribute to the better survival of grafted PST/SCs. 
However, we are unable to provide any explanation to the phenomenon like the 
protection of PSA against serum and growth factor withdrawal. One potential mechanism 
is that PSA may prevent the aggregation of P2X7R subunits to form the pores that leads 
to cell death. Further experiments need to be carried out to explore the underlying 
mechanisms.  
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Chapter 5 
Migration of transplanted Schwann cells in uninjured and injured 
spinal cord 
 
5.1 Abstract 
Lack of migration is one of main drawbacks that limit the success in using SC 
transplantation for neural repair after neurotrauma. In order to promote the migratory 
capability of the transplanted SCs, we genetically modified SCs to over-express PSA to 
reduce the adhesion of SCs. PST/SCs or GFP/SCs (as control) were first injected into 
uninjured rat spinal cord and it was found that expression of PSA on SCs did not enhance 
the motility of transplanted SCs in uninjured spinal cord. However, when SCs were 
transplanted 2.5 mm caudal to a spinal cord lesion site, in contrast to the GFP/SCs which 
only spread a short distance towards the lesion site, PST/SCs showed enhanced migration 
toward the lesion site along the degenerating dorsal column, and some PST/SCs were 
found within the lesion cavity 3 weeks after transplantation. Furthermore, when 
transplantation of PST/SCs was combined with LV/PST-GFP injection around the lesion 
site to induce the expression of PSA in the host spinal cord, more PST/SCs penetrated the 
glial scar and migrated into the lesion cavity. Similarly, GFP/SCs transplantation 
combined with LV/PST-GFP injection demonstrated increased migration of GFP/SCs 
along the PSA+ pathway toward the lesion site, but migration distance was shorter than 
that of PST/SCs combined with LV/PST-GFP injection. These results demonstrate that: (1) 
some molecules released from the spinal cord injury site are chemotactic factors for SCs; 
(2) PSA expression on SCs enhanced their migration towards lesion site; (3) PSA 
expression around the lesion site can render the scar more permissive and further 
facilitate SC migration and penetration into the lesion site.   
 
5.2 Aims 
In this study, we aimed to study: (1) whether PSA expression on SCs can enhance their 
migration in uninjured spinal cord or (2) in injured spinal cord; (3) whether PSA 
expression on the spinal cells around the lesion site can further enhance PSA 
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expressing-SCs migration and infiltrate to the lesion site. 
 
5.3 Results 
5.3.1 Migration of Schwann cells in uninjured spinal cord.  
To investigate the migration of SCs in uninjured spinal cord, 24 Wistar rats from each 
group received either GFP/SCs or PST/SCs transplantation with ciclosporin injection 
daily to reduce the effect of immune rejection. Animals were killed 1, 7, and 30 days after 
transplantation. It was found that transplanted SCs concentrated at the injection site, with 
some cells spreading a short distance rostrally and caudally along the axis of the spinal 
cord 1 day, 7 days, and 30 days after transplantation in both PST/SCs and GFP/SCs 
groups. Distances of 20 cells spreading the furthest from the epicenter of the transplants 
on three selected sections from each animal was measured. The migration distance for 
GFP/SCs and PST/SCs group were 768 ± 96 µm vs. 807 ± 109 µm at 1 day and 731 ± 
162 µm vs. 828 ± 111 µm at 7 days post transplantation respectively. No marked 
difference in the distribution of cells in both groups between 1 day and 7 days post 
transplantation was found, which indicates SCs implanted into uninjured spinal cord do 
not migrate. At 30 days post transplantation migration distances in both groups showed 
tendency of decreasing (580 ± 48 µm vs. 644 ± 106 µm for GFP/SCs and PST/SCs 
respectively), although the decrease was not statistically significant compared with those 
at 1 and 7 days. The decrease in migration distances may be explained by cell death over 
time. 
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Fig. 5-1 Migration of Schwann cells in uninjured spinal cord.  
Distance of 20 cells spreading furthest from the epicentre of the transplants on three 
selected sections from each animal was measured with ImageJ programme to assess the 
migration of SCs. There is no difference in migration distances between PST/SCs and 
GFP/SCs at 1 day or 7 days after transplantation. Decreased migration distances were 
observed in both groups at 30 days after transplantation. n = 8. 
 
 
5.3.2 Migration and infiltration of Schwann cells in injured spinal cord.  
To study the migration of transplanted SCs in injured spinal cord, PST/SCs or GFP/SCs 
(n = 6 per group) were injected 2.5 mm caudal to the lesion site of a crush injury at T8 
level. Animals were treated with ciclosporin daily. Three weeks after transplantation, 
significantly more PST/SCs were seen to migrate from the centre of the grafts towards 
the lesion site than GFP/SCs (1440 ± 211 vs. 696 ± 111 µm, p < 0.05, Fig. 5-2B-C). Most 
of the migrating PST/SCs were located close to the glial scar around the lesion site, while 
GFP/SCs were found drifting a short distance towards the lesion site (Fig. 5-2A, C). The 
results indicate that some molecules released from the lesion site act as chemotactic 
factors for SC migration and PST/SCs are more mobile than GFP/SCs. Density of GFP+ 
SCs within the lesion cavity defined by lack of GFAP fluorescence was measured. In two 
out of six animals, a large number of PST/SCs migrated into the lesion cavity,while in 
GFP/SCs group, only a very small proportion of the GFP/SCs migrated into the lesion 
cavity in one out of six animals (Fig. 5-3).  
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Fig. 5-2 Migration of Schwann cells transplanted caudal to the lesion cavity of spinal 
cord. 
Consecutive parasagittal sections showing GFP/SCs (A) and PST/SCs (B) migrating 
toward the lesion site. (C) Distances of SC migration from the injection site towards the 
lesion site 3 weeks after transplantation. *p < 0.05. Axes indicate the orientation of the 
spinal cord. Scale bar = 100 µm. n = 6. 
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Fig. 5-3 Infiltration of transplanted Schwann cells into the injury site of the spinal 
cord.   
Quantification of transplanted SCs migrated into the lesion site 3 weeks after 
transplantation. Integrated density of GFP-ir within the lesion cavity was measured using 
imageJ. Each dot represents an individual animal.  
 
We then explored whether engineered expression of PSA in the glial scar around the 
lesion site would further enhance the migration and infiltration of PST/SCs into the lesion 
cavity. Four groups of rats received four different combinations of treatments (Table. 5-1, 
Fig. 5-4). Briefly, GFP/SCs or PST/SCs were transplanted 2.5 mm caudal to the lesion 
site of spinal cord, immediately followed with LV/mCherry or LV/PST-GFP injection 
around the lesion site (n = 5-7). It was found in the group of GFP/SCs transplantation 
plus LV/mCherry injection, the migration distance of GFP/SCs was similar to that in the 
group without mCherry expression. Likewise, expression of mCherry also did not affect 
the migration of PST/SCs towards the lesion. In contrast, expression of PSA in spinal 
tissue around the lesion site significantly promoted the migration of both GFP/SCs and 
PST/SCs towards the lesion (Fig. 5-5B, D, F). In the group of PST/SCs plus LV/PST-GFP 
injection, PST/SCs penetrated the glial scar and migrated into the lesion cavity 3 weeks 
after transplantation in 4 out 5 rats (Fig. 5-5G); while SC migration into lesion cavity was 
only observed in 1 out 7 rats in the GFP/SCs plus LV/PST-GFP injection group, and 2 out 
of 5 in PST/SCs plus LV/mCherry injection group (Fig. 5-5G). There was no transplanted 
SC in the lesion cavity in the group of GFP/SCs plus LV/mCherry injection.  
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 Since CSPGs is one of the main inhibitory molecules secreted by astrocytes, we also 
checked whether LV/PST-GFP injection around the lesion site would alter the CSPGs 
expression. High level of PSA expression was found in LV/PST-GFP injection group, 
however, no marked difference was found in CSPGs expression levels in groups with or 
without LV/PST-GFP injection (Fig. 5-6).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 5-4 Diagam illustrates the surgery used to assess the migration of SCs 
 
 
Table. 5-1 Schwann cell transplantation plus LV injection  
Group GFP/SCs + 
LV/mCherry 
GFP/SCs + 
LV/PST-GFP 
PST/SCs + 
LV/mCherry 
PST/SCs + 
LV/PST-GFP 
Animal 
number 
6 7 5 5 
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Fig. 5-5 Migration of Schwann cells transplanted caudal to the injury site of spinal 
cord.  
SCs were injected 2.5 mm caudal to the lesion and the animals were sacrificed 3 weeks 
after transplantation. Migration of transplanted GFP/SCs combined with LV/mCherry (A) 
or LV/PST-GFP (B) injection around the lesion site. Migration of transplanted PST/SCs 
combined with LV/mCherry (C) or LV/PST-GFP (D) injection around the lesion site. (E) 
Adjacent section to (D) showing PST/SCs within the lesion cavity. Arrows point to the 
injection sites. (F) Graph illustrating the distance of SC migration from the injection 
cavity towards the lesion site 3 weeks after transplantation. (G) Quantification of 
transplanted SCs migrated into the lesion site 3 weeks after transplantation. Integrated 
density of GFP-ir within the lesion cavity was measured using imageJ. Each dot 
represents an individual animal. *p < 0.05. Axes indicate the orientation of the spinal 
cord. Scale bars = 250 µm for A-D, 100 µm for E. 
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Fig. 5-6 PSA expression does not alter CSPGs expression.  
Expreesion of PSA (blue) and CSPGs (red) around the lesion site of spinal cord with or 
without LV/PST-GFP injection. No marked difference was found in CSPGs expression 
level in groups with or without LV/PST-GFP injection 3 weeks after surgery. Scale bar = 
100 µm.  
 
 
5.3.3 Remyelination of axons by PST/SCs 
The potential of the grafted SCs to remyelinate axons was evaluated by detection of 
GFP+/P0+ myelin internodes. Nine weeks after transplantation of SCs directly into the 
lesion site of a hemi-transection injured T8 spinal cord, strong P0-ir was found within the 
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transplants (Fig. 5-7B-C) and the pattern of distribution of P0-ir closely matched the GFP 
fluorescence from transplanted SCs. Confocal photomicrograph confirmed that many 
PST/SCs around neurofilament (NF)+ axons were P0+ (arrowheads in Fig. 5-7D). Some 
P0+ internodes were GFP negative indicating that they originated from the host (Fig. 
5-7C-D). 
 
Fig. 5-7 Myelination of axons by PST/SCs. 
LV/PST-GFP and LV/GFP co-transduced SCs (A) grafts stained with P0 (B) 9 weeks after 
transplantation. (C) is the merged image of (A) and (B). Confocal photomicrograph 
shows PST/SCs (green) stained with P0 (red) and NF (blue) antibodies. Arrowheads point 
to the PST/SCs co-expressing P0 protein around NF+ axons. Scale bar for A-C = 100 µm; 
scale bar for D = 20 µm. 
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5.4 Discussion 
     PSA has been shown to play an important role in progenitor cell migration during 
development (Franceschini et al., 2004; Zhang et al., 2008). The underlying mechanisms 
are unclear. It was suggested that the large negatively charged PSA chain may act as a 
spacer that reduces adhesion force between cells, thereby, allowing dynamic changes in 
membrane contacts and promoting morphological plasticity and cell movement 
(Rutishauser et al., 1988). In vitro PSA-expressing SCs demonstrated increased migration 
potential when they were injected into a slice culture of postnatal brain (Lavdas et al., 
2006). However, when the same STX-transduced SCs (STX/SCs) were transplanted 0.5 
mm rostrally to the lesion site of mouse spinal cord STX/SCs did not show enhanced 
migration capability (Papastefanaki et al., 2007). This observation contradicts our result 
that PST/SCs show enhanced migration towards the lesion site. The lack of enhanced 
migration of STX/SCs in Papastefanaski’s study was explained by the early 
down-regulation of PSA on the transplanted SCs. In the current study, we also found PSA 
down-regulation over the periods after transplantation (See chapter 3, Fig. 3-4) and 
PSA-ir was hardly detected on PST/SCs nine weeks after transplantation. However, 
compared with STX/SCs, the expression of PSA on transplanted SCs driven by PST 
lasted for much longer periods, which led to delayed myelination by PST/SCs 
(unpublished observation). Our results agree with the report that prolonged expression of 
PSA on implanted neural precursors driven by PST-GFP fusion protein is associated with 
delayed mylination (Franceschini et al., 2004). Down-regulation of PSA on 
oligodendrocyte precursor cells has been reported to be necessary for these cells to 
differentiate into myelin-forming cells (Fewou et al., 2007). Although the mechanism 
regulating PSA expression remains obscure, it might result from post-transcriptional 
regulation triggered by SC differentiation after grafting. As a consequence, 
over-expression of PSA in SCs did not impair their myelinating potential. Indeed, we 
found strong P0-ir presented within the PST/SCs grafts nine weeks after transplantation; 
some P0+ internodes were GFP-negative indicating that they originated from the host. It is 
consistent with the previous report that endogenous SCs recruited from the periphery to 
the lesion site through the dorsal root entry zones contribute to remyelination (Beattie et 
al., 1997). It appears that STX- and PST-transduced SCs show differential response to the 
 150 
myelinating signals when they were transplanted into the spinal cord. This may not be 
surprising, since STX is mainly expressed in early developmental stage, while PST is 
expressed in the postnatal and persists in adult nervous system, and they may respond 
differently to the different environment signals (Ong et al., 1998). Furthermore, it was 
also reported that differentiation of PSA+ neuroblastoma cell lines induced by retinoic 
acid led to decrease in STX mRNA level, in contrast, it resulted in a dramatic increase of 
PST mRNA level (Seidenfaden and Hildebrandt, 2001). In another study, different levels 
of induced expression of PSA in chick retina by retroviral delivery of PST and STX has 
also been reported, i.e., PST induced PSA expression in retina resulted in severe localized 
alterations in retinal morphogenesis, while STX did not induce PSA expression or affect 
morphogenesis (Canger and Rutishauser, 2004). 
Our current data showed over-expression of PSA on SCs did not have effect on 
their migration ability when they were transplanted into uninjured spinal cord, but 
faciliated the migration of the cells along the degenerating dorsal column toward the 
lesion site, indicating that some molecules released from the injury site act as chemotactic 
factors to attract the transplanted SCs to the injury site. This result is consistent with 
previous studies. It was shown that oligodendrocyte progenitor migration in response to 
injury of glial monolayers required PSA on the progenitors (Barral-Moran et al., 2003). It 
was also found that PSA was necessary for directional migration of oligodendrocyte 
progenitors toward a gradient of PDGF in vitro and removal of PSA severely impaired 
PDGF gradient mediated directional migration while the directional migration of 
progenitors toward basic fibroblast factor source was not affected by the removal of PSA 
(Zhang et al., 2004). Furthermore, PSA has been shown modify the ability of cells to 
sense accurately to other growth factor gradients such as BDNF (Muller et al., 2000; 
Vutskits et al., 2001) and CNTF (Vutskits et al., 2003). These results suggest that PSA 
expression plays an instructive role in the guidance of migrating cells to the molecular 
cues released from the lesion site. In Papastefanaski’s study both the STX/SCs and the 
control alkaline phosphatase transduced GFP SCs were injected 0.5 mm rostral to the 
compression lesion site, which was much closer to the lesion site than in our study (2.5 
mm). In 4 weeks, SCs from both groups populated the lesion site, which also indicates 
the molecules released from the lesion have strong attraction to the transplanted SCs. In a 
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recent study it was reported that STX transduced macaque SCs did show enhanced 
migration to a demyelinated site in the spinal cord of nude mice when STX/SCs were 
transplanted 2 mm from the lesion site, and the STX/SCs were observed to migrate along 
laminin+ structures in the spinal cord (Bachelin et al., 2010). The requirement for the 
presence of chemotactic cues for the migration of transplanted PSA-expressing SCs may 
explain why they did not migrate when transplanted into uninjured spinal cord. In injured 
spinal cord, PSA may facilitate SCs migration by reducing cell adhesion and/or priming 
the cells to respond to chemotactic factors.  
The cellular mechanism by which the PSA-expressing scar tissue permitted the SCs 
migration and penetration remains unclear. It is difficult to detect the subtle change of the 
scar tissue by over-expression of PSA. The action of PSA may occur at the level of 
contact dependent cell singalling and buffer the detrimental effects of growth inhibitory 
molecules present in the scar tissue, such as CSPGs. However, it was found that PSA 
expression does not alter CSPGs after injury which is consistent with previous study (El 
Maarouf et al., 2006).  
The current study showed that when PST/SCs transplantation was combined with 
induced expression of PSA in the spinal cord close to the caudal lesion site more 
PST/SCs were observed migrating into the lesion cavity. Similarly, induced expression of 
PSA in the spinal cord also enhanced the migration of GFP/SCs, but to a lesser extent 
compared with PST/SCs. Our previous study showed that engineered expression of PSA 
in the dorsal root entry zone and spinal cord increased migration of endogenous SCs 
along the PSA+ pathway into the spinal cord (Zhang et al., 2007c). Likewise, engineered 
expression of PSA on astrocytes located along a path extending from the SVZ to a lesion 
near the cortical surface increased the recruitment of precursor cells along the path and 
into the injury site (El Maarouf et al., 2006). We have previously shown that expression 
of PSA on glial scar around spinal cord lesion site loosen the glial scar and rendered it 
permissive for axon growth (Zhang et al., 2007b). Taken together, it suggests that 
over-expression of PSA in the host tissues can create a more permissive environment and 
facilitate migrating cells penetrating into the lesion cavity. 
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Chapter 6 
Interaction of Schwann cells with astrocytes in vivo and in vitro 
 
6.1 Abstract 
Transplantation studies of SCs in animal models have revealed several drawbacks such as 
causing stress response of host CNS tissues that limit the integration of transplanted SC 
(Lakatos et al., 2003a). In this study, we investigated whether expression PSA on SCs 
could modify their interaction with host tissues in vivo and interaction with astrocytes in 
vitro. In the in vivo experiments it was shown that the transplanted GFP/SCs formed a 
sharp boundary with host tissues and caused stress response of host tissues, demonstrated 
by increased expression of GFAP-ir and CSPGs-ir in the adjacent host tissues. In contrast, 
transplanted PST/SCs intermixed with the host cells and did not cause such stress 
responses of the host spinal cord. Using in vitro SCs/astrocytes confrontation assay we 
mimicked the interaction of the two types of cells in vivo and found that significantly 
more PST/SCs crossed a 300 µm line drawn along the SCs/astrocytes confrontation 
boundary (23.0 ± 1.6 cells in PST/SCs group vs. 5.6 ± 0.5 cells in GFP/SCs group, p < 
0.001). By measuring the areas of individual astrocytes at the boundary it was shown that 
GFP/SCs caused significant hypertrophy in comparison with PST/SCs (7843 ± 411 µm2 
in GFP/SCs group vs. 3635 ± 136 µm2 in PST/SCs group, p < 0.001). Significantly more 
astrocytes proliferated when they were co-cultured with GFP/SCs than with PST/SCs.  
There was no difference in astrocytes proliferation when they were exposed to 
conditioned medium from both groups. The results indicate that expression of PSA on 
SCs can modify the property of SCs and make them less hostile to astrocytes. 
 
6.2 Aims 
In this study, we addressed whether PST/SCs behaved differently from GFP/SCs when 
they interacted with astrocytes both in vivo and in vitro. We tested (1) the integration of 
PST/SCs or GFP/SCs with host tissues and the stress response of the spinal cells to the 
transplanted SCs; (2) the interaction of PST/SCs or GFP/SCs with astrocytes using 
confrontation assay and co-culture assay. 
 153 
6.3 Results 
6.3.1 CSPG expression on naïve astrocytes and Schwann cells 
Since CSPGs are one family of the main inhibitory molecules secreted by astrocytes after 
spinal cord injury, we first detected and compared CSPG expression on naïve astrocytes 
and SCs in vitro. After permeabilization astrocytes were immunostained with antibodies 
against CSPG and GFAP, and SCs were immunostained with antibodies against CSPG 
and p75NTR. CSPG-ir was found to be localized in the cytoplasma in many GFAP+ 
astrocytes, while only detected in a few p75NTR+ SCs (Fig. 6-1).  
 
Fig. 6-1 Detection of CSPG expression in astrocytes and Schwann cells in vitro. 
CSPG expression was detected by immunostaining with CS-56 antibody in astrocytes (A) 
and SCs (B). High-level CSPG-ir was detected in many astrocytes (GFAP+, green in A) 
but was only present in a small population of SCs (p75NTR+, green in B). Scale bar = 100 
µm. 
 
 
6.3.2 Response of host tissues to the transplanted Schwann cells  
6.3.2.1 PSA expression in Schwann cells reduced stress response of neighbouring 
astrocytes in vivo.  
To investigate the interaction of SCs grafts with host tissue, sections of spinal cord 
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containing the transplanted SCs were immunostained with antibodies against GFAP or 
CSPG. It was found that grafted GFP/SCs formed a sharp boundary with the host 
astrocytes (Fig. 6-2A) while PST/SCs intermixed well with the host astrocytes (Fig. 
6-2B).  
 
 
Fig. 6-2 Interaction of transplanted Schwann cells with host astrocytes.  
Confocal images showing that transplanted GFP/SCs (A) formed a sharp boundary with 
the host GFAP+ astrocytes in the spinal cord while PST/SCs (B) integrated well with the 
host astrocytes. Scale bar = 50 µm. 
 
Increased GFAP and CSPG expression has been regarded as a sign of astrocytic 
stress. In this study we found that transplanted GFP/SCs induced increased expression of 
GFAP-ir (Fig. 6-3A-C) and CSPGs-ir (Fig. 6-3G-I) in the neighbouring astrocytes close 
to the transplanted GFP/SCs. In contrast, much weaker GFAP-ir (Fig. 6-3D-F) and 
CSPGs-ir were observed close to the transplanted PST/SCs (Fig. 6-3J-L). The results 
indicate that PSA expression on SCs changed their properties and made them less hostile 
to the astrocytes. 
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Fig. 6-3 GFAP and CSPG immunoreactivities around the transplanted Schwann 
cells. 
GFP/SCs (A) and PST/SCs (D) immunostained with a GFAP antibody (B, E) 7 days after 
being grafted into rat spinal cord. (C) and (F) are merged images of (A), (B), and (D), (E) 
respectively. GFP/SCs (G) and PST/SCs (J) immunostained with CS-56 antibody (H, K) 
7 days after being grafted into rat spinal cord. (I) and (L) are merged images of (G), (H) 
and (J), (K), respectively. There is less GFAP-ir and CSPG-ir around PST/SCs. Scale bar 
= 100 µm. 
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6.3.3 Response of astrocytes to induced expression of PSA in vitro  
We have previously shown that PSA expression did not alter the level of CSPG expression 
in astrocytes transduced with LV/PST-GFP in vivo (see Chapter 5, Fig.5-7). Proliferation 
is another index to evaluate astrocytic stress response. Here we tested whether PSA 
expression could change the proliferation of astrocyte in vitro. Astrocytes were 
transduced with either LV/GFP or LV/PST-GFP. Cells were maintained in culture medium 
for a few days to achieve high level of transgene expression. BrdU (20 µM) was then 
added 16 h before the cells were fixed. It was found that PSA expression in astrocytes did 
not alter their proliferation (27.9 ± 2.0% vs. 28.8 ± 1.8% for LV/GFP and LV/PST-GFP 
transduced astrocytes respectively, Fig. 6-4).  
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Fig. 6-4 Expression of PSA in astrocytes did not alter the proliferation. 
(A) Astrocytes transduced with LV/GFP stained with PSA. (B) Astrocytes transduced 
with LV/PST-GFP double stained for PSA (red) and GFAP (green). PSA-ir was detected 
in Golgi apparatus where PST-GFP was located when cells were permeabilized. (C1-C3) 
Astrocytes transduced with LV/GFP with BrdU staining. (D1-D3) Astrocytes transduced 
with LV/PST-GFP with BrdU staining. (E) Graph shows the percentage of BrdU+ nuclei 
of astrocytes transduced with LV/PST-GFP or LV/GFP. No difference was found between 
these two groups. Scale bar = 25 µm. Experiments were repeated three times. 
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6.3.4 Interaction of Schwann cells with astrocytes in vitro 
6.3.4.1 Confrontation assays 
Confrontation assays have been used to demonstrate that SCs are less capable of mingling 
with astrocytes and induce hypertrophy of astrocytes (Lakatos et al., 2000; Fairless et al., 
2005; Santos-Silva et al., 2007). In this study, an in vitro confrontation assay was set up 
to investigate the interaction of PST/SCs with astrocytes in comparison with GFP/SCs. A 
strip containing 50,000 Schwann cells in 20 µL medium was set up opposing a parallel 
strip containing 50,000 astrocytes in 20 µL on a PLL-coated coverslip. Cells were 
allowed to attach for 30 min before washing with DMEM to remove non-attached cells. 
Cultures were then maintained in 10% DMEM-FBS over a period of 12–14 days, giving 
time for cells to make contact and interact. Cells were then fixed. Astrocytes were 
immunolabelled using a monoclonal anti-GFAP antibody and SCs using a polyclonal 
anti-p75NTR antibody. For quantification, a 300 µm line was drawn along the interface 
between astrocytes and SCs. The number of SCs that crossed the cell interface was 
counted and averaged over five randomly chosen fields on each coverslip (8 coverslips 
per group per experiment) and experiments were repeated three times. Here, we 
confirmed that GFP/SCs formed a distinct boundary with astrocytes when the two 
populations of cells came into contact with each other (Fig. 6-5A, C) and only a few SCs 
crossed into astrocyte territory (Fig. 6-5E). In contract, no clear boundary was formed at 
the interface between PST/SCs and astrocytes (Fig. 6-5B, D). Significantly more 
PST/SCs crossed the line drawn at the interface of the two types of cells and intermingled 
with astrocytes (Fig. 6-5E). To assess the hypertrophy of astrocytes in contact with 
PST/SCs or GFP/SCs, the cytoplasmic areas of astrocytes (100 each) defined by GFAP-ir 
were measured using ImageJ and expressed in µm2. It was found that GFP/SCs contact 
induced significantly higher level of astrocyte hypertrophy compared with PST/SCs 
(7843 ± 411 µm2 vs. 3635 ± 136 µm2 for GFP/SCs and PST/SCs group respectively, p < 
0.001, Fig. 6-5F). 
 159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6-5 Schwann cell and astrocyte confrontation assay in vitro. 
Photomicrographs (A and C) showing that a distinctive boundary formed when GFP/SCs 
encountered astrocytes. Photomicrographs (B and D) showing that PST/SCs penetrated 
the astrocyte boundaries and populated the astrocytic domain. The yellow line illustrates 
a typical 300µm line drawn to quantify the number of cells that have crossed the 
boundary between the astrocytes and either PST/SCs or GFP/SCs. (E) Quantification of 
the numbers of SCs crossing the boundary line. (F) Quantification of the cytoplastic areas 
of the individual astrocytes along the boundary with GFP/SCs or PST/SCs as indicator 
for cell sizes. ***p < 0.001. Scale bars = 100 µm. Experiments were repeated three 
times. 
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6.3.4.2 Assessment of hypertrophy and proliferation of astrocytes in astrocyte & 
Schwann cell co-culture 
To assess whether astrocytes require direct contact with SCs for the induction of stress 
response, co-cultures were set up to further study the interaction of PST/SCs with 
astrocytes in comparison with GFP/SCs. Primary cultures were generally maintained for 
2 – 4 weeks before setting up the assays. Astrocytes and SCs were mixed at a ratio of 3:1 
and 2 × 105 cells in total were plated on PLL-coated 10 cm dish in DMEM- 10%FBS. 
These cultures were maintained for 10-14 days. BrdU (20 µM) was added 16 h before 
fixation of cells to assess the proliferation of astrocytes. To analyze the proliferation of 
astrocytes, 10 randomly selected fields of view per coverslip under a 20× objective lens 
of a Leica microscope were captured for counting. Six coverslips were used per 
experiment and the experiment was repeated three times. Astrocytes were identified with 
GFAP antibody. The data are expressed as the ratio of double GFAP+/BrdU+ cells over 
double GFAP+/DAPI+ cells for the level of proliferation of astrocytes. It was found that 
significantly more astrocytes proliferated in the GFP/SCs and astrocytes co-culture than 
in the PST/SCs and astrocytes co-culture (22.6 ± 1.2% vs. 17.8 ± 1.0%, p < 0.01, Fig. 
6-6).   
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Fig. 6-6 Brdu incorportation assay for astrocytes in cultured with Schwann cells.  
(A-E) GFP/SCs and astrocytes co-culture with BrdU staining. (F-G) PST/SCs and 
astrocytes co-culture with BrdU staining. (K) Percentage of BrdU+ nuclei of astrocytes. 
Significantly more astrocytes proliferated in the GFP/SCs and astrocytes co-culture than 
in the PST/SCs and astrocytes co-culture. Scale bar = 100 µm. **p < 0.01. Experiments 
were repeated three times. 
 
 
6.3.4.3 Assessment of hypertrophy and proliferation of astrocytes induced by 
Schwann cell conditioned medium. 
To assess whether released factors from SCs are responsible for the induction of 
astrocytic stress, we performed astrocyte culture with conditioned medium collected from 
GFP/SCs or PST/SCs. Briefly, when cultures of purified SCs were confluent (maintained 
in 60 mm culture dish in vitro for 1-2 weeks), they were rinsed twice with PBS and 4 ml 
of DMEM-10% FBS without added growth factors. Cultures were maintained for two 
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more days before medium collection.  Collected media were centrifuged to remove cell 
debris, and filtrated through a 0.2 µm filter (Millipore, Hertfordshire, UK). SC 
conditioned medium (SCM) was added to astrocyte culture at a 1:1 or 1:5 ratio with 
DMEM-10% FBS. The culture was maintained in SCM for 2 days. BrdU (20 µM) was 
added 16 h before fixation with 4% PFA and the cells were immunostained with 
antibodies against BrdU in order to analyze proliferation of astrocytes. It was found the 
proliferation level of astrocyte in GFP/SCs conditioned medium and PST/SCs 
conditioned medium were 25.7 ± 3.0% vs. 22.8 ± 3.3% (1:1 dilution in DMEM-10% 
FBS), 26.8 ± 2.4% vs. 22.0 ± 4.4% (1:5 dilution in  DMEM-10%FBS, p > 0.05, Fig. 
6-7). There was no significant difference between the GFP and PST groups. Also no 
difference between the 1:1 and 1:5 dilution groups. The results indicate that stress 
response of astrocyte induced by SCs is due to direct contact rather than secreted factors 
from SCs.  
 
 
Fig. 6-7 Effect of Schwann cell conditioned medium on the proliferation of 
astrocytes. 
SCM was diluted in DMEM-10% FBS at 1:1, and 1:5, and BrdU incorporation into 
astrocytes was measured. There is no significant difference between GFP/SCs and 
PST/SCs conditioned medium groups. Experiments were repeated three times. 
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6.3.5 PSA expression on olfactory ensheathing cells 
In previous studies, OECs have been reported to induce much less astrocyte stress 
compared with SCs and mingle well with host tissues (Lakatos et al., 2000; Lakatos et al., 
2003a; Santos-Silva et al., 2007). In this study, we found that PSA-expressing SCs 
behaved in the similar way as OECs when they interacted with astrocytes. OECs were 
classified into two cell types based on morphology and antigenic phenotype. OECs with 
astrocyte-like morphology express both GFAP and PSA (identified with a monoclonal 
IgM antibody) (Franceschini and Barnett, 1996). We postulate that PSA might be the key 
molecule that makes SCs to gain those OEC-like properties. In a preliminary study, we 
also examined PSA expression on OECs. OECs were obtained from Professor Geoffrey 
Raisman in UCL. They were isolated from olfactory bulb in adult Sprague Dawley rats. 
OECs were double immunostained for p75NTR (a commonly used maker for OECs as well) 
and PSA (mAb735), and it was found PSA was widely expressed on OECs (Fig. 6-8). An 
experiment will be carried out to study whether removal of PSA from OECs by Endo-N 
treatment will change their interaction with astrocytes.   
 
Fig. 6-8 Expression of PSA on olfactory ensheathing cells. 
PSA was detected on OECs with a monoclonal IgG anti-PSA antibody (mAb735). Cells 
were also immunostained for p75NTR (a marker for OECs as well as for SCs). Scale bar = 
25 µm. 
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6.4 Discussion  
Injuries to CNS cause activation of astrocytes, demonstrated by hypertrophy, proliferation, 
and increased expression of GFAP and CSPGs (Sofroniew and Vinters 2010). Astrocytes 
also display stress response when they come in contact with SCs both in vitro (Lakatos et 
al., 2000; Fairless et al., 2005) and in vivo (Lakatos et al., 2003a). Such response of 
astrocytes will isolate the SC graft and prevent the migration of the transplanted SCs. On 
the other hand, OECs, although share many biological and morphological characteristics 
with SCs, were reported not to cause significant stress response to astrocytes, migrate 
easily inside spinal cord, and intermingle well with the host spinal cells after 
transplantation (Lakatos et al., 2000; Lakatos et al., 2003a). Such properties of OECs 
make them a favourable candidate for neural repair (Fairless and Barnett, 2005; Franssen 
et al., 2007; Raisman et al., 2010). However, the inefficient in vitro expansion of OECs 
has limited their clinical usage although clinical trials using OECs have been carried out 
(Mackay-Sim et al., 2008). In this study, we used several in vitro experiments to 
investigate the interaction between SCs and astrocytes. Our approach is similar to those 
which have already been used to demonstrate poor migration of SCs in the presence of 
astrocytes and the hypertrophy induced in astrocytes by contact with SCs (Eng and 
Ghirnikar, 1994; Wilby et al., 1999). Our results showed that PSA over-expressing SCs 
gained many of the properties of OECs that are beneficial for transplantation. PST/SCs 
are able to cross into astrocyte territory and intermingle with astrocytes in confrontation 
assay, cause less proliferation of astrocytes than GFP/SCs in co-culture assay and do not 
induce significant level of expression of GFAP and CSPGs in the neighbouring areas of 
the transplants. Taken together, these results indicate SCs induce astrocytic stress and 
engineered expression of PSA on SCs significantly changes their interaction with host 
astrocytes and makes astrocytes more tolerable to the peripheral nerve derived glial cells.  
The underlying mechanism for the modification of astrocyte stress response to SCs is 
still unclear. The astrocyte stress response is reported to be mainly mediated by a FGF 
family member, and heparan sulfate proteoglycans (HSPGs) may be important for 
mediating the stress response in astrocytes via FGF2 (Santos-Silva et al., 2007). It has 
been speculated that the presence of PSA induces a conformational change in the NCAM 
to produce or enhance the HSPG binding site (Storms and Rutishauser, 1998). Thus, the 
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hypothesis is that PSA may modulate HSPG binding and then indirectly modify FGF 
signal pathway in astrocytes to alter astrocyte stress response. However, it remains 
unclear whether PSA actually binds to HSPGs or indirectly modulates a NCAM-HSPG 
interaction. Other molecules like N-cadherin, integrin, aggrecan, and ephrins are also 
reported to be involved in the interaction between astrocytes and SCs and may prevent 
the intermingling of the two types of cells and the migration of transplanted SCs (Fairless 
et al., 2005; Afshari et al., 2010a; Afshari et al., 2010b). Since the repulsion force of PSA 
can attenuate not only homophilic NCAM–NCAM binding but also affects heterophilic 
binding with other cell surface molecules such as L1, laminin, cadherin, and integrin 
(Acheson et al., 1991; Fujimoto et al., 2001; Johnson et al., 2005), expression of PSA on 
SCs may interfere with the interactions of multiple molecules and signal pathways that 
limit their intermingling with astrocytes and migration.  
PSA is expressed on one class of OECs (Franceschini and Barnett, 1996). In this 
current study, we also showed that PSA-ir was widely expressed on OECs by 
immunostaining. Taken together, we speculate that PSA might be responsible for the 
common features shared by OEC and PST/SCs. Since it is difficult to obtain enough 
OECs for transplantation, the beneficial features of PST/SCs will make them feasible for 
clinical trials.  
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Conclusion remarks and future work 
SCs as a candidate for cell transplantation for neural repair after neurotrauma have many 
merits over other types of cells. SCs transplanted into the spinal cord have been shown to 
promote axon sprouting and remyelination, and improve functional recovery in some 
animal models of spinal cord injury. However, poor migration, integration and survival of 
transplanted SCs in the CNS are common problems that limit their therapeutic potential. 
In this PhD project, I have genetically modified SCs by over-expressing PSA to change 
their biological properties to improve their survival and enhance their migration and 
integration within host spinal cord.  
I found that PSA-expression significantly enhanced the survival of transplanted 
SCs in comparison with the GFP-expressing SCs both in short-term (7 days) and 
longer-term (30 days). Immunosuppression improved the long-term survival of 
transplanted GFP/SCs; however, it did not further enhance the survival of PST/SCs, 
indicating that PSA may have similar effect as that of ciclosporin on transplanted 
GFP/SCs. It has been reported that sialic acids have anti-recognition effect, which is 
explained by their negative charges in combination with a bulky, hydrophilic molecule 
(Kelm and Schauer, 1997). I speculate that PSA may mask or shield antigenic sites on 
SCs, owing to its steric hydrotic structure, to protect them from the attack of host immune 
system. By using immunohistochmistry, we found there was no difference in either 
neutrophil or macrophage infiltration to the PST/SC and GFP/SC transplants, indicating 
that PSA-expression on SCs do not change the responses of inflammatory cells to the 
transplants. 
I further explored other potential underlying mechanisms for the improved survival 
of PST/SCs both in vivo and in vitro. I firstly investigated whether more PST/SCs 
proliferated in the spinal cord than GFP/SCs. BrdU incorporation assay showed PSA 
expression did not increase the proliferation of SCs both in vitro and in vivo. Secondly, I 
examined whether the improved survival of PST/SCs was due to reduced apoptosis. 
TUNEL assay of transplanted cells showed that the numbers of TUNEL+ SCs decreased 
over time (from 1 day to 19 days post transplantation) and there was no difference 
between PST/SCs and GFP/SCs groups, indicating that PSA-expression may not protect 
SCs from apoptosis in the time-window of TUNEL assay in this study. It was suggested 
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that PSA expression is inversely correlated with the expression of p75NTR in newborn 
neurons. In this study we also found p75NTR expression level was significantly decreased 
in PSA-expressing SCs in vitro by immunostaining. p75NTR has been shown to be 
involved in SCs death (Boyle et al., 2005; Gascon et al., 2007). I postulate PSA may 
enhance the survival of transplanted SCs via inducing the down-regulation of p75NTR 
expression on SCs. Further study needs to be carried out to investigate the expression 
level of p75NTR in transplanted PST/SCs and GFP/SCs to find out whether PSA 
expression can also reduce the expression of p75NTR in vivo. 
Though PSA enhanced the survival of transplanted SCs to a certain degree, the cell 
death was still extensive over time. Then I tested several factors that might have 
contributed to the death of transplanted cells in vitro. I first investigated the toxicity of 
glutamate and found SCs were insensitive to high concentration of glutamate. Serum and 
growth factor withdrawal over 26 h induced significant cell death and PSA expression 
partially rescued SCs from death induced by serum and growth factor withdrawal. The 
underlying mechanism is unknown.     
     By chance, I found that high concentration of ATP could induce significant SC 
death in vitro. As large amount of ATP can be released from cells in spinal cord after 
spinal cord injury or during cell transplantation procedures, I speculate that ATP may 
contribute to the death of transplanted SCs in the early stage. ATP induced apoptosis is 
mediated by the activation of P2X7R and I found that SCs in culture and in sciatic nerves 
expressed high-level of P2X7R. ATP induced SC death could be blocked by the 
irreversible P2X7R antagonist, oxATP. As I found out that it took over 4 h for SCs to 
become sensitive to ATP again after the removal of oxATP, I blocked the P2X7R on SCs 
and transplanted them into spinal cord. I did find that more oxATP-treated SCs survived 
than those untreated SCs. One crucial experiment I have started but not finished yet is the 
transplantation of the SCs from the P2X7R knockout mice to see whether they'll survive 
better than the SCs from the wild-type mice of the same genetic background. Since 
P2X7Rs are also expressed on NPCs/NSCs, and β islet cells, enhancing cell survival by 
blocking P2X7Rs should have a much wider impact in the field of cell therapy. As 
NPCs/NSCs have been studied as candidates for neural repair and the early cell death is 
also significant, it would be interesting to find out whether blocking P2X7R can enhance 
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their survival after transplantation. As oxATP is mildly toxic to cells at the concentration 
we used and blockade will be reduced after new P2X7Rs are synthesized, it is imperative 
to find new approaches to block the P2X7Rs. One such method is to use LV delivered 
short hairpin RNA (shRNA) to knock down P2X7Rs in SCs. Efficient knockdown of 
P2X7R in cell lines has been reported in several studies and the sequences can be used 
for the design of shRNA. Viral vector mediated knockdown should be stable and 
long-lasting. I do not expect long-term knockdown of P2X7Rs will affect their ability for 
myelinating regenerating axons as this receptor type is mainly involved in inflammation 
and the peripheral nerves of P2X7R knockout mice appear normal. Interestingly, I also 
found PSA could partially rescue ATP induced SC death in vitro and I also have no 
explanation for this phenomenon. 
     Over-expression of PSA on SCs did not have obvious effect on their migration 
ability when they were transplanted into uninjured spinal cord. It is not surprising as SCs 
need molecular cues for their migration. Therefore, even PST/SCs are more motile, they 
may not migrate without the induction of chemotactic factors. A spinal cord lesion 
produced such molecular cues for the transplanted SCs and PST/SCs moved much faster 
towards the lesion site. The enhanced migratory capability of PST/SCs may be explained 
by the reduced cell adhesion, but it does not exclude other mechanism. One of them 
might be that PSA expression on SCs modifies the response of SCs to the chemotactic 
factors and initiates stronger migratory potential. Recent findings indicated that NCAM 
polysialylation is necessary for the directional response of neural or glial progenitors to a 
variety of growth factors (Glaser et al., 2007). TrkB can bind to NCAM directly and 
regulate neurite outgrowth (Cassens et al., 2010). As SCs also express TrkB (Frisen et al., 
1993), I speculate that PSA may modify the interactions of signalling molecules such as 
NCAM and TrkB in lesioned spinal cord.  
 Moreover, over-expression of PSA on spinal cord cells facilitated migration of both 
PST/SCs and GFP/SCs. It further confirms that reduced cell adhesion by PSA is 
beneficial to the migration of transplanted SCs. PSA expression around spinal cord lesion 
site could render the glial scar permissive to facilitate the penetration of migrating SCs 
into the lesion cavity as it was observed in this study that more PST/SCs migrated into 
the lesion cavity. Expression of PSA on spinal cord cells was also shown to promote the 
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migration of endogenous SCs into the spinal cord. Therefore, expression of PSA on SCs 
in combination with expression of PSA on spinal cord cells should be an effective 
strategy to move the SCs transplanted close to the lesion site into the lesion cavity. It has 
been known that transplantation of SCs directly into the lesion cavity causes significant 
cell death due to lack of extracellular matrix support and the lack of growth factors. It 
would be interesting to compare whether more PST/SCs will survive if they are 
transplanted adjacent to the lesion site instead of directly into the lesion site, which would 
be more practical clinically. 
Using confrontation assay I mimicked the interactions between astrocytes and SCs 
in vivo. Expression of PSA on SCs significantly changed their behaviour when they 
encountered astrocytes. They were able to cross into astrocytic territory and did not cause 
hypertrophy of astrocytes. Such dramatic change of their biological property makes them 
more OEC-like. As it is known that OECs express PSA, it would be interesting to see 
how OECs will interact with astrocytes in the confrontation assay after the removal of 
PSA on OECs with Endo-N. The mechanism that PSA regulates the interaction between 
SCs and astrocytes still remains unclear. Based on the data from current in vitro studies, 
this effect is most likely mediated via direct cell-cell contact. PSA may interfere with the 
signalling pathways that trigger stress response of astrocytes. The astrocyte stress 
response is reported to be mainly mediated by a FGF family member (Santos-Silva et al., 
2007), and we may examine the activation of its intracellular downstream signalling 
pathways, such ERK pathway, in astrocytes after confrontation with SCs to see whether 
PSA can reduce the activation of the pathways.   
     Last but not the least, the regulation of myelination by PSA over-expression is 
another issue needs to pay attention to. Due to its bulk volume, it is logical to believe that 
PSA expression should be in an inverted relationship with myelin formation. (Charles et 
al., 2000; Jakovcevski et al., 2007). In this study, we found that PSA-ir decreased over 
time after transplantation, which is in agreement with the results from other studies 
(Papastefanaki et al., 2007; Bachelin et al., 2010); PST/SCs could still myelinate axons 
nine weeks after transplantation when the PSA-ir can hardly be detected. PSA 
down-regulation, observed at later time points, may be a prerequisite for SC 
differentiation into myelin forming cells. Although the mechanism regulating PSA 
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expression remains obscure, it might result from post-transcriptional regulation triggered 
by SC differentiation. As a consequence, over-expression of PSA in SC did not impair 
their myelinating potential.  
     In conclusion, the findings from present study demonstrate that PSA expression on 
SCs is able to enhance their survival after transplantation, facilitate their migration 
towards lesion site in spinal cord, and improve their integration with astrocytes. Such 
modification would make SC transplantation more feasible for clinical application in the 
treatment of neurotrauma.  
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